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Abstract
Cancer, a class of diseases, characterized by abnormal cell growth, has demonstrably high
impact on human life: complex lifestyle changes, caused by malignancy, affect not only
patients, but also family and friends. Cancer development has been linked to genetic and
epigenetic abnormalities that affect the regulation of key genes that control cellular mech-
anisms. These alterations, which target stem cells, may be different or less immediately
adverse from one person to another, as various risk factors are cumulative and variable in
effect. However, a major issue in cancer research is the lack of precise information on tu-
mour pathways; therefore the delineation of these and of the processes underlying disease
proliferation is an important area of investigation.
Here, we present a hybrid computational model following a multi-scale approach, which
has been developed for colorectal cancer dynamics by linking information from micro-
molecular to cellular and tissue levels, (e.g. epigenetic events, stem cells, intestinal crypts).
The current work aims to i) investigate genetic and epigenetic interdependencies leading to
colon cancer initiation and progression; ii) to analyse influence of different risk factors at
both molecular and cellular levels during cancer development; iii) to examine aberrant DNA
methylation variation in malignant intestinal systems; iv) to evaluate the effect of inhibiting
methylation modifications in abnormal colon crypts over time; and v) to assess the impact
of deregulations in intestinal crypt dynamics with respect to tumour development. Given its
crucial role in cancer development, DNA methylation is the main feature of the colorectal
cancer model.
Computational modelling is performed at different levels. A network-based model,
xvii
namely the Epigenetic-Genetic (E-G) Network Model, has been developed to explore in-
terdependencies between genetic and epigenetic events, recorded at different stages of col-
orectal cancer, (with a focus on gene relationships and tumour pathways). Micro-molecular
modifications are studied in relation to ageing and gender, considered to be major risk
factors in cancer development. Further, an agent-based model, AgentCrypt, with agents
representing three cell types: stem, progenitor and differentiated cells in the colon (and
with addition of a Paneth cell group in small intestine), has been developed to describe the
dynamics of the intestinal crypt. Comparative analysis on methylation variation between
colon and small intestine crypts during cancer initiation and under carcinogen influence is
performed. A further extension concentrates on analysing the impact of potential inhibitors
on methylation level in the intestinal crypt. Finally, a logistic model, LogisticCrypt, (focus-
ing on cell division, differentiation and apoptosis rates and on cell competition related to
the intestinal crypt space), has been built to provide information on the crypt structure at
specific time points and to investigate time-intervals to occurrence of major crypt phenom-
ena (such as ‘crypt fission’ and the ‘bottleneck effect’), due to deregulations in intestinal
cell number.
Keywords: Epigenetic and Genetic events; gene relationship; tumour pathway; car-
cinogen; methylation inhibitor; stem cell dynamics; colon crypt; small intestine crypt;
cross-comparative analysis; hybrid computational model; Bayesian network; agent-based;
logistic model.
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Chapter 1
Introduction
1.1 Motivation
Colorectal cancer, (CRC), is the third most common cancer type world-wide, [Ferlay et al.,
2014], accounting for around 8.6% and 13% of all new cancer cases in the US (2013),
[SEER, 2013b], and UK (2010), [Cancer Research UK, 2014b], respectively. In addition, it
has been reported to be the second leading cause of cancer-related deaths for the combined
sexes in US (2013) and UK (2011), accounting for around 15% and 10% of all cancer deaths
in these countries. In Ireland, CRC is the second most common cancer type, accounting for
around 2,270 new cases diagnosed in 2009, [Irish Cancer Society, 2014], with a total of
around 37,000 new cases identified during 1994-2011, [National Cancer Registry Ireland,
2014]. It is also the second most common cancer-related cause of death, [BowelScreen,
2014].
Epigenetic events, or the micro-molecular interactions that influence gene expression
without altering the DNA sequence, have been detected (i) in the earliest stages of cancer
initiation, (ii) in the ageing process and also (iii) in response to cellular stress. Over recent
decades, diverse studies have shown that epigenetic modifications are reversible, [Yoo and
Jones, 2006; Dworkin et al., 2009], and have revealed the potential of using this informa-
tion in developing possible treatments for incipient cancer stages, [McCabe et al., 2012].
Therefore, understanding these phenomena, which are also considered markers for tumour
1
initiation, [Baylin and Jones, 2011], may increase the success of cancer therapy in affected
patients. In addition, in the context of recent efforts on personalised medicine and targeted
treatments, a novel research direction concentrates on the identification of intra-individual
epigenetic variation linked to cancer predisposition and development, i.e. epigenome-wide
association studies, (EWASs). However, a major challenge of the EWASs is acquiring repet-
itive assays from the same individuals, particularly from internal tissues.
Given time and cost implications for laboratory experimentation and human epigenome
studies, a range of computational models and tools has been developed over recent years, to
help scientists and clinicians to better understand the impact of malignant molecular events
on tumour pathways and to investigate new strategies that can be applied in cancer treat-
ment, (e.g. [McCabe et al., 2012]). However, although extensive biocomputational work
has been performed, to date, understanding of the interdependencies between genetic and
epigenetic mechanisms leading to cancer initiation and progression is still limited. There-
fore, given the current accessibility of genome-wide approaches, epigenetic-related experi-
mental datasets require bioinformatics and computational approaches to assist in data anal-
ysis, hypothesis validation and results interpretation.
1.2 Scope and contribution
1.2.1 Research Objectives
This work aims to develop a simplified computational prototype of CRC dynamics, in order
to explore aberrant mechanisms in CRC at different layers, i.e. micromolecular, cellular
and tissue levels, and to identify critical events that can be used as potential targets for
CRC therapy. A healthy intestinal crypt is characterised by specific relationships between
cell division, differentiation and apoptosis rates in order to maintain homeostatic1 control
over time, [Eisenhoffer et al., 2012]. Consequently, interest centres on how modifications
in these indicators can affect crypt dynamics and subsequent tumour development. Dis-
1homeostatic = characteristic related to the potential of a biological system, (e.g. an organism or cell) to
conserve the internal stability, [Merriam-Webster, 2014].
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ease phenotype has been associated with modifications of the DNA methylation (DNAm)
patterns and it has been suggested that genome-wide analysis on DNAm variation can in-
form on tumour predisposition, [Rakyan et al., 2011]. Interdependencies exist between
genetic and epigenetic events in malignant conditions and data on their occurrence and on
signalling pathways in CRC have become increasingly available, (Chapter 3). Ageing and
gender are considered major risk factors in tumour development, (Chapter 2). Abnormal
micro-molecular modifications have been found to be accumulative in different systems
over time, [Fraga et al., 2007], and gender differences have been reported for CRC devel-
opment, [Ogino et al., 2006b]. In addition, external factors such as chemical radiation and
environmental features are known to induce deregulation in biological system dynamics
leading to tumour initiation and progression, (Section 2.6.2). Nevertheless, the reversibil-
ity property is of interest and several epigenetic drugs are already in use for blood cancer
therapy, (Section 2.7). Thus, the main Research Objective of this Thesis is:
To build a model base for investigation of methylation level variation at cellular and
tissue levels in human intestinal systems, with respect to i) genetic - epigenetic inter-
dependencies, ii) patient characteristics, iii) potential methylation inhibitors and iv)
carcinogen2 influences during CRC initiation and progression, and to evaluate quan-
titatively the impact of deregulations on crypt dynamics with regard to tumour devel-
opment.
The current work aims to establish plausibility of this information linkage for monitoring
and prediction. Subsidiary research objectives include:
RO. 1. To quantify the impact of genetic and epigenetic interdependencies on the methy-
lation level in CRC development and to estimate the influence of ageing and gender
with respect to methylation level in abnormal colon cells;
RO. 2. To evaluate quantitatively methylation level variation in intestinal tissues under dif-
ferent external conditions during cancer initiation and progression;
2A carcinogen is a substance or an agent causing cancer.
3
RO. 3. To assess the effect of deregulation on intestinal crypt dynamics with regard to
tumour development.
1.2.2 Contribution
Clearly, cancer is a complex process generated by abnormal genetic and epigenetic interde-
pendent modifications in cellular mechanisms that exhibit different dynamics. Therefore,
one formalism was never likely to be adequate and a joint network, agent-based and lo-
gistic approach has been implemented. The Colorectal Cancer Model contains three main
computational components, namely:
I. Epigenetic-Genetic (E-G) Network Model, which explores i) the interdependencies
between genetic and epigenetic events, recorded at different CRC stages, and ii) the
way in which these are influenced by patient characteristics, (e.g. ageing, gender).
II. AgentCrypt Model, an agent-based model on crypt dynamics, which handles crypt
intra- and inter-dependencies and performs a comparative analysis on DNAm level
between the colon and small intestine tissues. Potential carcinogens are also consid-
ered and their impact on tumour pathways examined. Moreover, a set of potential
methylation inhibitors, (defined by different prevention patterns of de novo methyla-
tion modifications over time), is investigated in abnormal intestinal crypts.
III. LogisticCrypt, a logistic model on crypt structure at specific time points, which fo-
cuses on cell division, differentiation and apoptosis rates and on cell competition re-
lated to crypt space.
The structure of the Colorectal Cancer Model and the relationships between model com-
ponents are illustrated in Figure 1.1. Specifically, E-G Network incorporates on patient
features and provides information on cell methylation level at specific time, which may be
considered as input data for AgentCrypt. In addition, cell population dynamics are investi-
gated in abnormal intestinal systems following both bottom-up and top-down approaches.
The CCM components described in the Thesis can be used in personalised medicine
for CRC development. Specifically, they can be used for prediction (the E-G Net-
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Figure 1.1: Structure of the Colorectal Cancer Model
The relationships between model components may refer to R1) average methylation level
for gene network / intestinal cell; R2) patient features; R3) intestinal crypt dynamics, ex-
plored following bottom-up and top-down approaches.
work and the LogisticCrypt) and exploration of tumour dynamics, (all three). The
AgentCrypt provides a framework for DNAm variation in comparative analysis of in-
testinal tissues and can be viewed as a proof of concept in EWASs. In addition, the
AgentCrypt can be extended for investigation of intra- and inter-individual epigenetic
variation in other cancer types, (e.g. liver, lung).
1.3 Thesis structure
Chapter 2 provides a brief introduction to Epigenetics and CRC mechanisms and considers
three system layers, namely i) micromolecular, ii) cellular and iii) tissue levels. In Chapter
3, the basis for different computational models and databases developed for investigation
of key-questions related to CRC dynamics, are reviewed. In addition, the importance and
challenges of the multi-scale modelling approach are highlighted.
An initial version of the E-G Network model was presented in Roznova˘t¸ and Ruskin
[2013a]. This has been extended to include information on signalling pathway information
and refinements of different sets of dynamics, (such as those involved in the methylation
level update process), and is described in Chapter 4. Inclusion of ageing and gender influ-
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ences in E-G Network was presented in Roznova˘t¸ and Ruskin [2013c]. Methods proposed
for cancer progression decision, details of implementation extensions and results obtained
are described in Chapter 5. The AgentCrypt and the LogisticCrypt model components are
presented in Chapters 6 and 7, respectively. (An earlier version of AgentCrypt and prelim-
inary results on epigenetic inhibitor and carcinogen influences during CRC development
were outlined in Roznova˘t¸ and Ruskin [2013b].) Finally, Chapter 8 summarises the main
findings and limitations of the overall Colorectal Cancer Model and proposes future re-
search directions.
Appendix A provides a “Glossary” of key terms in the Biology of intestinal cancer sys-
tems, (which appear in text with the following format: apoptosis˜). These are gathered
together for ease of reference in the text. Extended information related to CRC features,
(e.g. key-genes, major types, age-group classification), is included in Appendix B. The
lists of i) Epigenetics resources, ii) the several databases on cancer mechanisms and iii)
BN-generator software, which were interrogated for the Colorectal Cancer Model develop-
ment, with addition of iv) a gene group included in this thesis, (with information on gene
symbol and names according to the GeneCards database, [Safran et al., 2010]), are tabulated
in the Appendix C. Detailed information on the mathematical calculation of the relation-
ships between cell division, differentiation and apoptosis rates within the intestinal crypt,
(Chapter 7), is provided in Appendix D. Finally, Appendix E provides a list and summary
abstracts of publications arising from this work.
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Chapter 2
Biological background
2.1 Introduction
Colorectal cancer (CRC) has been a major area of focus of research for years due to its
impact on human health. According to statistical studies, CRC is the third most common
cancer type, after lung and breast cancers, and global numbers of new cases and deaths
associated with it in 2012 have been estimated at around 1.3 million and 0.7 million, re-
spectively, [Ferlay et al., 2014]. Over the last two decades, it has been shown that both ge-
netic and epigenetic events can stimulate abnormal micromolecular modifications, leading
to cancer development. A major characteristic of cancerous systems, making them difficult
to understand and investigate, is cancer diversity; in effect, given no two individuals are the
same, then no two cancers are the same, [Hutchinson, 2011]. However, in order to explore
the aberrant phenomena involved in cancer initiation and progression, features of normal
biological systems must be well-understood. To this end, an overview of mechanisms ob-
served at micro-molecular, cellular and tissue levels in both normal and abnormal systems,
(with a focus on the intestinal system and CRC development), is provided in this chapter.
The first section briefly introduces principles of Genetics for reference in the rest of this
Thesis. Secondly, the nature of epigenetic events and their involvement in cancer develop-
ment are introduced, (Section 2.3), and are followed by a description of the intestinal crypt
structure and dynamics, (Section 2.4). A summary of malignant system features is given in
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Section 2.5, and information related to CRC initiation and progression, (e.g. CRC types,
risk factors), is presented briefly in Section 2.6. Finally, an overview of cancer therapies
involving epigenetic events is included, (Section 2.7).
2.2 A brief introduction to Genetics
The cell is the basic structural and functional unit of the biological systems. Its functions are
encoded by genes, which are segments of DNA. DNA, (or deoxyribonucleic acid) is well-
known to the public due to recent research breakthroughs, (as well as popular TV culture),
and is the macromolecule that contains genetic information, (inherited from both parents).
The DNA helix form has been regularly illustrated and consists of two strands of nucleotides
formed from a nucleobase, a sugar and a phosphate chemical compound. The primary
nucleobases are adenine (A), cytosine (C), guanine (G) and thymine (T), which form A-T
and C-G base pairs. RNA, (ribonucleic acid), is a macromolecule, involved in gene coding,
regulation and expression. It has a single strand form with A, C, G and uracil (U), which
replaces the thymine nucleobase from DNA. The proteins are large molecules performing
the functions encoded by genes, (e.g. cell division, differentiation). This transcription
& translation process is usually summarised by the Central Dogma of molecular biology,
[Crick, 1970]:
DNA→ RNA→ protein (from chains of amino acids).
Histones are proteins that package the DNA sequence in nucleosome, (i.e. basic units),
which are grouped and form chromatin. Chromatin be found in two forms in cells, namely
heterochromatin, (highly condensed chromatin, characterised by low levels of gene tran-
scription), and euchromatin, (less compacted, characterised by high levels of gene tran-
scription). Chromosomes are pairs of organized DNA packages in cells, where deletions or
duplications of parts of chromosomes are possible, resulting in a state called chromosomal
instability.
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Two types of genes have been identified in the human genome1, namely the non-coding
RNA genes, (briefly presented in subsection 2.3.3), and protein-coding genes. Gene expres-
sion is dictated by its promoter2 and regulatory elements, located typically at distant regions
from the gene body.
Mutations, (i.e. abnormal modifications of the DNA sequence), can occur with high
rates during the cell cycle, primarily during division, (when DNA is replicated and genetic
information is transmitted from mother to daughter cells). However, there are several mech-
anisms that protect cells from mutation. The DNA repair mechanism, dictated by the DNA
repair genes3, is active constantly in normal systems to identify such aberrant changes and
correct them. If mutations can not be corrected, two major actions can be induced in nor-
mal systems, namely i) programmed cell death, (i.e. apoptosis), or ii) senescence, i.e. when
a cell is not considered to undergo further divisions and dies eventually. However, in ab-
normal systems, a mutated cell can escape from these mechanisms and continue division,
(often with faster dynamics), leading to tumour development. This occurs due to dereg-
ulation of the expression patterns of three major gene types, namely tumour suppressor
genes˜, (TGS), proto-oncogenes˜ and DNA repair genes. A TSG is a gene that protects
a cell from progressing increasingly along the path to cancer and its inactivation leads to
disease predilection because if correct expression of the protein is inhibited, the apoptosis
of abnormal cells cannot be dictated, [Desper et al., 1999]. Initially, a normal cell con-
tains proto-oncogenes, which can become oncogenes˜ in tumour cells due to mutation or
epigenetic activation, [Vogelstein and Kinzler, 2004]. Oncogenes can induce aberrant cell
proliferation. Aberrant modifications of the DNA repair genes are associated with failure
of correcting the DNA sequence errors that arise before cell division.
1The human genome, i.e. the complete set of DNA information found in a human body, has 23 pairs of
chromosomes and approximative 20,000 protein-coding genes.
2Promoter is a segment of the DNA sequence, usually located just before a gene. In the transcription
process, it acts as a binding site for RNA polymerase (an enzyme that synthesises RNA from DNA template)
and transcription factors, (proteins binding to specific DNA sequences). Generally, a gene contains a single
promoter; however, recently, genes with two promoters have been also identified.
3Example: MLH1 gene, with its aberrant expression leading to genomic instability and cell proliferation,
Table B.1.
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2.3 Epigenetic Mechanisms in Normal and Malignant Systems
Although cells share essentially the same genetic information within a body, various cell
types exist and these show highly diversified gene expression patterns reflecting different
functionalities. Over recent decades, biological research has focused on studying epigenetic
phenomena, i.e heritable changes in chromatin structure that do not include modifications in
DNA sequence, but affect gene expression, [Allis et al., 2007]. Conversely, the ‘all-genetic’
paradigm, which considers that phenotype is influenced only by genotype and environment,
has been abandoned in favour of this detailed description, which includes epigenetic mech-
anisms, (i.e. an additional layer of gene regulation, as illustrated in Figure 2.1).
Major epigenetic mechanisms that have been identified as assisting gene regulation
within a body are i) DNA methylation, ii) histone modification, and more recently, iii)
small non-coding RNAs. These mechanisms form part of the epigenome˜4, which has rapid
dynamics compared to the genome, and can be influenced by cell environment, [Alegrı´a-
Torres et al., 2011]. Epigenetic events have been detected in the earliest stages of different
malignancies and act as biomarkers˜5 for cancer initiation, [Baylin and Jones, 2011]. Ad-
ditionally, their unique reversibility property, (not shared by genetic mutations, [Yoo and
Jones, 2006; Dworkin et al., 2009]), is already exploited in some therapy regimes, (Section
2.7). Therefore, understanding of epigenetic alterations can give improved insight on the
way in which aberrant modifications characterize cancer initiation and progression.
2.3.1 DNA methylation
DNA methylation (DNAm) is a molecular process that involves the addition of a methyl
group to a cytosine ring, [Bestor, 2000; Bird, 2002]. In addition, adenine methylation has
been reported recently in prokaryotes6; however, this modification has been observed less in
4Epigenome includes the totality of epigenetic information in an organism.
5In Genetics/Epigenetics, a biomarker can refer to an event, (or a modification), associated with risk to
disease development. Biomarkers can be used for identification of overall tumour occurrence, but also of
specific tumour stages and subtypes, and can help in tumour prognosis, informing on tumour response, and in
treatment selection.
6A prokaryote is a simplistic organism, composed from a single cell that has no distinct nucleus, [Merriam-
Webster, 2014].
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mammals, ([Aguilar and Craighead, 2013] and references therein). The DNAm process is
driven by the DNA methyltransferase (DNMT) family of enzymes7, (reviewed in [Carey
et al., 2011]). Specifically, de novo methylation is catalysed by DNMT3A, DNMT3B
and DNMT3L, while DNMT1 is involved in maintaining DNAm patterns during DNA
replication. Recently, other cytosine patterns, (i.e. 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC), 8), have been also identified and po-
tentially associated with the intermediate states during the DNA demethylation process,
[Kriaucionis and Heintz, 2009; Ito et al., 2011; Pfaffeneder et al., 2011].
In cancer development, aberrant DNAm patterns have been found in two distinct forms:
hypo-(H-) and hyper-(H+) methylation. DNA hypomethylation, an epigenetic event spe-
cific to cancer initiation, is associated with proto-oncogene activation, [Bjornsson et al.,
2004; Allis et al., 2007], and chromosomal instability, [Herman and Baylin, 2003]. Both of
these can promote cell proliferation and lead to an increase in cell predisposition to muta-
tions. Of particular interest in cancer research are those ‘CpG islands’ from the promoter
region of different TSGs. A CpG island is a genomic region of at least 200 base pairs, con-
taining a high frequency of CG dinucleotides, (the CG percentage > 50%, i.e. cytosine and
guanine comprise more than half of the total nucleotides present), and with the Observed-to-
Expected (OE) CpG ratio9 > 60%, [Gardiner-Garden and Frommer, 1987]. Normally un-
methylated, CpG islands become targets for DNA hypermethylation during pathogenesis,
commonly leading to unscheduled gene silencing, [Herman and Baylin, 2003; Bjornsson
et al., 2004; Allis et al., 2007; Meissner et al., 2008].
7Enzymes refer to biological molecules that act as catalysts in biochemical reactions.
85hmC, 5fC and 5caC are DNA methylation variants resulted from sequential processes of methylation
cytosine (5mC) oxidation, (regulated by the Tet (ten eleven translocation) protein group), as illustrated by the
following relationships:
5mC oxidation−−−−−−→ 5hmC oxidation−−−−−−→ 5fC oxidation−−−−−−→ 5caC, (dictated by Tet proteins).
9The OE CpG ratio is calculated based on formula proposed in Gardiner-Garden and Frommer [1987]:
OE =
CG number
C number ×G number × Sequence length. (2.1)
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2.3.2 Histone modifications
Similar to DNAm, modification of histones influences changes in chromatin structure,
[Jenuwein and Allis, 2001]. There are five known families of histones H1/H5, H2A, H2B,
H3 and H4, grouped into two categories: the core group, (H2A, H2B, H3, H4) and the
linker histones, (H1 and H5), [Ito, 2007]. In addition, several variations of these histones
have been identified and denoted collectively as histone variants, (e.g. H2A.X, H3.3), (re-
viewed in [Sarma and Reinberg, 2005]). Histone modification (HM) may be cumulative and
may take a number of forms, including methylation, acetylation, phosphorylation, ubiquity-
lation, and sumoylation, [Kouzarides, 2007; Suganuma and Workman, 2008]. The histone
modification nomenclature10 is usually by histone name, (e.g. H1, H3, H4), followed by
the amino acid abbreviation and position in the protein, (e.g. K9 for Lysine at position
9), [Turner, 2005]. The type and number of modifications, (e.g. Me3 for trimethylation),
can be specified also, [Turner, 2005]. For example, H3K27me3 refers to trimethylation of
histone at lysine 27, [Cedar and Bergman, 2009].
Two of the most studied histone modifications are histone methylation and acetylation,
where addition/removal of specific chemical compounds are driven by different protein
families, including the histone methyltransferase (HMT)/ demethylases (HDM), and acetyl-
transferases (HAT)/ deacetylases (HDAC) respectively. Histone acetylation is characterised
by rapid changes in the acetyl state at specific lysine part and histone methylation is defined
as addition of maximum three methyl groups to lysine and arginine residues˜11.
The effect of HM depends on both the histone and the modification types. For ex-
ample, H3K27me3 and H4K20me2 have been associated with transcriptionally inactive
genome regions, (i.e. gene repression), while both acetylation and methylation on H3K4
have been linked to transcriptionally active chromatin, (i.e. gene activation), [Kouzarides,
2007]). Moreover, the trimethylation and acetylation of H3K9 have been associated with
gene silencing and activation, respectively, [Koch et al., 2007].
10The Brno nomenclature is a standard system used for histones and histone modification notation.
11A residue is a small remainder from a substance, resulted following a chemical/ physical process applied
to the considered substance.
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2.3.3 Small non-coding RNAs
Small non-coding RNAs (sncRNAs), (including the three major categories: small interfering
RNA (siRNA), micro RNA (miRNA) and piwi-interacting RNA (piRNA)), are involved in
different developmental phases and are considered to have a major role in protecting cells
against various external influences such as viral infection, [Carthew and Sontheimer, 2009;
Ghildiyal and Zamore, 2009; Mattick et al., 2009]. The sncRNAs are also implicated in
directing the patterns of other epigenetic events, such as DNA methylation, [Carthew and
Sontheimer, 2009; Ghildiyal and Zamore, 2009; Mattick et al., 2009].
MicroRNAs, (or miRNAs), are small sequences of RNA, (∼ 19 - 22 nucleotides), which
are involved in the cell cycle, (e.g. division, differentiation, apoptosis). They can act as
TSGs or oncogenes and can be abnormally down- or up-regulated during disease develop-
ment, [Negrini et al., 2009], as a consequence also of aberrant DNA methylation patterns,
[Yang et al., 2009]. Over recent years, it has been shown that miRNAs can be considered
biomarkers for malignant tumour stages, (including for CRC, [Schetter et al., 2011]).
2.3.4 Interplay between DNA methylation and Histone modification
It has been recently established that DNA methylation and histone modifications can influ-
ence one another, [Vaissie`re et al., 2008; Cedar and Bergman, 2009; Ikegami et al., 2009].
In Cedar and Bergman [2009], authors reported that histone acetylation depend on un-
methylated DNA, leading to an open chromatin structure, while non-acetylated histones
are associated with DNA methylation, determining more compact chromatin. It was also
observed that DNA methylation level can be increased by histone methylation, [Cedar and
Bergman, 2009]. Moreover, DNAm was found to inhibit some histone modifications, such
as H3K4 methylation, [Cedar and Bergman, 2009].
In addition, different dynamics have been reported for DNAm and HM. For instance,
DNAm is considered to be highly stable in nature, while HM occurrence can follow a much
faster dynamic, (for example, histone deacetylase is a rapid mechanism).
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2.4 The Intestinal Crypt
The intestinal crypt is considered to be the structural and functional unit of the intestinal
tissues, (e.g. colon, small intestine). The small intestine and colon crypts present a number
of both similarities and differences with respect to their structure, (e.g. cell location, number
and cycle duration). The intestinal crypt cell population consists of stem, progenitor and
differentiated cells in the colon, with the addition of the Paneth cell group in the small
intestine.
2.4.1 Crypt Structure and Dynamics
Normal stem cells are undifferentiated cells that can divide in an unlimited way, in order
to produce new stem cells, or differentiate into specialized cells, [Reya and Clevers, 2005].
Additionally, they have the property of conserving epigenetic patterns during cell division
and transmitting these from generation to generation, [Probst et al., 2009]. A stem cell
can divide either asymmetrically, (when a stem cell and a progenitor cell are born), or
symmetrically, when two identical stem cells are produced, after which it is replaced by the
daughter stem cell, [Humphries and Wright, 2008]. The lifecycle duration for a stem cell is
linked to the time period for cell division, which has been determined to be approximately
seven days for the human colon, [Potten et al., 2003; Frank, 2007], and five days for the
small intestine, [Potten et al., 2003], respectively. The stem cell compartment is found at the
base of the colonic crypt, [Bock, 2012], or proximate to the crypt base in the small intestine,
[Clevers and Bevins, 2013]. Progenitors, which are located in the crypt to the left and right
of the stem cell group, are more specialized than stem cells and undergo a limited number
of divisions, while differentiated cells, (i.e. enterocytes, goblet and endocrine cells), occupy
the upper part of the colon crypt and represent fully-specialized cells, [Khalek et al., 2010;
Vaiopoulos et al., 2012].
In normal conditions, i.e. in healthy phenotypes, a major difference between the struc-
tures of the colon and small intestine crypts is given by the presence of Paneth cells at the
base of the small intestine crypt, [Sancho et al., 2003], and their absence from the colon
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crypt, [Nicolas et al., 2007], as illustrated in Figure 2.2. Paneth cells are differentiated cells
that protect the stem cell group within the small intestine crypt against bacterial infections,
[Umar, 2010]. Although Paneth cells can be observed sometimes in the ascending12 colon,
their presence in this tissue has been associated with a certain disease stage, [Humphries
and Wright, 2008]. Unlike progenitors and differentiated cells that migrate to the top of the
intestinal crypt, Paneth cells move closer to crypt base, [Kim et al., 2005]. The Paneth cell
cycle has been determined to be equal to around 20-30 days, [Sancho et al., 2003; Clevers
and Bevins, 2013].
Figure 2.2: Simplified structure of a) colon and b) small intestine crypts - Comparison
Cells are illustrated by rectangles with different shading patterns: i) stem cell (dark-shaded
rectangle) at the base/ close to the base of colon and small intestine crypts, respectively; ii)
progenitor cells, (grid pattern shading), to left and right of stem cell group; iii) differenti-
ated cells, (unshaded rectangle), at the top of the crypts; iv)Paneth cells, (diagonal-hashed
shading), occur only at the base of the small intestine crypt. Image adapted from McDonald
et al. [2006].
In addition, differences between the small intestine and colon crypts have been reported
with regard to cell numbers. While the colon crypt contains around 16 - 19 stem cells,
[Brittan and Wright, 2004; Khalek et al., 2010], within a total of 2000 cells, [Nicolas et al.,
2007; Khalek et al., 2010; Vaiopoulos et al., 2012], the small intestine crypt is shorter, with
12The colon has four major subdivisions: the ascending, the transverse, the descending, and the sigmoid
colon, ([Fritsch and Ku¨hnel, 2008], page 202).
16
1-6 stem cells within a total of around 250 cells, [Sancho et al., 2003]. Abnormal cell
population growth, (as a consequence of deregulation in cell cycle control mechanisms),
has been associated with tumour pathways, [Humphries and Wright, 2008; Jin et al., 2009],
and aberrant augmentation in the Paneth cell group has been related to Crohn’s disease, (a
major type of inflammatory bowel disease˜13 linked to increased risk for intestinal cancer
development, [Canavan et al., 2006; Clevers and Bevins, 2013]).
2.4.2 Intra- and inter-crypt influences
Intercellular communication can occur between adjacent cells through ‘gap junctions’,
(regulated by the connexin family). The connexin gene is considered to have a tumour
suppressor property and downregulation of its expression, caused by aberrant epigenetics
events, has been linked to deregulation in cell division, differentiation and apoptosis in
several human cancer types, (reviewed in Vinken et al. [2009]).
Inter-crypt interactions have been reported also in the colon epithelium14, where an
aberrant crypt can influence its neighbours’ homeostasis˜, (i.e. the balance or stable state
that characterises the internal environment of a normal biological system), by inducing
deregulation in the local environment, [Humphries and Wright, 2008].
2.5 Malignant Systems: a brief overview
Cancer is caused by the deregulation of key genes that control cellular mechanisms, such
as division, differentiation, apoptosis, and movement. Cellular processes are directly regu-
lated by TSG and proto-oncogenes, (denoted as ‘gatekeepers’). The activity of a TSG can
be reduced in malignant cells by genetic mutations, insertions and deletions or epigenetic
silencing, a condition that causes failure of apoptosis within abnormal cells, [Vogelstein
and Kinzler, 2004]. In addition, aberrant oncogene activation can increase the formation of
13Inflammatory Bowel Diseases refer to disorders of the Gastrointestinal tract that cause intestine inflam-
mation. Crohn’s disease and ulcerative colitis are two major types of inflammatory bowel diseases, [Canavan
et al., 2006; Clevers and Bevins, 2013; Merriam-Webster, 2014].
14Epithelium is one of the four major animal tissue types, (together with connective, muscle and nervous),
and is characterised by high cell division rate and small intercellular gaps. The epithelium ensures functions of
e.g. tissue protection, hormone secretion, nutrient absorption, sensation detection, [Merriam-Webster, 2014].
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those proteins that dictate excessive cell growth, while alterations of DNA repair or care-
taker genes allow a rapid accumulation of modifications in other genes that control the cell
cycle, [Michor et al., 2004]. Finally, abnormal modifications of another gene category, i.e.
landscaper genes, lead to increased cell susceptibility to malignant transformation, [Michor
et al., 2004]. A simplified representation of interdependencies between genetic and epige-
netic mechanisms and the influence of several risk factors in biological systems leading to
cancer development is illustrated in Figure 2.3.
Figure 2.3: Malignant system features - Simplified representation
Aberrant genetic and epigenetic modifications of different genes deregulate the cell cycle
causing abnormal cell proliferation and lead to cancer development. Tumour pathways are
influenced also by different risk factors, such as ageing, gender, lifestyle and environmental
features, (discussed in subsection 2.6.2). Reprinted by permission from Macmillan Pub-
lishers Ltd: Nature Reviews Cancer, ([Timp and Feinberg, 2013]), copyright (2013).
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Signalling pathways Of particular interest in cancer research are those genes involved in
signalling pathways. By definition, a signalling pathway (SP) is a chain of molecules that
work together to control cell functions. An aberrant event recorded for the first molecule
of a SP will induce abnormal activation on the second one. This process is repeated for
all molecules of the SP and results, after activation of the last molecule in the chain, in
loss of cell function. Studies of signalling pathways can help in the design of targeted
therapeutic strategies that enable slowing down or halting of the malignant cellular modifi-
cations. Some of the well-known analyses of signalling pathways in cancer research include
WNT/β-catenin, [Clevers, 2006], TGF-β, [Derynck et al., 2001], MAPK, Eph/Ephrin and
Notch, [De Matteis et al., 2013]. Mutations in these pathways have a high impact on the
development of various cancer types, (such as colon, breast, ovary, lung cancer, leukaemia),
in both hereditary and sporadic˜15 forms, [Derynck et al., 2001; Clevers, 2006]. A com-
prehensive database of curated signalling pathways involved in human cancer development
is the KEGG PATHWAY database, [Kanehisa et al., 2014].
Stem Cell hypothesis In recent years, the Cancer Stem Cell hypothesis, which postulates
that the initiation and progression of cancer are associated with accumulation of aberrant
genetic and epigenetic modifications within stem or stem-like cells, has become increas-
ingly accepted as a plausible tumorigenesis hypothesis, [Boman and Wicha, 2008; Clevers,
2011; Papailiou et al., 2011]. Conversely, diminishing scientific support has been given
to the traditional hypothesis of cancer development, which considers that every cell within
the malignant population has the ability to promote disease, [Khalek et al., 2010; Molina-
Pea and lvarez, 2012; Vaiopoulos et al., 2012]. Stem-like cells are abnormal cells that are
changed during disease development and present similar characteristics to a normal stem
cell, in terms of proliferation capacity and transgenerational epigenetic information trans-
mission, [Johannes et al., 2009].
15Cancer sporadic refers to cases when individuals develop cancer, without having inherited DNA modifica-
tions that can increase malignancy risk.
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Cancer Stages Cancer staging denotes the severity and degree of tumour development
and extension, and provides a guideline for the medical profession in terms of identifying
suitable treatment required. Thus, Overall Stage Grouping is a system used to describe
cancer progression and classifies tumours/ disease status as I, II, III, and IV (as well as
0), where the most advanced cancer stage is denoted by IV. Stage 0 is referred to also as
‘carcinoma in situ’. Defined as a cell having high potential to become abnormal, carcinoma
in situ corresponds e.g. to ductal carcinoma in situ of breast cancer, to Bowen’s disease
in skin melanomas, or to adenoma16 phenotypes in CRC. In addition, the designations
carcinoma and invasive carcinoma correspond to Stages I, II, III, while metastasis refers
to the Stage IV tumour phase, where cancer has spread throughout the body or to another
organ. Thus, a tumour can progress from carcinoma in situ, to invasive carcinoma and,
potentially, to metastasis.
2.6 Colorectal Cancer (CRC)
CRC development is a complex multi-step process associated with deregulations of both
genetic and epigenetic events targeting stem cells in colon and rectal tissues. A brief de-
scription of several CRC features is included in this section. Information on CRC initiation
and progression phases is provided, together with a summary of several key-genes identi-
fied in CRC and an overview of both sporadic and hereditary CRC forms. Further, ‘crypt
fission’ and the ‘bottleneck effect’, two major intestinal crypt phenomena, for which an
increase in occurrence rate has been associated with CRC development risk, are also de-
scribed. Finally, the impact of several risk factors for CRC initiation and progression is
discussed.
Benign to Malignant in CRC development Initially, cell growth rate increases in several
crypts leading to polyp˜ formation at epithelium’s surface. Polyps are considered to be be-
16Colon adenoma = phenotype characterised by benign modifications in colonic epithelium, which can be-
come malignant if not removed, leading to colon cancer.
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nign˜17, (i.e. Stage 0), but one type, (namely the colon adenomatous polyps), may increase
their size and become cancerous over time, if not removed. Once presenting malignant˜
characteristics, adenoma is referred as adenocarcinoma. As the disease progresses, cancer
cells accumulate aberrant changes that facilitate cell proliferation within polyps and even-
tually migration. At Stage I, more of the inner colonic epithelium is involved, and in Stage
II, the tumour affects nearby tissues, but not the lymph˜ nodes; tumour extension to these
is thus specific to Stage III. Finally, CRC can invade other organs, such as the liver and
lungs18, leading to metastasis˜. In addition, recurrent˜ CRC includes those cases when
malignant modifications reappear after treatment, affecting parts of the colon, rectum or
other organs.
Key genes in CRC development Information on the characteristics of several key-genes
identified in CRC development is provided in Table B.1, in Appendix B, together with
principal references. The list includes TP5319, (a TSG with crucial role in cell cycle control
and whose mutation/deletion was detected in more than 50% of human diseases [Knudson,
2001]), APC20, (abnormally changed in the earliest CRC stages [Suehiro et al., 2008]),
RASSF1A21, KRAS22, BRAF23 and MGMT24, (highly mutated and hypermethylated in
CRC, [Grady and Markowitz, 2002; Suehiro et al., 2008; Dworkin et al., 2009; Ahmed
et al., 2013]), MCC25 and MLH126, (in which alterations were associated with sporadic
and hereditary forms of CRC, respectively, [Niv, 2007; Fukuyama et al., 2008]).
Sporadic and Hereditary forms of the CRC CRC presents in both sporadic and heredi-
tary forms, [Cunningham et al., 2010; Al-Sohaily et al., 2012; De Matteis et al., 2013]. Most
cases are sporadic, (≈ 85% of total cases, [Half et al., 2009]), with major groups associated
17While benign refers to non-cancerous modifications/ features, malign indicates cancer presence.
18The liver and lungs are the most-affected organs by colorectal metastasis
19TP53: Tumour Protein p53, [Safran et al., 2010]
20APC: Adenomatous Polyposis Coli, [Safran et al., 2010]
21RASSF1A: Ras-associated domain family member 1, [Safran et al., 2010]
22KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, [Safran et al., 2010]
23BRAF: v-raf murine sarcoma viral oncogene homolog B
24MGMT: O6-methylguanine-DNA methyltransferase, [Safran et al., 2010]
25MCC: Mutated In Colorectal Cancers, [Safran et al., 2010]
26MLH1: MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli), [Safran et al., 2010]
21
with i) chromosomal instability, (CIN), and ii) hypermethylation at CpG islands of differ-
ent gene promoters, (i.e. the CpG Island Methylator Phenotype (CIMP)). The hereditary
category includes primarily i) Familial Adenomatous Polyps (FAP), ii) Lynch syndrome, (or
Hereditary nonpolyposis colorectal cancer (HNPCC)), and iii) MYH-Associated Polyposis,
(MAP), which has been recently detected and presents similar characteristics to FAP. Major
characteristics of the CRC types are briefly summarised also in Table B.2, in Appendix B.
2.6.1 Major intestinal crypt phenomena
Two major phenomena, which are exhibited in the intestinal crypt cycle, are ‘crypt fission’,
(i.e. longitudinal crypt division, producing two daughter crypts, [McDonald et al., 2006]),
and the ‘bottleneck effect’. Crypt fission, (caused by doubling the stem cell number at the
crypt base, [Jin et al., 2009]), is considered to be a rare event in normal intestinal tissue,
with time to occurrence estimated to be around 25 years for the human colon, [Graham
et al., 2011]. Increased crypt fission incidence is considered to facilitate tumour expansion,
[Brittan and Wright, 2004], and has been linked to colon adenoma risk, [Preston et al., 2003;
Chen et al., 2005; Humphries and Wright, 2008]. Over an intermediate time-interval, (ap-
proximately 8.2 years for normal human intestinal tissue), the stem cell number decreases
to a single stem cell, which is capable of regenerating the entire crypt, [Yatabe et al., 2001;
Brittan and Wright, 2002; Sancho et al., 2003; de Lau et al., 2006; van der Flier and Clevers,
2009]. Denoted as the ‘bottleneck effect’, this phenomenon also has been suggested to be a
tumour promotion mechanism, given that - if mutated, the original stem cell transmits the
abnormal changes to the entire cell population during cell division. Due to a growth advan-
tage bestowed by mutations on an aberrantly changed stem cell, there is a higher probability
for a crypt to be populated with cells descending from a mutated stem cell rather than from
a normal one, [Leedham and Wright, 2008]. However, if the mother-stem cell is a normal
cell, a healthy crypt will be regenerated.
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2.6.2 Risk factors for CRC development
Cancer is considered to be a class of diseases that affects mostly older people, [Christensen
et al., 2009], (e.g. more than 60% of diagnosed cancer cases are people aged 65 years and
more), and is rarely found in children and young adults, [Cancer Research UK, 2014a]. As
shown in Figure 2.4, CRC incidence increases during ageing, for both genders. CRC pre-
disposition is also influenced by other characteristics, such as gender, [Brenner et al., 2007],
personal and familial cancer history, [American Cancer Society, 2013], physical activity,
diet, [Cancer Research UK, 2014d], and environmental factors, [Hou et al., 2012]. These
features are referred as ‘risk factors for cancer development’, with potential to increase the
chance for an individual to develop malignant tumours. Risk factors are typically denoted
personal, (i.e. can not be changed), and external (i.e. lifestyle-related) categories; several
of those associated with CRC development are discussed further.
Figure 2.4: CRC incidence rate world-wide for both genders, i.e. males (blue color) and
females (red color). The incidence rate of CRC development increases during ageing. In
addition, male predisposition to CRC can be observed. Source: GLOBOCAN 2012 - In-
ternational Agency for Research in Cancer (IARC) - http://globocan.iarc.fr/, [Ferlay et al.,
2014].
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Personal risk factors Due to influence on molecular signals (genetic and epigenetic),
ageing is considered to be a major risk factor in cancer initiation and progression, [Fraga
and Esteller, 2007]. Studies have reported that DNA methylation and histone modifications
accumulate progressively over time, e.g. Fraga et al. [2007]. CRC incidence increases
markedly after age 50, with the highest rate observed between the ages 65-75, [SEER,
2013a]. Four age groups, distinguished in cancer statistics, are given, (e.g. [SEER, 2013a;
Cancer Research UK, 2014a; Ferlay et al., 2014]), based on common features observed in
tumour initiation and progression, (with a focus on CRC incidence rate˜). These are age
ranges (0 - 14) + (15 - 29): children and young adults; (30 - 49): adults in middle-age; (50
- 74): older adults; (75+): elders. The Table describing characteristics of these groups is
given in Appendix B, (see Table B.3), and includes key study references.
Moreover, in recent decades, a range of experiments has been developed to investigate
age-related methylation leading potentially to abnormal methylation patterns and malig-
nant tumour development. A list of genes, identified as sensitive to age-related methylation
in different cancer types, include, for example, insulin-like growth factor II (IGF2), myo-
genic differentiation 1 (MYOD1), paired box 6 (PAX6), tumor protein p73 (TP73), secreted
frizzled-related protein 1 (SFRP1) genes in CRC, Hypermethylated in Cancer 1 (HIC-1)
gene in prostate and brain tumours, and estrogen receptor (ER) and N33 in colon and liver
diseases, (Issa and Ahuja [2000]; Teschendorff et al. [2010]).
In addition, gender has been reported in the literature as important in colon cancer
initiation, [Brenner et al., 2007]. Studies have shown that the risk of developing colon
cancer is greater for males than for females, [Ogino et al., 2006b; Cancer Research UK,
2014a], with an approximate 5-year difference between genders suggested for initiation of
CRC screening, [Brenner et al., 2007; Frank, 2007], (illustrated in Figure 2.4).
According to Knudson [2001], multiple successive ‘hits’ are required to transform a
normal cell into an abnormal one: fewer mutations are thus needed to produce malignancies
if some changes are already inherited. The impact of heredity in cancer can be measured
by the familial relative risk ratio27 coefficient. Heritable tendencies have been identified
27The highest RR was reported for breast cancer (RR=2.02), followed immediately by those for lung (RR
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for cancers of the colon, breast, lung and others, [Risch and Plass, 2008], as well as for
skin melanomas, [Hemminki et al., 2003]. While familial cancer is less common than
spontaneous manifestations, genetic patterns are gradually being established, which may
contribute to the identification of those at greater risk.
Finally, individual characteristics such as personal history of CRC and the presence of
inflammatory bowel disease, are also associated with an increased risk of CRC develop-
ment, [Canavan et al., 2006; Burt et al., 2010; Baumgart and Sandborn, 2012].
External risk factors The significant impact of viral and bacterial infections on human
tumours has been highlighted in many recent studies, [Carrillo-Infante et al., 2007; Samaras
et al., 2010]. Viruses, such as human papilloma (HPV), hepatitis B, and Epstein-Barr have
been associated with cancer initiation, [Carrillo-Infante et al., 2007], due to their capacity to
damage normal cell control in the infected organisms by inducing unscheduled cell growth
and by avoiding apoptosis. In Perrin et al. [2010], the authors have shown that Helicobacter
pylori plays a key role in gastric cancer development owing to aberrant increase of DNA
methylation level in gastric cells. Further, in Antonic et al. [2013], the authors reviewed
several bacteria (e.g. Streptococcus bovis, Helicobacter pylori) and viruses, (e.g. John
Cunningham virus (JC virus)), which have been associated with the CRC phenotype. The
involvement of the Fusobacterium bacteria also in CRC was recently suggested, [Kostic
et al., 2012; Antonic et al., 2013; McCoy et al., 2013].
Discussions on the impact of environment and lifestyle on cancer development have
also featured in the literature, [Hou et al., 2012; Cancer Research UK, 2014g]. For instance,
tobacco usage has been associated with a fifth of all cancer cases in the UK, according to a
report published in December 2011, [Cancer Research UK, 2014f], and is considered to be
a major risk factor in the development of malignancies, [Giovannucci, 2001; Sasco et al.,
2004; Mucha et al., 2006; Zisman et al., 2006; Irigaray et al., 2007]. In addition, excessive
alcohol consumption increases the probability of developing different cancer types, such as
oral cavity, pharynx, oesophagus, liver, breast cancer, and is considered to be a high risk
≈2.00) and prostate cancer with RR=1.89 (Risch and Plass, 2008).
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factor in colon cancer, [Zisman et al., 2006], where it has been associated with aberrant
changes in DNA methylation, [Davis and Uthus, 2004]. Moreover, lifestyle characteristics
such as lack of physical activity, high fat diet, have been associated with an increased risk
of CRC development also, [Slattery et al., 2003; Irigaray et al., 2007; Watson and Collins,
2011].
Finally, chemicals such as arsenic and cadmium have been highlighted as carcinogens28
for CRC since exposure to these substances can induce epigenetic alterations in cells, (e.g.
global DNA hypomethylation), leading to colon cancer, [Hou et al., 2012]. In consequence,
studying the impact of risk factors on different molecular mechanisms can improve under-
standing of tumour pathways and aid in the search for treatment strategies, but is a major
challenge.
2.7 Epigenetic therapies
Although first postulated by Waddington in 1942, epigenetic alterations have only become
a focus of interest in cancer research relatively recently, due to their potential use in diag-
nostics and cancer therapy. Epigenetic drugs may be useful not only for cancer, but also
for other human diseases, (e.g. neurodegenerative disorders˜, [Abel and Zukin, 2008; Ur-
dinguio et al., 2009]). The aim is to find small chemical compounds that can bind specific
epigenetic modifications, inhibit their function and reverse the epigenetic process, [Min-
ucci and Pelicci, 2006]. Based on usage and activity, epigenetic inhibitors are classified
into five major groups including: (i) DNMT, (ii) HMT, (iii) HDAC, (iv) HAT and (v) HDM
Inhibitors.
Epigenetic drugs already approved by U.S. Food and Drug Administration include
inhibitors for DNMT (e.g. vidaza and decitabine) and HDAC, (e.g. vorinostat and ro-
midepsin), which are used for blood cancer, [Kaminskas et al., 2005; Richon, 2006; Rodrı´guez-
Paredes and Esteller, 2011]. Additional drugs, which target for example HDM, HAT, HMT,
are currently undergoing clinical and preclinical trials, (Lohse et al. [2011]; Santer et al.
28Carcinogen: an agent with direct involvement in causing cancer
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Figure 2.5: Epigenetic drugs and their epigenetic targets in cancer therapy. Note: suffix ‘i’
refers to ‘inhibitor’, (e.g. DNMTi = inhibitor for DNA methyltransferases, (DNMT)) and
SIRTi refer to sirtuins inhibitors, a class of HDACi. Reprinted by permission from Macmil-
lan Publishers Ltd: Nature Medicine, (Rodrı´guez-Paredes and Esteller [2011]), copyright
(2011).
[2011]; McCabe et al. [2012], respectively), illustrated in Figure 2.5.
Epigenetic therapy is an active research area in pharmaceutical companies, where the
focus is on development of both active formulations and strategies that aim to minimize
the potential side-effects of epigenetic drug usage and extend patient survival, [Azad et al.,
2013]. In addition, the combination of epigenetic therapy with other cancer treatment ap-
proaches, (e.g. standard chemotherapy˜), is anticipated to have an high impact on cancer
mechanisms, [Azad et al., 2013]. Efforts are also ongoing currently for identification of
combined epigenetic drug treatment that can be applied in a large number of malignant
tumours as well as to other disorders with epigenetic alterations, [Stein, 2014].
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2.8 Summary
Figure 2.6: Overview of cancer mechanisms discussed
This chapter focused on presenting the biological background (on Epigenetics and CRC
dynamics), which is fundamental to understanding the features to be represented in the
development of appropriate computational models. Specifically, the aberrant mechanisms
leading to CRC development were discussed for three major system layers, (illustrated in
Figure 2.6), and including:
• micromolecular, (e.g. genetic and epigenetic events, signalling pathway);
• cellular, (e.g. cell cycle, stem cell property);
• tissue, (e.g. the intestinal crypt).
In addition, the influence of different risk factors, (e.g. ageing, lifestyle characteristics),
was briefly reviewed in relation to CRC initiation and progression. The mechanisms de-
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scribed in this Chapter can be applied to other cancer types as well. For example, heredity
has been reported to have a high impact on breast and lung tumours; for lung, the risk of
malignancy development can be increased by around 50% for people having a sibling or
a parent diagnosed with lung cancer, with the risk marked in the former compared to the
latter cases, [Cancer Research UK, 2014e]. Having a first degree female relative affected by
breast cancer can double the chance of tumour development. In these conditions, screening
tests are recommended to start several years earlier than for groups with no such familial
history, [American Cancer Society, 2013; Cancer Research UK, 2014c; NICE - National
Institute for Health and Care Excellence, 2014].
Major types of CRC, (e.g. sporadic, FAP), and the cancer staging system were also
summarised. The state-of-art with respect to therapies based on epigenetic inhibitors, to-
gether with the challenges of epigenetics-based strategies in cancer treatment, were briefly
outlined. The overview of major aspects of cancer, its development and treatment, is nec-
essarily limited but aims to provide the platform required to motivate and inform the com-
putational approach.
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Chapter 3
Modelling background and context
3.1 Introduction
Cancer research has become a multi-disciplinary area involving collaboration among ex-
perts from a large array of scientific fields including biology, medicine, physics, chemistry,
psychology, engineering and not least mathematics and computer science. The term of ‘P6’
- i.e. Participatory, Personalised, Predictive, Preventive, Psychocognitive and Public1 - has
been proposed for describing the recent perspective of cancer medicine, [Bragazzi, 2013].
Computational and mathematical models can help by crossing the boundaries of in vivo
and in vitro experiments caused by the complexity of the features, specific to malignant
systems, and can facilitate understanding of the aberrant mechanisms involved in tumour
pathways. Cancer dynamics exhibit a range of spatial and temporal scales; for example,
while micromolecular modification can occur at nanosecond scales, cancer development
needs several years or decades, [Deisboeck et al., 2011]. Computational simulations can
permit exploration of carcinogenesis specifics in real-time, thus, contributing to advances
in cancer research.
1participatory = keeping the patient continuously informed with regard to their disease status and avail-
able treatment options; personalised = the therapeutic program tailored to individual patient characteristics;
predictive = predicting disease initiation and progression based on e.g. DNAm level information, (discussed
in Section 3.4; preventive = informing on risk of tumour development based on different individual features,
(e.g. familial cancer history), and monitoring their healthy state; psycho-cognitive = providing qualified guid-
ance and psychological support to patients; public = sharing information related to diseases and treatments on
Internet through specialised websites and organizations.
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This chapter provides a review of computational approaches in Cancer Epigenetics and
aims to establish the potential for development of hybrid multi-scale models for genetic and
epigenetic dynamics in CRC. An overview of the major topics discussed here is illustrated
in Figure 3.1, and the structure of this chapter is as follows. A brief description of the
Cancer research context, (including recent world-wide initiatives, several commonly-used
technologies and methods for DNAm and HM analysis and a set of Genetics and Epigenet-
ics resources), is included in Section 3.2. Concept formalism and examples are provided for
several computational and mathematical approaches, (including Bayesian Network, Agent-
based, Logistic and Multiscale modelling), used to investigate aberrant modifications at
different scales, (i.e. micromolecular, cellular and tissue levels), leading to disease devel-
opment, (Section 3.3). These modelling approaches were considered from the perspective
of their applicability to human intestinal systems. In addition, epigenome-wide associated
studies - a recent trend in Cancer Epigenetics research - is addressed in Section 3.4. Fi-
nally, several issues for Computational Epigenetics, which are noted to arise in the context
of CRC initiation and progression, are indicated in Section 3.5, and the Thesis focus stated.
A brief summary is given in Section 3.6.
3.2 Cancer Research context: brief presentation
3.2.1 World-wide projects on Genetics and Epigenetics
Following complete sequencing of the Human Genome, the investigation of the Human
Epigenome has become a major area of interest in Cancer research, [Collins et al., 2003;
Eckhardt et al., 2004; Jones and Martienssen, 2005; Esteller, 2006]. The Human Epigenome
Pilot Project2, which revealed information on DNAm patterns in human chromosomes 6,
20 and 22 in different tissues, [Eckhardt et al., 2006], established the feasibility for devel-
oping Epigenome projects at large scale. Since then, a considerable number of large-scale
initiatives, aimed at detection and interpretation of the epigenetic markers in normal and
2The Human Epigenome Pilot Project was launched as a scientific collaboration between the Wellcome
Trust Sanger Institute (United Kingdom), Epigenomics AG (Germany) and The Centre National de Gnotypage
(France), in early 2000. url: http://www.epigenome.org/index.php?page=pilotproject.
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Figure 3.1: Overview of major topics related to Cancer Systems discussed in Chapter 3
The i) Input and ii) Output components correspond respectively to i) Research Questions
& Objectives given the Biological context, (i.e. Chapters 1 and 2), and ii) Main findings,
(addressed in Chapter 8).
malignant human systems, has been launched. Several of these world-wide efforts are pre-
sented briefly in the next paragraphs and information on a list of Epigenetics resources
consulted for this Thesis is included in Table C.1, (Appendix C).
Large amounts of epigenetic data are becoming available and a recent direction in can-
cer research is represented by the identification of common genetic and epigenetic features
among various cancer types and the integration of such micromolecular modifications in
strategies for tumour progression, diagnosis and treatment, [Ashworth and Hudson, 2013].
For example, the Encyclopaedia of DNA Elements (ENCODE)3 project focuses on the anal-
ysis of the functional elements, (e.g. histone modification), in the human genome, while the
3ENCODE project started in 2003 funding from the National Human Genome Research Institute; url:
http://encodeproject.org/ENCODE/
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Roadmap Epigenomics Project4 and the BLUEPRINT Epigenome Consortium5 aim to ex-
plore the epigenetic landscape in stem cells and blood tissues, respectively, [Bernstein et al.,
2010; Adams et al., 2012; ENCODE Project Consortium, 2012]. In addition, epigenome
studies in 250 cell types are being conducted under the direction of the International Human
Epigenome Consortium (IHEC)6 and comprehensive analyses on micromolecular modifica-
tions in around 50 cancer types have been performed by the International Cancer Genome
Consortium (ICGC)7, [Jones et al., 2008; Hudson et al., 2010]. Moreover, through the
The Cancer Genome Atlas (TCGA)8 efforts, detailed characterisations are available for
the genetic and epigenetic markers involved in a wide array of human cancers, includ-
ing the ovarian, lung, colorectal, breast, endometrial, and renal malignancies, as well as for
acute myeloid leukemia, (e.g. Cancer Genome Atlas Research Network [2011, 2012a,b,c,
2013a,b,c]). As an illustration: from these data, a set of 127 significantly mutated genes in
malignant systems has been identified in a study on 12 cancer types, (described in Kandoth
et al. [2013]).
Translational medicine, which aims to reduce the gap between research and real treat-
ment options and to improve the collaboration between academia and industry in order to
achieve this, is another recent direction in Cancer Research. The Innovative Medicines Ini-
tiative (IMI)9 is considered the largest initiative between private and public sectors within
Europe and contains around 47 projects, including OncoTrack, among others, [Kamel et al.,
2008]. The OncoTrack10 project combines information on genetic and epigenetic events
specific to CRC with diverse computational modelling strategies targeted to identification
of biomarkers that can be used in personalised therapy regimes and also in prognostic strate-
gies for CRC, [Elsner, 2011].
These world-wide initiatives also involve rapid advances in high-throughput technolo-
4Roadmap Epigenomics Project: url: http://www.roadmapepigenomics.org/
5BLUEPRINT-Epigenome Consortium (2011): url: http://www.blueprint-epigenome.eu.
6IHEC: (launched in 2010); url: http://ihec-epigenomes.net/.
7ICGC (launched in 2008): url:https://icgc.org/.
8TCGA Project (launched in 2005); url: http://cancergenome.nih.gov/.
9IMI was launched in 2008 under the European Union and the European Federation of Pharmaceutical
Industries and Associations; url: http://www.imi.europa.eu/content/home.
10OncoTrack: url: http://www.oncotrack.eu/.
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gies, (e.g. microarrays and next-generation sequencing (NGS)), used for genomics and
epigenomics data analysis; thus, information on micromolecular events at genome-wide
scale is now more accurate and more efficiently-obtained (from both cost and duration per-
spectives) than several years ago. However, differences between microarrays and NGS are
evident and any choice of technology must consider limitations and advantages of applica-
tion type. For example, while NGS can explore larger areas in shorter time-periods than
microarrays, the former are more expressive than the latter, [Metzker, 2009]. Excellent
recent reviews of the features of these technologies are included in Harrison and Parle-
McDermott [2011]; Rivera and Ren [2013]; Soon et al. [2013] and references therein, and
an overview of NGS-based technologies applied to epigenetic events patterns is illustrated
in Figure 3.2. While full discussion of epigenetic technologies is beyond the scope of this
Thesis, the next subsection aims to provide a summary of the most common techniques
applied to investigate DNA methylation (DNAm) and histone modification (HM).
Figure 3.2: A summary of the NGS-based technologies developed for epigenetics analyses
over the recent years. Reprinted from Cell, Vol. 155 (1), Rivera, C.M. and Ren, B., Mapping
Human Epigenomes, Pages No. 39-55, Copyright (2013), with permission from Elsevier.
3.2.2 Techniques and methods for DNA methylation and histone modification
assay
Given their importance both in normal human system operation, (e.g. cell differentiation),
and abnormally perturbed systems, (e.g. cancer), DNAm and HM have been intensively
studied from both quantitative and qualitative perspectives over recent years, [Coleman and
Rivenbark, 2006; Soon et al., 2013]. Several of the principal technologies used to explore
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these epigenetic mechanisms are described in the next paragraphs.
Methods for DNA methylation analysis DNAm analysis is highly dependent on the
goal of the study, so that methods applied focus on two major directions, namely gene
specific and genome-wide methylation, [Esteller, 2007; Shen and Waterland, 2007]. A
classical method for global DNA methylation quantification is High-performance liquid
chromatography, (HPLC). Although highly-reproducible, HPLC requires large amounts of
DNA, [Oakeley, 1999], so a most important development in DNAm analysis (and in can-
cer epigenetics), was the ‘bisulfite’ approach. Specifically, unmethylated cytosine from a
DNA sequence is transformed to the corresponding uracil base after sodium bisulfite appli-
cation and can be separated further by methylated cytosine, [Esteller, 2007]. In addition,
the bisulfite treatment combined with e.g. the polymerase chain reaction, (bisulfite PCR)
can approximate global DNAm levels using relatively little DNA, [Esteller, 2007], and can
measure PMR (the percentage of methylated reference or degree of methylation) for a spe-
cific gene in malignant systems, [Ogino et al., 2006a]. A quantitative real-time PCR method
(MethyLight) was introduced to assay the promoter methylation degree for different genes,
(such as MGMT, MLH1, CDKN2A:p16 in colon cancer), [Ogino et al., 2006a]. Alterna-
tively, the PMR average (PMRA) measurement can be applied in some experiments, where
PMR values for a specific gene show variation across multiple runs, [Coleman and Riven-
bark, 2006]. Recently, genome-wide DNAm investigations have proved possible through
NGS-based methods such as reduced representation bisulfite sequencing (RRBS), MethylC-
seq, methylated DNA immunoprecipitation, (MeDIP-seq), which benefit from the paralleli-
sation strategies specific to NGS technologies, (reviewed in Rivera and Ren [2013]; Soon
et al. [2013]).
Methods for Histone modification analysis Two major approaches used for HM anal-
ysis are I) Mass Spectrometry, which requires histone digestion, (reviewed in Witze et al.
[2007]), and II) Chromatin immunoprecipitation (ChIP), which can be applied for i) gene-
specific analysis, e.g. ChIP-qPCR, or ii) genome-wide analysis, e.g. ChIP-chip, (ChIP
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combined with microarrays), ChIP-Seq, (i.e. ChIP combined with NGS technologies). Of
fairly recent introduction, ChIP-Seq is considered a powerful and efficient technique given
its fast processing-time and genome-accessibility features, (reviewed in Schones and Zhao
[2008]).
Large amounts of data on genomics and epigenomics are being generated in Cancer re-
search and collective efforts are being made to integrate this information in specialised
resources, with a view to dissemination through the scientific community. Several of these
important databases related to cancer mechanisms are reported in the next subsection.
3.2.3 Databases on genetic and epigenetic events
Over the last few decades, databases that focus on aspects of tumour pathways have in-
creasingly been developed and populated. These include major resources such as i) Gene
Expression Omnibus (GEO)11, ii) KEGG PATHWAY12, and smaller dedicated efforts, de-
veloped by localised groups, such as iii) Embryonic Stem Cells Database, (ESCDb)13 and
iv) StatEpigen14, and some of them are briefly described in the next paragraphs as such data
constitute the primary support for information on cancer mechanisms, considered for the
Colorectal Cancer Model presented in this Thesis. Information on a more comprehensive
list of databases consulted for the current project is included in Table C.2, (in Appendix C).
GEO is a large public repository on genomic and epigenomic data generated by high-
throughput technologies and contains two major components, namely GEO DataSets, (stor-
ing both original and curated data), and GEO Profiles, (providing only curated information).
Data retrieval is facilitated by an advanced searching system that integrates attributes such
as author, studied organism, type of the applied technology and targeted gene name.
KEGG PATHWAY is a database-component from the Kyoto Encyclopedia of Genes
and Genomes (KEGG) resource, containing data on pathways involved in different human
11GEO is developed by the National Center for Biotechnology Information, US.
12KEGG PATHWAY is developed by the Kanehisa Laboratories, Japan.
13ESCDb is developed at the Bioinformatics, Algorithmics, and Data Mining Research Group, Estonia, [Jung
et al., 2010]. url:http://biit.cs.ut.ee/escd/
14StatEpigen was developed by SCI-SYM Research Center, Dublin City University, Ireland.
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diseases. KEGG resource includes a collection of databses that provide information at
molecular, gene and system levels in addition to data on drug and human diseases, (e.g.
KEGG GENE, KEGG DRUG, KEGG DISEASE, reviewed in Kanehisa et al. [2014]).
StatEpigen is a manually - curated database that has been designed to provide specific
information on conditional relationships between genetic and epigenetic events affecting
various genes at different pathology phenotype levels, [Barat and Ruskin, 2010]. Although
currently specialised to colon cancer research, StatEpigen also contains data on other cancer
types, (such as stomach, lung, liver).
In this section, an overview of the context, world-wide of Cancer Epigenetics research
in recent years, was provided. In addition to improving technologies and generating mi-
cromolecular event data, a number of computational and mathematical models has been/ is
being developed in order to explore human cancerous systems. The next section elaborates
on some of these modelling approaches, applied to biological systems, but specifically as
these can be used to address CRC development.
3.3 Previous Model development and related analyses
Computational and mathematical approaches can be applied to translate biological ques-
tions into formal algorithmic languages and to explore various hypotheses related to both
normal and abnormal biological systems. This can help understand the aetiology of com-
plex diseases and their evolution and to propose new research directions and therapeutic
strategies. Major classes of mathematical and computational models include i) discrete
versus continuous (depending on the way of changing variable states, i.e. at specific time
points or continuously over time), ii) static versus dynamics, (given by system property of
evolving over time), iii) deterministic versus stochastic (probabilistic) models; (if a model
does not include any probabilistic component is considered deterministic; otherwise, it is a
stochastic model). Stochastic models are used for prediction and estimation, (given that the
outcome is random), and are developed using methods such as Markov chain, Monte Carlo,
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Bayesian network, (reviewed in Wilkinson [2009]).
Various modelling approaches, (including construction of Boolean and artificial neu-
ral networks; support vector machines and K-nearest neighbours; Bayesian methods and
decision trees; agent-based and multi-scale modelling), have been applied previously to
investigate the complexity of tumour phenomena, (reviewed in e.g. Bock and Lengauer
[2008]; Tracqui [2009]; Lowengrub et al. [2010]; Lim et al. [2010]; Rejniak and Anderson
[2011]; De Matteis et al. [2013]; Johnson et al. [2013]; Wang et al. [2014]). Details for
several of these, (including Bayesian network, agent-based, logistic and multi-scale mod-
els), are presented briefly in this section, as these constitute the basis for the computational
components developed in this Thesis. Specifically, in targeting the ultimate objective of
investigating colorectal tumorigenesis by linking microscopic effects to macroscopic out-
comes, the Bayesian network is the fundamental layer of the E-G Network Model, (Chap-
ters 4 and 5), the agent-based model approach describes the dynamics of the AgentCrypt
model, (Chapter 6), and logistic modelling features have been integrated in LogisticCrypt,
(Chapter 7). Examples of models, based on similar principles, that have been applied to
other biological systems are also provided.
3.3.1 Bayesian Network
Concept formalism A Bayesian network, (BN), is effectively a probabilistic graphical
model that describes joint and conditional probability distributions for a set of variables X
= (x1, x2, .., xm). Formally, P(xi | xj) is interpreted as the probability of xi given xj , (xi,
xj ∈ X), [Heckerman, 1998; Lucas et al., 2004]. The network is graphically represented
by a directed acyclic graph, where each node represents a variable or group of variables.
A directed edge, (i.e. an arrow), between two nodes signifies conditional dependence be-
tween the variables, [Heckerman, 1998; Lucas et al., 2004]. Additionally, the absence of
an arrow between two nodes indicates that no reliable information is available on the con-
ditional relationship between those variables, [Lucas et al., 2004]. A node ni is defined to
be the parent for node nj if there is a direct influence between ni and nj , illustrated by an
arrow ni −→ nj in graph, (with the set of parents for the node nj denoted as Parents(nj)).
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Consequently, the node nj is referred as a child for ni. The probability values of the con-
ditional dependencies between a node child and its parents are defined by a conditional
probability table. A BN follows the Markov assumption such that a variable depends only
on its parents, i.e. is independent of the rest of the variable set. Thus, the formula used to
describe the joint probability among a set of variables, X = (x1, x2, .., xm), can be simplified
as follows:
P (X) =
∏
i=1,m
P (xi | Parents(xi)) (3.1)
where the index i = 1..m runs over all m nodes in the BN. An example of a (very simple) BN
for a set of five variables, (A, B, C, D, E), is illustrated in Figure 3.3. Considering formula
3.1, the probability for the given variable set is:
P (A,B,C,D,E) = P (C| A)× P (D| A, B)× P (E| D)× P (A)× P (B) (3.2)
Figure 3.3: An example of a small Bayesian network
The BN approach can encode conditional relationships between genes, allowing in-
tuitive representation for input data, as well as handling noisy and incomplete data sets,
(common to biological systems). In addition, BN can handle continuous, (non-integer) val-
ues in the [0, 1] range, while a Boolean network can integrate only discrete (and binary)
values. However, during framework development for any realistic problem, a BN requires
initial knowledge of many probabilities, [Heckerman, 1998], and it is limited by exclusion
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of cycles, (see definition); so that, during development, methods for cycle avoidance and
removal must also be considered. Nevertheless, ab initio models based on BN-approaches
have been developed to investigate diverse research questions and hypotheses. Some exam-
ples follow.
Examples of BN models BN models have been applied successfully in different fields
requiring diagnosis or forecasting, e.g. Heckerman et al. [1995]; Lucas et al. [2004], and
where prior knowledge on data causality was available. In biomedicine and bioinformatics,
such approaches have been used for prediction of i) protein-protein interactions in yeast
and in other model systems, based on both homogeneous and heterogenous data types, (e.g.
Jansen et al. [2003]; Troyanskaya et al. [2003]; Browne et al. [2009]); ii) functionality for
a newly-identified set of proteins in the Drosophila system, [van Bemmel et al., 2013], and
iii) mutation interdependencies in different cancer types, [Gerstung et al., 2009], amongst
others. In addition, BNs have been constructed to study conditional relationships between
different protein types found in chromatin, (e.g. van Steensel et al. [2010]), in various his-
tone modifications, (e.g. in S. cerevisiae, [Cui et al., 2011]), between histone methylation
and gene expression, (e.g. Yu et al. [2008]), between gene expression levels, [Friedman
et al., 2000; Hartemink et al., 2002; Pe’er et al., 2002], and to compare HM and DNAm pat-
terns at CpG islands, (e.g. Kim and Jung [2009]; Lv et al. [2010]). The BN approach has
been applied also for improving protein-protein interaction prediction using Gene Ontology
hierarchies, [Wang et al., 2010], for estimating DNAm levels using data from experiments
based on the methylated DNA immunoprecipitation technologies, [Down et al., 2008], as
well as for identifying miRNA profiles specific to certain cancer types based on compara-
tive analysis of 51 solid cancers and leukaemia, and corresponding samples from normal
tissues, [Volinia et al., 2010]. Moreover, BN models have been used to address cancer
type-specific hypotheses; for instance, in breast cancer, for predicting microcalcifications
15, (e.g. Burnside et al. [2006]), assisting mammography results and investigating cancer
risk development, (e.g. Rubin et al. [2004]; Cruz-Ramı´rez et al. [2007]; Maskery et al.
15Tiny abnormal flecks that usually appear in the female human breast and can be a cancer indicator
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[2008]).
3.3.2 Cellular Automata & Agent-based Model
Given the relationship between Cellular Automata and Agent-based Modelling, the compu-
tational approach is described for both as follows.
Concept formalism The Cellular automaton (CA) is a discrete model usually visualised
as a set of identical cells, which are distributed on a one, two or many-dimensional grid
and can be found in a discrete and finite number of states. At each time-step, every cell
changes its state as a result of a transition rule, which takes into account its previous state
and information received from its neighbours. One well known and early 2D CA appli-
cation is Conway’s “Game of Life”, where cells can be found in two states, namely alive
and dead, and have eight neighbours each, [Conway, 1970]. In this example, the state of
a cell is decided based on the number of its neighbours; for example, a live cell with less
that two neighbours dies, while one with exactly two lives. Obliviously, there are many
interpretations of this Game and the basic concept was used at an early stage to describe
e.g. competition among species, different models of propagation and similarly, (e.g. Sil-
vertown et al. [1992]; Sirakoulis et al. [2000]). Abundant examples occur in nature, in
seashell patterns, leaf gas exchange and other plant dynamics, in physical phenomena such
as avalanche and sandpiles formation, (e.g. Peak et al. [2004]; Kronholm and Birkeland
[2005]; Cervelle et al. [2007]; Coombes [2009]). Indeed the question has also been raised
at to whether The Universe is a CA and there are a number of supporters of CA-physics.
Importantly, the cellular automata concept has also found many applications in information
theory and at Biology - Computer Science interface, whether e.g. in database searching,
in evolutionary & genetic algorithms, in detection of errors, (reviewed in Ganguly et al.
[2003]). CA models are deterministic models and a significant extension was introduction
of stochastic CA, where rules are updated based on probabilities. Stochastic CA models
have been developed recently to describe e.g. cell dynamics and infection spread, [Garijo
et al., 2012; Duan et al., 2013]). In consequence, the flexibility of the CA approach for
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multi units/ cells is well-established.
An extension to CA concepts, agent-based modelling (ABM) refers to the representation
of a system by its constituent basic units to which attributes can be assigned. ABM is a
discrete and dynamic approach that describes interactions between individuals, taking into
account also their features and environment influences. Specifically, ABM can be applied
to heterogeneous complex systems, described by the following typical characteristics: i)
large number of different types of entities, (denoted as agents); ii) agent interaction, (or
‘social’ ability): agents can exchange different types of information, (e.g. information on
their location, internal state); iii) agent autonomy, (decision-making capability): agents can
operate without intervention from user, i.e. they have a degree of self-determination with
respect to their actions; iv) agent reactivity: agents can respond to stimuli received from
their environment, (e.g. can change their position) and v) agent adaptation: agents follow
an adaptive process, (or self-learning capability), [Bandini et al., 2009; Macal and North,
2010] and references therein.
In biology, there is often a need to describe basic processes that direct individual ac-
tions, (e.g. cell division, migration), and to aggregate these in order to understand higher
level dynamics, (e.g. tumour spread to other locations). ABM provides a natural manner
to characterise complex heterogeneous system behaviours following a bottom-up approach
and can also integrate emergent phenomena. In addition, ABM is flexible as agents can
be both ‘rational’ and ‘adaptive’, (can evolve) and can generate new hypotheses. Disad-
vantages of ABM include the need of detailed knowledge of individual behaviour as well
as of assumptions on which behaviour aspects are crucial for overall system investigation
and which can be ignored. In addition, considerable computational expertise is required for
ABM development and significant time has to be allocated for computational simulation
run, given that large systems of e.g. thousands or million of agents can be also modelled
using this approach.
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Examples Over recent decades, CA, (extended form to permit more than two possible
states for cells) and ABM methods have been applied to explore dynamics of different
biological systems including immune systems response to viral infections including HIV16
and M. tuberculosis, (e.g. Mannion et al. [2000]; Ruskin et al. [2002]; Segovia-Juarez
et al. [2004]; Perrin et al. [2006a,b]), drug dissolution, (e.g. Barat et al. [2006]; Bezbradica
et al. [2014]), and human tumour growth, (reviewed in Hwang et al. [2009] and references
therein). In addition, ABMs have been built to analyse e.g. cell dynamics in systems with
different calcium concentrations, [Walker et al., 2004], abnormal stem cell proliferation
caused by APC mutation, [Boman et al., 2001], aberrant methylation and gastric cancer
initiation induced by bacterial infection, [Perrin et al., 2010], and intestinal crypt dynamics,
[Pitt-Francis et al., 2009]. An excellent review for intestinal crypt and CRC applications,
drawing on these modelling techniques, is provided in De Matteis et al. [2013].
3.3.3 Logistic Model
The growth rate of a biological population in an ‘ideal’ environment, (e.g. no limitations of
food or space), is proportional to population size, i.e. a certain number of new individuals
is produced per unit of time. In general, this rate is described by simple differentiation
equations, (first and second order), with population size represented by e.g. exponential
forms, (unconstrained natural growth):
dP/dt = r × P (3.3)
P (t) = P0 × ert
where P = population as a function of time t, P0 = population at time t = 0, and r = the
proportionality constant. In a logistic model, the aim is to define the relations between
the constituent elements in terms of how these affect e.g. growth or decline, constraints
given by e.g. limited space and food resources. Inter- and intra-specific competitions refer,
respectively, to interactions between more than one and within one species using the same
16HIV = human immunodeficiency virus
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resources. Consequently, in the present instance, we define i) intra-specific competition in a
population of cells as relationships between current and maximum cell population size, and
ii) inter-specific competition between more cell type populations in the intestinal crypt as
relationships between current and maximum cell numbers of the whole crypt, (i.e. between
space, currently-occupied by compound cell populations, and crypt capacity). Of interest,
from the viewpoint of work presented here, is the potential to use logistic model to explore
deregulations of cell population size over time leading to increased incidence of major crypt
phenomena such as ‘crypt fission’ and the ‘bottleneck effect’, (Section 2.6), associated with
CRC development risk.
Concept formalism The population with intra-specific competition has been described
mathematically by the density-dependent coefficient, (DDC), [Sinclair and Pech, 1996],
using equation 3.4
DDC =
K −N
K
(3.4)
where N is the population size at a certain time, K is denoted as the carrying capacity (and
represents the maximum allowed size for a species within a specific environment, i.e. has
a constant value in a specific environment), [Hui, 2006]. The rate of population growth
in a system with intra-specific competition is given by the product r × DDC, where r is
the population growth rate in a similar system without intra-specific competition; DDC is
calculated as for Equation (3.4), and takes a value in the [0, 1] range, (given N ≤ K).
Thus, by including the DDC, the population growth rate slows down as population size (N)
increases, i.e. the growth rate depends on the density of the population.
Examples Mathematical models have been built to examine abnormal crypt dynamics,
(reviewed in Van Leeuwen et al. [2006] and references therein), [Nowak et al., 2002; John-
ston et al., 2007], for cell migration mechanisms, (e.g. Simpson et al. [2007] and references
therein), and to investigate stem cell growth, determined by de-regulation in methylation
patterns over time, [Yatabe et al., 2001]. Moreover, considering cancer as a heterogeneous
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complex system (having multiple species), a class of mathematical models, which focuses
on both intra- and interspecific competitions, has been applied in studies for gene therapy,
[Tsygvintsev et al., 2013], tumour-immune cell relationship, [Nagy, 2004], carcinogene-
sis mutations, [Forys´, 2009], and colonic crypt population growth, [Smallbone and Corfe,
2014].
3.3.4 Multi-scale modelling
Concept formalism Multi-scale modelling have attracted increased attention in recent
years as further improvements in computing power have offered the potential to view sys-
tems rather than just components of these. As such, the Systems Biology approach to cancer
research, with the ultimate aim of facilitating investigation and treatment of malignancy is
gaining momentum. Multi-scale descriptions span the micromolecular level, (i.e. genetic
and epigenetic landscape), through molecular and cellular levels, (e.g. signalling pathway
and cell division mechanisms, respectively), to macroscopic scales, (where tumour develop-
ment can be observed), [Deisboeck et al., 2011]. Thus, major advantages of the multi-scale
modelling approach include the possibility of including experimental data at all system
levels, exploring inter-scale phenomena interactions and testing drug effects on the whole
body or organ. Although considered a powerful approach, multi-scale computational mod-
elling presents many major challenges, including the complexity of different temporal and
spatial scales as well as multiple parameters required for system description. Specifically,
both rapid dynamics and small spaces, (with alterations that can occur at nanosecond scales
inside cell nucleus), and low dynamics and large spaces, (e.g. metastasis affecting more
than one tissue, phenotype change over years or even decades), must be accommodated.
Given these demands, different modelling strategies have been used to describe biological
phenomena at various scales. Specifically, network-based models have been developed to
characterise the micromolecular level, ordinary differential equations have been used for
investigations at molecular levels, while both partial differential equations and the agent-
based modelling approach have been applied for exploring mechanisms at cellular level.
Finally, continuous models have been built to describe cell population dynamics at tissue
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level. In consequence, “one size fits all” is an unlikely hypothesis.
Examples Multi-scale models have been developed to explore e.g. the therapeutic impact
of cytostatic agent use in cancer development [Ribba et al., 2006], tumour angiogenesis17,
dynamics of avascular tumour progression over time, alterations during the development of
lung, breast and prostate cancers and brain tumours, (reviewed in Mantzaris et al. [2004];
Peirce [2008]; Tracqui [2009]; Deisboeck et al. [2011]; Chakrabarti et al. [2012] and ref-
erences therein). In CRC research, multi-scale computational models have been developed
for exploring e.g. the aberrant crypt foci18 expansion in both normal and abnormal colon
systems, or relationships between Wnt signalling pathway, cell neighbour influences and
cell cycle activity in intestinal crypts, [Van Leeuwen et al., 2009; Figueiredo et al., 2013].
In a recent multi-scale model for Epigenetics research, [Przybilla et al., 2014], the authors
conclude that alterations in gene transcription and epigenetic inheritance mechanisms may
be a cause of decline observed during ageing in hematopoietic stem cells. In consequence,
developments are exciting, but non-trivial to achieve.
3.3.5 Complexity of Interdependent Epigenetic Signals in Cancer Initiation
The Colorectal Cancer Model, described in this Thesis, was proposed as part of the Com-
plexity of Interdependent Epigenetic Signals in Cancer Initiation, (CIESCI), project, a sci-
entific collaboration between three main partners: the Centre for Scientific Computing and
Complex Systems Modelling, (SCI-SYM)19, School of Computing, Dublin City Univer-
sity, the Bellvitge Institute for Biomedical Research, (IDIBELL)20, Barcelona, (Spain), and
the Bioinformatics, Algorithmics, and Data Mining Research Group (BIIT)21, Institute of
Computer Science and Estonian Biocenter, University of Tartu, (Estonia). The CIESCI
project aimed to investigate interdependencies between epigenetic events related to can-
17angiogenesis = formation of new blood vessels from vessels that exist already; it has been associated to
benign to malign transformation.
18Aberrant crypt foci is a colon tissue phenotype prior to adenomas occurrence that detected with screening
methods.
19SCI-SYM: url: http://sci-sym.dcu.ie/.
20IDIBELL: url: http://www.idibell.cat/.
21BIIT: url: http://biit.cs.ut.ee/.
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cer initiation, incorporating three main elements: i) laboratory experiments (carried out at
IDIBELL); ii) data mining (establishing pipeline and analysis of new data at BITT); iii)
computational models (developed at SCI-SYM).
The SCI-SYM contribution to this project is also linked to other projects on computa-
tional modelling for molecular events in malignant diseases as well as in-depth bioinfor-
matics investigations of curated data from primary and secondary sources, (represented by
the StatEpigen database described in Section 3.2.3). In the former, an agent-based model
was developed by DCU and collaborators to determine the risk of gastric cancer from con-
sideration of the aberrant DNA methylation level induced in cells, following infection with
Helicobacter pylori, [Perrin et al., 2010]. In addition, a framework has been built to give
better insights on interdependencies between micromolecular events, (such as DNAm and
HM), in abnormal situations, [Raghavan and Ruskin, 2011].
Computational and mathematical modelling has been promoted strongly as a powerful
field in Cancer Epigenetics research, [Bock, 2012]. Given recent technological progress,
computational models are needed to explore features of biological systems, which incor-
porate large amounts of data, and to highlight evidence of tumour development. Several
modelling approaches were outlined here, (with a focus on intestinal tumours), demonstrat-
ing that investigation can be performed at single or multiple scales, for specific or general
systems. In additional to offering new insights, results from computational analyses of
initial queries can indicate new therapy strategies and research directions.
3.4 Epigenome-Wide Association Studies
One such new direction is that of EWASs or Epigenome-Wide Association Studies. Major
features and limitations of EWASs are briefly reviewed in what follows, providing mo-
tivation for the cross-comparative computational analysis on DNAm in intestinal tissues,
(Chapter 6).
EWASs aim to detect genome-wide differences in epigenetic marks that can be corre-
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lated with predispositions to cancer development, [Rakyan et al., 2011; Verma, 2012; Mill
and Heijmans, 2013]. Given that DNAm has been reported to be more stable in nature
than histone modification, [Cedar and Bergman, 2009], and that a range of high-throughput
technologies has been developed for DNAm analysis, EWASs have focused mainly on iden-
tification of DNAm differences that can be associated with disease phenotype, [Verma,
2012]. DNAm patterns specifically characterise tissues, [Rakyan et al., 2011], and varia-
tions, reported on measurements performed between tissues within the same individual, (i.e.
intra-individual, inter-tissue), are noted to be much larger than those recorded on the same
tissues, for a group of individuals, (i.e. inter-individual, intra-tissue), [Mill and Heijmans,
2013]. While considered to be a highly promising development, with regard to epigenetic
variation as a cancer biomarker, the EWAS approach faces several difficulties, not least
sample selection. Intrinsic limitations apply to collection of samples from the same group
of patients, especially from internal tissues. In consequence, integrated samples from more
accessible tissues such as blood or buccal, (e.g. Lowe et al. [2013]; Shenker et al. [2013];
Petersen et al. [2014]), have been used to examine the different biological hypotheses to
date. For instance, an association between body-mass index and methylation level varia-
tions has been reported in a recent study performed on blood and adipose tissues, [Dick
et al., 2014]. Thus, given accessibility, white blood count is one of the most commonly
used tissues in EWASs; however, in this case, cell heterogeneity must be considered during
interpretation of DNA methylation analysis findings, [Paul and Beck, 2014]. Another ma-
jor challenge for EWAS viability is selection of the most significant patient-category for a
given research question, (i.e. based on personal characteristics such as ageing and gender,
as well as lifestyle features such as chemical exposure and tobacco usage), [Verma, 2012].
As an illustration from one such study, white blood cell samples for a group of breast and
colon cancer patients, (described in Shenker et al. [2013]), were assessed to investigate the
impact of smoking on epigenetic alterations during cancer development.
Computational modelling offers some possibilities of overcoming these restrictions as
examination of a range of epigenetic patterns and variations in internal tissues over time can
be simulated from available data. The potential for computational comparisons on intra-
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and inter-tissue DNAm variation in the intestinal systems is discussed in the next section.
3.5 Limitations and proposed focus
Although Cancer Epigenetics research is gaining ground, computational models that assim-
ilate information on epigenetic alterations in human malignancies are still relatively few.
One reason for this is that in silico investigations of the epigenetic mechanisms are per-
formed usually for ‘generic’ biological systems. While exploration of common features
among malignancies provides an overview of the tumour pathways, the advantages of can-
cer type-specific models would be development of personalised treatment strategies (aimed
at improvement in therapy efficiency and reduction of drug adversity). Such extended mod-
els would also permit information on individual characteristics (such as ageing and gender)
and on environmental features (such as chemical radiation and tobacco usage) to be in-
cluded. Further, given the EWASs problems with internal tissue sample collections, no
comparison on epigenetic variation (in human intestinal systems) is currently available (or
known of). Small intestine cancer incidence is considerable lower than that of CRC, with a
global 2014 estimate of around one-sixteenth the number of new cases compared with the
latter, [SEER, 2013a,b]. While this difference is partially explain by the presence of toxic
residuals at colorectal level, as well as morphological differences between intestinal tissues,
(e.g. high colon cell division rate), the ways in which tissue-specific mechanisms affect epi-
genetic patterns leading to disease development are not well understood yet. Finally, while
contribution of epigenetic therapy is already recognised in some treatment strategies for
blood cancers and, potentially, for solid tumours, (Section 2.7), the analysis of the impact
of methylation inhibitors in CRC systems over time is still limited despite preliminary work.
Given these limitations on the state-of-the-art, a computational model following a hy-
brid approach, (BN, agent-based and logistic), is proposed in this Thesis to investigate
human CRC dynamics, with a focus on DNAm level modifications for three main system
layers. These are: i) micromolecular, (genetic and epigenetic mechanisms), ii) cell (crypt
inter- and intra-communications), and iii) cell population, (crypt phenomena). The influ-
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Figure 3.4: Simplified representation of the relationships between the Colorectal Cancer
Model developed in this Thesis and other CIESCI-related work developed at SCI-SYM
ences of individual characteristics, environmental features and potential epigenetic inhibitor
presence are also considered. Moreover, a theoretical comparison between human colon
and another gastrointestinal tract tissue, (small intestine), for DNAm changes in both nor-
mal and abnormal systems is also undertaken. The relationship between the dynamic CRC
model proposed here and other CIESCI-related projects, developed in SCI-SYM, are illus-
trated in Figure 3.4. Specifically, input data on micromolecular events affecting different
genes in CRC are drawn from the StatEpigen database, while information on DNAm and
HM levels can be provided by the micromolecular framework described in Raghavan and
Ruskin [2011]. Moreover, given similarities between the stomach and colon crypt struc-
tures, the agent-based model on gastric cancer described in Perrin et al. [2010] can be used
as a proof of concept for CRC dynamics, (Chapter 6).
Although toolkits for developing BN, agent-based and multi-scale models exist, the
computational models for CRC dynamics described within the next chapters follow ab ini-
tio developmental strategies. Both commercial and free tools, (e.g. Analytica, BayesiaLab,
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Chordalysis, GeNIe), have been developed for generating BN-based applications over re-
cent decades. (A larger list of these tools is included in Table C.3, in Appendix C.)
The gRain package from Bioconductor also provides functionality for generating BNs,
[Højsgaard, 2012]. In addition, a comprehensive review of toolkits available to generate
ABM, (including major ABM-frameworks such as Repast22, NetLogo23 and Swarm24), is
provided in Nikolai and Madey [2009]. Authors have considered several criteria for clas-
sification including i) programming language used for model implementation, ii) operating
system (OS) needed for running the framework, iii) licence options, iv) customer/user sup-
port availability and v) application domain, (e.g. biological, social, educational systems).
However, although such tools are widely-used, (e.g. GeNIe has around 2000 users), their
applicability is less good for specialised studies where for instance, integration of heteroge-
neous data types or different dynamics among the variable sets are needed. An analysis of
these software solutions potential, (for both BN and ABM), including known limitations,
[Nikolai and Madey, 2009], plus other issues, parallelisation options, were considered. This
indicated that such toolkits were not suited for the purpose of this study, since the computa-
tional components of the Colorectal Cancer Model need to have the same configuration set
with respect to the programming language used, (e.g. C++), to permit simulation running
on both Windows and Linux OS, inclusion of additional libraries, (e.g. MPI25), and con-
nectivity of developed components. Open-source software for building multi-scale models
also exists. For instance, Charste26 is a platform developed in C++, supported by Linux,
and tailored to modelling i) cardiac behaviour and ii) cell population dynamics related to
cancer development with an initial focus on CRC, [Mirams et al., 2013]. However, although
Charste has been used to develop several multi-scale models for CRC, (e.g. Van Leeuwen
et al. [2009]; Fletcher et al. [2012]), it does not provide functionality suitable for describing
genetic-epigenetic interdependencies at the micromolecular scale.
22Repast url: http://repast.sourceforge.net/
23NetLogo: url: https://ccl.northwestern.edu/netlogo/
24Swarm: url: http://savannah.nongnu.org/projects/swarm
25Message Passing Interface (MPI) is a standardized library for message-passing and includes functions that
permit code paralellisation.
26Charste stands for Cancer, Heart and Soft Tissue Environment, url: http://www.cs.ox.ac.uk/chaste/.
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3.6 Summary
This chapter builds on the biological background summarised in Chapter 2 to describe com-
putational and mathematical modelling approaches used to investigate abnormal biological
systems. To address gaps, the development of a hybrid computational model for human
CRC dynamics is proposed, to be developed for three main layers, (namely micromolec-
ular, cellular and tissue levels). The next chapters describe the components of the model
framework, starting with the Bayesian network for genetic and epigenetic events in CRC.
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Chapter 4
Epigenetic-Genetic (E-G) Network
Model
4.1 Introduction
The E-G Network Model, the development of which is described in this chapter, is a novel
framework for genetic and epigenetic events observed at different stages of colorectal can-
cer development, with a focus on gene relationships and tumour pathways. Specifically, the
E-G Network targets the first research objective of our research, i.e. “To quantify the impact
of genetic and epigenetic interdependencies on the methylation level in CRC development
and to estimate the influence of ageing and gender with respect to methylation level in ab-
normal colon cells”, (Subsection 1.2.1). The E-G Network is the first component of the
overall Colorectal Cancer Model (as illustrated in Figure 4.1) and its potential connection
with other components developed during this research is discussed in Chapter 8. Given the
advantages of Bayesian networks, (subsection 3.3.1), this approach can be used to describe
abnormal micromolecular events and their interdependencies in the CRC context. The gene
framework integrates empirical data on conditional relationships between molecular signals
found in CRC development, obtained from the StatEpigen database, [Barat and Ruskin,
2010]. In addition, information on signalling pathways involved in CRC development, (e.g.
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Figure 4.1: Structure of the Colorectal Cancer Model - focus on the E-G Network model
The relationships between model components may refer to R1) average methylation level
for gene network / intestinal cell; R2) patient features; R3) intestinal crypt dynamics, ex-
plored following bottom-up and top-down approaches.
Wntβ catenin, MAPK), is included from the KEGG Pathway database, [Kanehisa et al.,
2014], and available literature. Known to have a crucial role in cancer development, DNA
methylation and how it changes constitute the main objective of the E-G Network Model.
The base E-G Network is described in this chapter, (with its extensions presented in
Chapter 5). Specifically, the data set and gene framework structure, together with an
overview of the interdependencies between the gene network layers, are detailed in Sections
4.2 and 4.3. The algorithm proposed for the identification of the most plausible pathways
in a given gene network is introduced in Section 4.4. The expressions for gene methylation
update and major assumptions made in model formulation, (such as the value-ranges con-
sidered for DNA methylation for the cancer stages), are specified in Sections 4.5 and 4.6.
The network dynamics and the main contributions and limitations of the E-G Network are
also discussed.
4.2 Data set
The E-G framework consists of a network built to represent gene relationships, based on
empirical statistical data from StatEpigen. The gene relationships are designated: simple,
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(recording incidence of a micromolecular event affecting a gene, given the phenotype of the
analysed samples), and conditional, (giving pairwise affected gene dependence at certain
cancer stages). These data are used to inform the set of conditional interdependencies for
the Bayesian network, (see Figure 4.2). In general, the conditional relationships (CR) from
StatEpigen are expressed mathematically by:
CR(G2, G1, e2, e1, s, c) = P ((G2, e2)|(G1, e1), s, c) (4.1)
i.e. the probability of an event e2 to occur for gene G2 given the presence of the event e1
for gene G1, in the stage s of cancer type c. Similarly, a simple relationship (SiR) is the
probability that event e occurs for gene G at stage s of cancer type c, i.e.
SiR(G, e, s, c) = P ((G, e), s, c) (4.2)
Moreover, in the current thesis, a conditional relationship between two molecular events,
observed for the same gene, is referred to as a ‘self-relationship’ (SeR), being expressed
mathematically by:
SeR(G, e2, e1, s, c) = P ((G, e2)|(G, e1), s, c) (4.3)
i.e. the current micromolecular modification e2 depends on the previous event e1 ob-
served for the same gene G. This is illustrated by an example for the APC gene, a tumour-
suppressor gene (TSG) that is found to be frequently mutated and/or hypermethylated in the
very early stages of colon cancer, (see Subsection 2.6). From the StatEpigen data, [Barat
and Ruskin, 2010]:
P (APC mutation | APC H+, adenoma, colon) = 0.538 (4.4)
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which determines
SeR(APC, mutation, H+, adenoma, colon) = 0.538 (4.5)
The numerical values are subject to refinement as further data become available and the
network itself can be subjected to ‘stress-testing’ to determine its reliance on given values,
(i.e. sensitivity analysis).
4.3 Gene framework structure
Structured in three main layers, (micromolecular events, gene relationships and cancer
stages), the E-G Network explores the effect on phenotype of a number of key genetic and
epigenetic factors. These include DNA methylation, (both hyper and hypomethylation),
and histone modifications, combined with tumour pathway information relating to genetic
mutations and gene expression.
While colon cancer is the initial focus, the gene framework is designed to be extended
to other types of cancer. Therefore, more general terms, such as ‘carcinoma in situ’ or ‘in-
vasive carcinoma’ have been used to denote colon cancer stages, instead of more disease-
specific usage. Thus, the gene framework recognizes ‘healthy’ state and three main cancer
stages: carcinoma in situ, invasive carcinoma and metastasis. The interdependence be-
tween current and extended framework levels is illustrated in Figure 4.2, interpreted as
follows:
• The lowest level is that of the micromolecular events, (hyper-/ hypomethylation, mu-
tations, gene expression, histone modification and histone variants), and contains
information seen as ‘external’ input for the gene network. For example, resources
such as GEO, ENCODE, KEGG or COSMIC, (Chapter 3), can be interrogated here
for data on DNA methylation, gene expression and histone modification levels and
for information on mutation and signalling pathways.
• The mid-layer is that of the gene relationships and is represented by the Bayesian
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network, (built based on input from StatEpigen database).
• The final layer is that of ‘cancer initiation and progression’, giving information on
outputs at the network cancer stage. This layer includes three sublevels: carcinoma
in situ, invasive carcinoma and metastasis.
Information on risk factor influence, (such as ageing, gender, heredity, environmental fea-
tures, viral and bacterial infection) in cancer development and the stem cell property should
be ideally integrated in the extended gene framework.
Figure 4.2: Dynamics of the E-G Network Model
The middle layer describes gene relationships associated with three types of cancer, generi-
cally labelled C1, C2, and C3, where G1 to G10 substitute for actual gene labels. Risk factor
influence is also illustrated. Legend: empty circle: gene found in one cancer type, circle
with hatch-shading and grid patterns: gene found in two or three cancer types, respectively.
Edge: gene relationship.
According to the construction methods presented in subsection 3.3.1, a connected graph
is built of genes as nodes, (represented by circles in Figure 4.2). The conditional rela-
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tionship between two genes is denoted by an arrow between the nodes that include those
two genes. Information on conditional gene relationships can be taken from e.g. StatEpi-
gen database, which provides data on genetic and epigenetic interdependencies at different
stages of various cancer types, [Barat and Ruskin, 2010]. Additionally, the node shading
indicates gene affiliation to one or more types of cancer. For example, gene G3, (illustrated
by an empty circle), has been observed in cancer type C1, (e.g. NR3C11 in colon cancer,
[Barat and Ruskin, 2010]). The circle with hatched shading, (e.g. G7), indicates a gene seen
in two types of cancer, such as C2 and C3, (e.g. RASSF1A in lung and stomach cancer), and
finally, a gene that has been identified as being abnormally changed in three cancer types,
(such as KRAS in colon, lung and stomach), is illustrated graphically by a circle with grid
pattern, (e.g. G6). An example of the biological data from StatEpigen that feeds into the
gene layer in Figure 4.2 is shown in Table 4.1; the definition of symbols for these genes
are presented in Table C.4, according to information from the GeneCards Database, [Safran
et al., 2010].
Table 4.1: Genes involved in different genetic and epigenetic events (hypermethylation
(H+), gene expression (GE), mutation (Mut)) in colon, lung and stomach cancer phenotypes
Group
from table
Genes Colon Cancer
(C1)
Lung Cancer
(C2)
Stomach Can-
cer (C3)
G1 CRABP1 Present (H+)
G2 NORE1 Present (H+)
G3 NR3C1 Present (H+)
G4 MLH1 Present (H+; GE)
G5 MGMT Present (H+; GE)
G6 KRAS Present (Mut) Present (Mut) Present (Mut)
G7 RASSF1A Present (H+) Present (H+)
G8 APC Present (H+; Mut)
G9 TP53 Present (Mut; GE)
G10 CDKN2A:P14 Present (H+)
1NR3C1: nuclear receptor subfamily 3, group C, member, [Safran et al., 2010]
58
4.4 The d-plausible pathways in gene network - different routes
of cancer development
With respect to pathways linking gene changes, we refer to d-plausible pathways which
consist of sets of inter-related gene modifications that can occur in the gene network with
higher probabilities than a threshold value, calculated based on ‘d’ attribute and the network
structure, (as shown further). Their detection in the E-G Network Model is of particular
interest since they can be studied in association with known signalling pathways for CRC
development, (subsection 2.5). For example, if some genes from a SP are found to lie on a
plausible pathway in a given gene network, then there is a high chance that this SP will be
activated.
In the connected gene network, each node has been labelled with one of three position
attributes: i.e. as a start, middle or final node, based on its position in the current acyclic
graph2. An initial definition of the ‘parent’ and ‘child’ nodes was given (subsection 3.3.1).
Similarly, a gene Gi is defined to be a parent for a gene Gj in the gene network if there
is a conditional relationship CR(Gj , Gi, ej , ei, s, c) in the analysed data, where ei, ej are
the molecular events observed, respectively, for Gi, and Gj at the stage s of cancer type c,
(i, j are indices with value range from 1 to the total number of genes in network). Further,
the gene Gj is referred to as a child for Gi. Hence, a start node is a gene that has no
parents in the gene framework, while a final node is a gene that does not have any children.
Subsequently, a middle node illustrates a gene that has both parents and children, i.e. can
be either argument in two or more different conditional relationships for the given gene
network. Furthermore, if the assumption is made that a pathway is a directional connection
of graph edges, beginning at a start node and containing zero or more middle nodes and
ending in a final node, [Sedgewick and Wayne, 2011], it is relatively easy to determine all
pathways in the gene network. Given this result, the decision on which pathway is more
plausible is made by comparing the pathway score value and the d-Network Threshold
2The gene network is a Bayesian network, which is defined as a directed acyclic graph, where edges describe
dependencies between a set of variables, represented by nodes. The edge weights are given by the values of
conditional probabilities among the set of variables, (subsection 3.3.1).
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(dNT). These are computed as follows.
Pathway score calculation The pathway focuses on the relationships between the ge-
netic and epigenetic changes observed for different genes, (i.e. excluding the ‘self-gene’
relationships, where the molecular event depends on the previous status of the same gene).
The total probability of a set of independent events is given by P = Πni=1 Pei , where Pei
= probability of an independent event ei from the considered set, [Heckerman, 1998; Lu-
cas et al., 2004]. Based on this, the probability of a pathway in the gene network can be
given by the product of all compound, conditional gene relationship probabilities and the
simple relationship probability for the start gene. In addition, logarithm in base 10 (log10)
is applied in order to facilitate calculation, (i.e. use sum instead of product). Therefore,
the pathway score is defined as the sum of all logarithms of the compounds, conditional
gene relationship probabilities and the simple relationship probability for the start gene,
multiplied by the pathway contribution coefficient. This last quantity is equal to the ratio
between the pathway length, (n = the number of genes found in the current pathway), and
the total number of network genes, (V). The score of the kth pathway in the gene network
is described by the following expression, (with the variables of interest included in Table
4.2):
SCORE(k) = [log10(SiR(G
k
St, e
k
St, s, c))+
n∑
i=1,j=1
(log10(CR(G
k
i , G
k
j , e
k
i , e
k
j , s, c))]×n/V
(4.6)
Table 4.2: Definition of variables for pathway score calculation, expression (4.6)
Variable name Variable description
GkSt the start gene of the k
th pathway from the network;
ekSt the molecular event corresponding to the G
k
St gene;
Gki , G
k
j the i
th, jth gene respectively of the kth pathway;
eki , e
k
j the molecular event corresponding respectively to the G
k
i , to the
Gkj genes;
n the number of all genes found in the kth pathway;
V the total number of the network genes;
s the stage of cancer for the current pathway;
c the type of cancer for the kth gene pathway.
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D-network definition A d-network in the E-G Network Model is defined to be a network
that has the same structure with a given gene network, (initially built by the E-G Network
Model), with the constraint that all its edges have the same weight value, equal to d, (d ∈ [0,
1]). These weights indicate that the value of every simple or conditional gene relationship
in d-network is equal to d, i.e.:
SiR(Gi, ei, s, c) = d (4.7)
CR(Gi, Gj , ei, ej , s, c) = d (4.8)
∀ Gi, = gene in network, Gj = parent of the gene Gi, i.e. Gj ∈ Parents(Gi), ei, ej = events
corresponding to Gi and Gj , respectively, i, j ∈ [1, V], V = total number of genes from
network, s = cancer stage, c = cancer type. In order to determine the dNT value, the score
for every pathway from the d-network is calculated based on expression (4.6). The highest
value from all these computed scores is assigned as the dNT parameter, which is used in the
decision step.
The d-network was defined in this way in order to highlight the impact of gene pathway
length rather than the compound edge weight values. In real systems, the plausibility of
e.g. three micro-molecular events occurring under specified conditions is higher than that
for say 100 events. For example, if two pathways, Path1 and Path2, with 3 and 100 genes,
respectively, are identified in a d-network of V genes in total, the pathway score, (calculated
with expression (4.6), are:
SCORE(Path1) = (log10d+ log10d)× 2/V = 22/V × log10d; (4.9)
SCORE(Path2) = (log10d+ ..+ log10d)× 99/V = 992/V × log10d. (4.10)
Because log10 d ≤ 0, ∀ d ∈ [0, 1]⇒ SCORE(Path1) > SCORE(Path2). Thus, the shorter
pathway has a higher score (is more plausible) than the longer pathway. Considering this,
comparison with a threshold, based on the former, would provide more accurate information
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on pathway plausibility than using the latter.
Decision on d-plausible pathway If the score of kth gene pathway, SCORE(k), is higher
than the assigned dNT value, then the kth gene pathway is considered a d-plausible pathway
in the gene network. We illustrate with an example.
Example on d-plausible pathway calculation A simple network of four genes, found in
the carcinoma stage of colon cancer, (consisting of APC, MLH1, MCC , CDKN2A:p16)
is represented in Figure 4.3. This network is based on data taken from StatEpigen, [Barat
and Ruskin, 2010], on the simple and conditional relationships in which this set of genes
is implicated. The weight information is given by the empirical probability value of the
gene relationships, (e.g. the weight of the edge between the nodes, MLH1 and APC genes,
is 0.688, equal to the probability of finding APC hypermethylated3 in CRC, given MLH1
hypermethylated, [Barat and Ruskin, 2010]). This set of gene relationships is given by:
P (CDKN2A : p16 HpM+ | carcinoma, colon) = 0.249; (4.11)
P (MLH1 HpM+ | carcinoma, colon) = 0.140;
P (APC HpM+ | CDKN2A : p16 HpM+, carcinoma, colon) = 0.244;
P (APC HpM+ | MLH1 HpM+, carcinoma, colon) = 0.688;
P (MCC HpM+ | APC HpM+, carcinoma, colon) = 0.269;
P (MCC HpM+ | CDKN2A : p16 HpM+, carcinoma, colon) = 0.794,
where CDKN2A:p16, MLH1, APC and MCC are genes involved in CRC development,
(Chapter 2), and HpM+ = hyermethylation.
The three distinct pathways that can be identified in this gene network together with
their score values4, (computed for each of these pathways using expression (4.6)), are:
1. Pathway 1: CDKN2A:p16→MCC;
3Hyper- and hypomethylation refer to increase and decrease, respectively, of methylation.
4Given that probabilities ∈ [0, 1], log10 of these takes values ≤ 0.
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Figure 4.3: Example of a small gene network for carcinoma, colon cancer. Legend: cir-
cle: gene in CRC, edge: conditional relationship between micro-molecular events affecting
different genes.
SCORE (Pathway 1) = [SiR(CDKN2A:p16, HpM+, carcinoma, colon) + CR(MCC,
CDKN2A:p61, HpM+, HpM+, carcinoma, colon)] × 2/4 =
= [log10(0.249) + log10(0.794)] × 2/4 = -0.351;
(Given that two genes are involved in Pathway 1, out of four genes in the gene net-
work, the contribution coefficient for Pathway 1 is equal to 2/4.)
2. Pathway 2: CDKN2A:p16→ APC→MCC;
SCORE (Pathway 2) = [SiR(CDKN2A:p1, HpM+, carcinoma, colon) + CR(APC,
CDKN2A:p1, HpM+, HpM+, carcinoma, colon) + CR(MCC, APC, HpM+, HpM+,
carcinoma, colon)] × 3/4 =
= [log10(0.249) + log10(0.244) + log10(0.524)] × 3/4 = -1.122;
(Three genes are found in Pathway 2, out of four genes in the gene network; thus,
contribution coefficient = 3/4.)
3. Pathway 3: MLH1→ APC→MCC;
SCORE (Pathway 3) = [SiR(MLH1, HpM+, carcinoma, colon) + CR(APC, MLH1,
HpM+, HpM+, carcinoma, colon) + CR(MCC, APC, HpM+, HpM+, carcinoma,
colon)] × 3/4 =
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= [log10(0.140) + log10(0.688) + log10(0.524)] × 3/4 = -0.972.
(Since three genes are included in Pathway 3, out of four genes in the gene network,
contribution coefficient = 3/4.)
The dNT must then be calculated for these gene pathways based on d value. Two
examples of dNT calculation are given, where d value is considered, sequentially, higher
and lower than the average of edge weight values, included in the gene network from Figure
4.3. Given that the average is ≈ 0.44, in the first example, a value of e.g. d = 0.60 was
assigned, (0.60 > 0.44), and in the second example, e.g. d = 0.40, (0.40 < 0.44). Other
choices for d values are, of course, possible and this parameter needs to be considered for
a sensitivity analysis. For example, d value can be chosen closer to the maximum and
minimum of the edge weight values, (i.e. extreme values) in the gene network. However,
if d is set to a high value (closer to maximum), the dNT will have a high value, which will
reduce the number of plausible pathways (example 3, with d = 0.70). If d value is taken
to be small, the threshold dNT will be low, allowing a high number of plausible pathways,
(example 4, d = 0.10). Thus, an optimal d value should be decided based on biological
questions - whether the interest is in the behaviour of the majority or in features exposed
only by a ‘peak’ of gene pathways.
Example 1, d = 0.60. In the d-network, with d = 0.60, SCORE values were computed
for all three pathways following the arrows in gene network, (Figure 4.3):
1. SCORE(0.60-Pathway1) = (log10 0.60 + log10 0.60) × 2/4 = - 0.22;
2. SCORE(0.60-Pathway2) = (log10 0.60 + log10 0.60 + log10 0.60) × 3/4 = -0.49;
3. SCORE(0.60-Pathway3) = (log10 0.60 + log10 0.60 + log10 0.60) × 3/4 = -0.49.
As result, -0.22 is assigned to dNT since it is the highest computed value. Given this ex-
ample, none of the identified pathways for the gene network from Figure 4.3 are d-plausible
pathways, with d = 0.60, because their score values are lower than that of the dNT, (-0.351
< -0.22, -1.122 < -0.22, -0.972 < -0.22).
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Example 2, d = 0.40. The score values computed for all identified pathways in a d-
network, where d = 0.40, are:
1. SCORE(0.40-Pathway1) = (log10 0.40 + log10 0.40) × 2/4 =-0.39;
2. SCORE(0.40-Pathway2) = (log10 0.40 + log10 0.40 + log10 0.40) × 3/4 = -0.89;
3. SCORE(0.40-Pathway3) = (log10 0.40 + log10 0.40 + log10 0.40) × 3/4 =- 0.89.
Given that -0.39 is the highest value from all computed, it is assigned to dNT, (when
d = 0.40). Considering the values identified for Figure 4.3, the Pathway 1 is detected as
d-plausible, (d = 0.40), because its score value is higher than that of dNT, (i.e. -0.351 >
-0.39).
Example 3, d = 0.70. The score values are computed for all identified pathways in a
d-network, where d = 0.70:
1. SCORE(0.70-Pathway1) = (log10 0.70 + log10 0.70) × 2/4 =-0.15;
2. SCORE(0.70-Pathway2) = (log10 0.70 + log10 0.70 + log10 0.70) × 3/4 = -0.34;
3. SCORE(0.70-Pathway3) = (log10 0.70 + log10 0.70 + log10 0.70) × 3/4 =- 0.34.
Given that -0.15 is the highest value from all computed, it is assigned to dNT, (when d
= 0.70, higher than average = 0.44). Considering the values identified for Figure 4.3, none
of the pathways shown are d-plausible pathways.
Example 4, d = 0.10. The score values are computed for all identified pathways in a
d-network, where d = 0.10:
1. SCORE(0.10-Pathway1) = (log10 0.10 + log10 0.10) × 2/4 = -1;
2. SCORE(0.10-Pathway2) = (log10 0.10 + log10 0.10 + log10 0.10) × 3/4 = -2.25;
3. SCORE(0.10-Pathway3) = (log10 0.10 + log10 0.10 + log10 0.10) × 3/4 = -2.25.
Given that -1 is the highest value from all those computed, it is assigned to dNT, (when
d = 0.10). Considering the values identified for Figure 4.3, Pathway 1 and Pathway3 are
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detected as d-plausible, (d = 0.10), since -0.351> -1 and -0.972> -1, i.e. their score values
higher than that of dNT, (d = 0.10).
This section presented an algorithm for identification of the d-plausible pathways in
the gene network, which can describe qualitatively pathways in gene networks, (i.e. to de-
cide whether they are plausible). We need to consider the initialization and update steps
for methylation level inside the gene network in order to investigate quantitatively DNA
methylation differences that can be induced by associated micromolecular events, includ-
ing mutation, hyper-/ hypomethylation, histone acetylation/ methylation during cancer de-
velopment.
4.5 DNA methylation
In the E-G Network model, gene methylation5 level update is a complex process, influenced
by a combination of at least five factors: cancer stage, gene relationship type, the nature of
the micromolecular events, signalling pathways and histone modifications. The next two
subsections describe how initial gene methylation levels are set and the expressions applied
to update the methylation level in the gene framework.
4.5.1 Methylation initialization step
Hypermethylation of CpG islands found in TSG promoter6 is typically associated with gene
silencing leading to tumour progression, where methylation increase depends also on the
cancer stage. For example, gene TP53 is thought to have a higher promoter methylation
level in CRC metastasis than in an incipient stage such as polyps. In E-G Network, the
gene methylation level is expressed as the PMRA7 value for that gene, i.e. ∈ [0, 100],
(Subsection 2.3.1). For example, if the PMRA value for the MGMT gene in a specific CRC
stage is reported to be equal to 33.13, [Ogino et al., 2006b], then, the MGMT methylation
5Note: In E-G Network, we refer to ‘gene promoter methylation level’ using the simplified formulation of
‘gene methylation level’, i.e. the word ‘promoter’ is implicit. Analogous, ‘methylation level’ is used instead of
‘promoter methylation level. However, when confusions can occur, the word ‘promoter’ is explicitly specified.
6Promoters are DNA sequences that indicate the locus where gene transcription begins, (usually located
upstream from transcript start sites).
7PMRA = average of PMR, where PMR = degree of methylation.
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level corresponding to the same CRC stage inside the gene framework is taken to be equal
to 33.13. In an ideal gene framework, initial methylation level values are known for every
compound gene at each cancer stage. However, such data are not always available; there-
fore, in the E-G Network, four value-ranges have been chosen to assign initial methylation
levels based on the given stages, (included in Table 4.3).
Table 4.3: Initial methylation ranges (PMRA values) for cancer stages
Raw Cancer stages Methylation ranges
1 Healthy 0 - 0.50
2 Carcinoma in situ 8.00 - 8.50
3 Invasive carcinoma 18.00 - 18.50
4 Metastasis 65.00 - 65.50
These value ranges were chosen based on the assumption that variation in DNAm level
is higher as tumour progresses. Specifically, from Table 4.3, it can be inferred that methyla-
tion level in the healthy phenotype is characterised by range [0, 8), (i.e. difference ' 8), in
carcinoma in situ by range [8, 18), (with difference ' 10), in invasive carcinoma by range
[18, 65), (i.e. difference ' 47) and finally, in metastasis by range [65, 100], (i.e. difference
' 35). Larger methylation variation seems to be permitted for invasive carcinoma than
for metastasis. However, ‘invasive carcinoma’ term is used to refer to three cancer stages
within the Overall Stage Grouping System8, namely Stage I, II and III, (Section 2.5). Thus,
methylation level difference for each of these stages is around 15 - 16, i.e. higher than that
considered for carcinoma in situ, and obviously, lower than that for metastasis. However,
other values can be considered as well, and a sensitivity analysis is planned for these value
ranges, (Chapter 8). In addition, the gene framework provides functionality for handling
external input to gene methylation level. Thus, the values specified in Table 4.3 can be
adjusted if additional or modifying information on methylation level becomes available.
During this step, the methylation level value for each gene is randomly-generated within
the determined ranges, according to the cancer stage information provided by gene rela-
tionships in StatEpigen, [Barat and Ruskin, 2010]. For example, suppose the following two
8Overall Stage Grouping is a system where cancer development is described by Roman numbers, (from I to
IV), in addition to 0, which is considered the least advanced cancer stage, (Section 2.5).
67
gene relationships occur in the network:
i) P(MGMT H+ | KRAS mutation, carcinoma in situ, colon) = 0.282;
ii) P(APC H+ | TP53 mutation, invasive carcinoma, colon) = 0.688.
where both relation values are indicated by StatEpigen. Thus, the initial methylation level
for the MGMT and KRAS genes will be a value in the 8.00 - 8.50 range, since this rela-
tionship was observed in carcinoma in situ, (row 2 in Table 4.3). Additionally, for APC
and TP53 genes, the methylation level is initially higher in this case because the second
relationship was observed in invasive carcinoma, (so value within the range given by row 3
in Table 4.3).
In conclusion, values within ranges from Table 4.3 are assigned to methylation level
only when new genes are introduced in the gene network. However, it is also important to
know how methylation level changes for genes that already exist in the gene network, i.e.
how gene methylation level is updated over time.
4.5.2 Methylation update step
In nature, modifications of the gene promoter methylation level do not follow a clear pattern
of occurrence. Given this, the assumption that methylation modifications appear at every
gene promoter in every cell during every cell division seems unrealistic. Therefore, in
the E-G Network, the update of the gene promoter mehtylation level is considered to be a
probabilistic event. In model terms, the methylation update step for a gene G is performed
only if a probability value R, (randomly-generated within [0, 1] range), is higher than the
value of the threshold ‘TH DNAM(G)’, calculated using expression (4.12). Of course,
every gene relationship in which a gene G is involved in the gene network can contribute to
gene G methylation updates. For example, if there are three gene relationships containing
the APC gene, three independent methylation update events for the APC gene are possible;
in consequence, three sets of Rk and TH DNAMk(G), k∈ {1, 3}, values will be calculated.
In addition, if the gene G is involved in a signalling pathway, whose deregulations contribute
to CRC development, there is a higher chance for G to be affected in the given network;
thus, the threshold value TH DNAMk(G) decreases. Specifically, TH DNAMk(G) value is
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given by 1 minus the value of the kth gene relationship in which gene G is involved in the
given network together with the value of a model input parameter, denoted as the signalling
pathway coefficient, (SIG), which indicates that the gene G has been observed in a signalling
pathway.
TH DNAMk(G) = 1− Pk(G)− SIG(G) (4.12)
where:
SIG(G) =

model input value, (constant for all genes in network) , with non− zero
value, if the gene G is known to form part from a signalling pathway;
0, otherwise.
Pk(G) is equal to the value of gene relationships where gene G is involved and can be given
by StatEpigen database. Specifically, Pk(G) represents:
• The probability of the kth conditional relationship that includes the gene G, if this
is a middle or an end gene. It represents the incidence of a molecular event for the
current gene, given the molecular events observed for its kth parent within the gene
network.
• The simple relationship probability of the gene G, if this is a start gene;
• The ‘self-relationship’ probability if the gene G is inside a ‘self-updating’ methyla-
tion step.
So, if the Rk value is higher than that of the TH DNAMk(G), then the methylation level
of a gene G is updated, using the following expression, (with variables of interest included
in Table 4.4):
M ′(G) = M(G)±Wk(G)× Parent(G)
(E + S)
(4.13)
In expression (4.13), the sign ’+’ or ’-’ is assigned according to the observed molec-
ular event present in the gene relationship: ’+’ corresponds to hypermethylation, ’-’ to
hypomethylation. For mutation, a random variable, internal to the network, decides whether
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Table 4.4: Definition of variables used in the update methylation level step, Expression
(4.13))
Parameter name Parameter description
M’(G) DNAm of gene G in the next Time-step;
M(G) DNAm of gene G in the current Time-step;
Parent(G) the number of the gene G parents (considered equal to 1 if G is a
start gene or belongs to a ‘self-relationship’).
E total number of edges from network;
S total number of ‘self-relationships’ from network, considered
zero in a non ‘self-relationship’ update step;
Wk a random value within range [10−3, 10−2] for hyper and
hypomethylation, or [5×10−4, 10−3] for mutations; these ranges
differ between hyper/hypomethylation and mutations, because
the former events affect methylation level directly, while the latter
can induce subsequent changes in methylation level. Therefore,
the Wk coefficient represents the contribution of the kth parent
to the new gene methylation level, based on the molecular event
history observed for the current gene.
’+’ or ’-’ is chosen, i.e. as to whether mutation causes an increase or decrease in methyla-
tion level. Based on expression (4.13), methylation level is updated at time T+1 based on its
value at time T and the several other factors. The number of parent genes, (i.e. Parent(G)),
indicates how a gene is connected to the rest of the genes in the network. This information
can be useful to identify the highly-connected genes, (‘hub genes’), and in analysis of their
disease contribution, in comparison with the other genes. Additionally, the ratio 1 / (E+S)
shows the strength of the gene network. For example, in a small network, (with fewer edges
and ‘self-relationships’ in the graph), the methylation level will be updated to a higher value
than in a larger network. As a result, the former network will register a faster progression
in tumour development than the latter.
4.6 Histone modification and the relationship with DNA methy-
lation
Similarly to DNAm, the histone acetylation or methylation levels are also considered to be
dependent on cancer stage, [Yoo and Jones, 2006]. In order to achieve similar representa-
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tion of DNAm and HM levels in the gene framework, histone modification levels are also
expressed as average methylation/ acetylation percentage values, (Section 2.3). Initially,
randomly-generated values within the ranges given in Table 4.5 are assigned to HM level,
according to the cancer stage of the entire gene network. Histone modification is less stable
in nature than DNam level, [Cedar and Bergman, 2009]. Considering this, lower differ-
ences between the value-ranges are taken for HM than for DNAm level initialization based
on cancer stages, (Table 4.3). The E-G Network provides also functionality for integration
of initial HM levels from external resources and the value-ranges from Table 4.5 can be
refined if information becomes available. However, this model requires prior information
on DNAm level in order to estimate HM level. A sensitivity analysis for these value-ranges
is also considered, (Chapter 8).
Table 4.5: Initial histone acetylation and methylation ranges (average percentage values)
based on cancer stage
Cancer stages Initial histone ranges
Healthy 0.010 - 0.019
Carcinoma in situ 0.020 - 0.032
Invasive carcinoma 0.033 - 0.075
Metastasis 0.076 - 0.090
The interplay between DNAm and HM, (discussed in Subsection 2.3.4), has also been
considered in the E-G Network Model. Thus, in addition to the data drawn from StatEpi-
gen, [Barat and Ruskin, 2010], the methylation level of a gene G is updated using expression
(4.14), (adapted from that given by Raghavan and Ruskin [2011]), which links the methy-
lation and acetylation of the core histones H3 and H4 to DNAm:
M ′(G) =

M(G)±Mean×R, if (M(G)±Mean×R) ≥ 0
0, otherwise.
(4.14)
where: M’(G) = DNAm of the gene G in the next Time-step; M(G) = DNAm of the gene
G in the current Time-step; R = random number (∈ [10−5, 10−4]). The sign ‘+’ or ‘-’,
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corresponding to methylation level increase or decrease, respectively, is decided by a ran-
dom variable, internal to the network. Mean is the average of acetylation and methylation
of the histones H3 and H4. Given that acetylation is less stable in nature than methylation,
the E-G model assumes that a percentage of the histone acetylation level can be lost during
a cell cycle, (i.e. between two successive model iterations); thus, only the remainder is
considered for Mean calculation:
Mean =
p×Ace+Me
2
(4.15)
where Ace, Me = acetylation, methylation level of histones H3 and H4; p ∈ [0, 1] is a
randomly-generated value.
The ‘feedback’ from DNAm to HM, i.e. the DNAm contribution to histone evolution
inside a gene G, is described by expression (4.16). Histone modification level at time T+1
is updated based on i) histone acetylation/ methylation level at time T, ii) changes occurring
during this time interval and iii) methylation level of gene G, (at promoter locus):
H ′E(G) =

HE(G)± [WE(G) +M(G)×R], if HE(G)± [WE(G) +M(G)×R] ≥ 0;
0, otherwise.
(4.16)
where: E = acetylation or methylation for the current histone; HE’(G) = the histone acetyla-
tion or methylation level (governed by event E) in the next Time-step; HE(G) = the histone
acetylation or methylation level (due to event E) in the current Time-step; R = random num-
ber (∈ [10−5, 10−4]); M(G) = DNAm of the gene G; WE(G) = the weight ratio for the event
E based on the cancer stage where gene G was indicated and is given by the product of two
randomly-generated values Perc and RW , i.e. WE(G) = Perc × RW , with Perc ∈ [0, 1] (i.e.
a percentage), and RW ∈ Table 4.5, which indicates that HM update rate is also dependent
on cancer stages). Again, ‘+’ or ‘-’ sign is randomly determined.
Similar to the gene methylation updates based on the relationships data, (subsection
4.5.2), the updates of DNAm and HM (based on their interdependency) are also considered
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to be probabilistic events. Thus, expressions (4.14) and (4.16) are applied only if the value
of a randomly-generated probability Rand is higher than that of a threshold TH HM, which
is provided as a model input parameter, (expression 4.17). A sensitivity analysis will include
also the TH HM parameter.
Rand ≥ TH HM (4.17)
Following the objective to investigate genetic and epigenetic interdependencies during
cancer development, DNAm and HM update steps are studied combined in the methylation
cycle, which represents the process of updating network methylation level over time.
4.7 Network dynamics
Given its overall importance, the DNAm update step is taken as the fundamental time-step
for the gene framework, as a whole. The gene methylation level change, from simple and
conditional relationships, is referred to as the STATIC UPDATE. Similarly, the methyla-
tion update, based on any ‘self-relationship’, is labelled as the DYNAMIC UPDATE. The
DNAm updates, based on HM, are labelled as the DNA METH UPDATE step, while the
evolution of histones, given the DNAm level, is referred to as the HIST MODIF UPDATE
step. Chronologically, a network methylation cycle starts with one DNA METH UPDATE
step, followed by a STATIC UPDATE phase, which is combined with one DYNAMIC UPDATE
iteration. Since DNAm has been reported to be more stable in nature than HM, [Cedar and
Bergman, 2009], different dynamics are needed to handle HM events in the E-G Network
Model. Hence, the methylation cycle ends with ‘m’ HIST MODIF UPDATE iterations, (m
> 1). The steps of the methylation cycle are briefly illustrated in the simplified Figure 4.4.
In the figure, MG denotes the methylation level of a generic gene G and H3,4 refers to
the methylation and acetylation of the histones 3 and 4 corresponding to gene G. The dual
influences between HM and DNAm are specified by the relationships (D1) and (D4). Addi-
tionally, the methylation level of the G gene is updated according to its conditional relation-
ships with other network genes (G’), (relationship (D2), Figure 4.4). A ‘self-relationship’
is also considered to contribute to the new methylation level of the gene G, (relationship
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Figure 4.4: Dynamics of the methylation cycle of a generic gene G, in the E-G Network
Model
Specifically, the D1 relationship refers to the DNA METH UPDATE step, D2 and D3 in-
dicate STATIC UPDATE and DYNAMIC UPDATE phases respectively, and finally, D4
illustrates HIST MODIF UPDATE iteration. Legend: MG: methylation of the gene G pro-
moter; G‘: the genes from the network which are found in conditional relationship with the
gene G; H3,4: average methylation and acetylation of the histones 3 and 4 corresponding
to gene G.
(D3), Figure 4.4).
The gene network is allowed to evolve over time for a number of methylation cycles, (∈
[102, 104]), and at the end of the simulation, the gene network is checked to ascertain if it
is still in the initial cancer stage or has advanced, in which case the new stage is identified.
The length of the simulation is determines by methylation cycle duration. Specifically, the
gene network mimics dynamics of human colon stem cells, for which, methyation cycle was
approximated to stem cell division time, i.e. around seven days, (Section 2.4). Thus, while
a number of 102 iterations can be approximated to 2 years, ( 100 iterations52 iterations/year ≈ 1.92 years),
a number of 104 iterations indicates ≈ 190 years. This extreme value is considered in order
to analyse conditions when cancer evidence is not marked. Moreover, the E-G Network
has been developed with potential for extension to other cell types, (such as progenitor
and differentiated cells), or other tissue types, (such as the small intestine). Lifetime of
both progenitor and differentiated cells is shorter than that of the stem cell; for example,
if progenitor cycle is approximated to 2 days, a number of 104 would correspond to ≈ 55
74
years, (104 iterations × 2days1iteration = 20000 days ≈ 55 years), which is realistic with respect
to human lifetime. Or, for example, if the gene network describes stem cell dynamics in a
small intestine system, (with stem cell division cycle ∼5 days), the iteration number range
[102, 104], can be approximated to 1.37 - 137 years. Thus, two approaches can be used
to set simulation time in the E-G framework. Specifically, these refer to: a) when gene
networks are allowed to evolve over time until cancer progresses to a specific stage and b)
when an iteration number, (calculated based on information on stem cell lifecycle duration)
is taken and cancer development assessed at the end of simulation.
Implementation of the E-G Network model The E-G Network is an object-oriented
framework written using C++. It also uses Visual Leak Detector, [CodePlex, 2014], to
detect plausible memory leaks in the code. System entities specific to the gene network,
including histones, genes, micromolecular events, gene relationships and the gene network
itself, are described by individual classes. In addition, functionality is provided for inte-
gration of information on patient features and for processing biological data from external
resources, which are considered model input. Details on the E-G Network implementation
is given in Section 5.3.3, following presentation of the extended E-G Network, (including
the decision methods considered for cancer development and ageing/ gender influences into
the model).
4.8 Discussion
The E-G Network, presented in this chapter, itself has a multi-layered structure, which con-
siders three important elements involved in cancer development: molecular signals (genetic
and epigenetic), gene relationships and the transitions between cancer stages.
The main contribution of the model is the introduction of an integrated framework to
analyse different micromolecular events and their interdependencies, with respect to their
impact on DNAm level measured at gene promoter location. An algorithm has been pro-
posed for detecting the most plausible tumour pathways in a given gene network based on
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genetic and epigenetic interdependencies observed at different CRC stages. This informa-
tion can be further combined with signalling pathway data and integrated into an extended
analysis on tumour routes. For example, given alterations of the generic gene G, what is
the likelihood that the Wnt signalling pathway will be affected? An answer can be given
using the ‘plausible pathway’ algorithm. If information on pathways between the gene G
and any genes involved in the Wnt pathway exists, then these genes can be connected in
a network, and the score of the pathway between them can be calculated. The immediate
question is clearly how to interpret the significance of this score value in the given network:
for instance, how different is a score of -0.33 from -0.31 or from -0.35? Secondly, the
‘methylation cycle’ has been introduced to represent the process of updating the gene pro-
moter methylation level based on information on five component elements: network cancer
stage, gene network structure, signalling pathways, HM and nature of the molecular event
observed for specific genes. For a given gene network, the methylation level of a gene G
can be updated according to information on micromolecular interdependencies affecting the
gene itself and the genes to which G is connected in the network. Information on signalling
pathway can also be considered. Thus, if two genes, known to be part of the same signalling
pathway, are connected in a gene network, abnormalities in one gene increase the chance of
the second gene being affected by genetic and epigenetic mechanisms involved. In addition,
both DNAm and HM levels are taken to be influenced by cancer stages. Based on the dual
relationships between these epigenetic patterns, (reported in literature), a set of expressions
has been proposed for updating DNAm and HM levels over time.
A limitation of basic E-G Network is the absence of methods to evaluate malignant
tumour development in the gene network. In addition, information on the influence of
risk factors, such as ageing and gender, in CRC initiation and progression is also lacking.
Considered a major risk factor in cancer development due to its influence on genetic and
epigenetic events, (subsection 2.6.2), the argument for inclusion of ageing, in any realistic
gene framework, is strong. In model terms, this can be linked to methylation level updates,
given the progressive accumulation of DNA methylation and histone modifications over
time, [Fraga et al., 2007]. Moreover, specific genes (such as ER, IGF2) that have been iden-
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tified to be more sensitive to age-related methylation must be considered in this context.
Given its reported influence on CRC initiation, specific account should also be taken of
gender in any extended genetic/epigenetic framework. In consequence, the extended E-G
Network Model, (described in the next chapter), integrates methods to asses cancer initia-
tion and progression based on genetic and epigenetic information and focuses on analysis
of ageing/gender impact on micromolecular events during CRC development.
77
Chapter 5
Extensions to E-G Network Model
5.1 Introduction
Following on from the limitations, notated in the prototype E-G Network Model, (Chapter
4), analysis methods for tumour progression, (as recorded by the E-G Network), and the
way in which different risk factors, (such as ageing and gender), influence the dynamics
of tumour initiation, are the main topics addressed in this chapter. Considered a major
risk factor in cancer development, we report on the incorporation of ageing in the E-G
Network model, as well as gender, as the influence of which is also implicit in colon cancer
initiation, (Subsection 2.6.2). In addition, information on a set of genes that have been
reported to be sensitive to age-related methylation in CRC development, (e.g. IGF2, ER),
[Issa and Ahuja, 2000; Teschendorff et al., 2010], is also explored and integrated into the
gene framework. The work presented aims to investigate the abnormal modifications from
carcinoma in situ to invasive carcinoma, colon cancer, by addressing questions, such as: i)
What differences are to be expected in tumour progression for males and females of similar
age? ii) What is the impact of aberrant modification in the promoter of a gene, such as IGF2,
that is considered to be sensitive to age-related methylation, (Subsection 2.6.2)? We address
these questions through case studies which aim to exploit the potential of extended E-G
Network Model. These case studies are based on synthetic patients, with profiles generated
by recourse to methods for methylation level initialization based on cancer stages, (Section
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4.5).
The methods, proposed for assessment of tumour progression in the gene network, are
presented in Section 5.2 and two case studies, which illustrate the contribution of ageing
and gender in tumourigenesis, are described in Section 5.3. Implementation details for the
extended E-G Network and ongoing parallelisation development are also presented. The
results obtained for each case study are reported in Section 5.4. Finally, a summary on the
inclusion of the ageing and gender influences in the E-G Network and any limitations are
given and the need for cell and tissue level modelling is highlighted.
5.2 Cancer progression evaluation
This subsection introduces the methods used to analyse tumour progression in the E-G
Network. The gene network is rated as being in ‘healthy’ state or in one of the three possible
cancer stages (namely carcinoma in situ, invasive carcinoma and metastasis), using two
methods:
A. Calculation of the average network methylation1 level, (network score);
B. Calculation of the percentage of highly methylated genes (due to influence of current
genetic and epigenetic events).
Firstly, the average network methylation level, network score, (Method A from above),
is tested against predefined methylation values (PMRA2 values) based on the cancer stage,
(Table 5.1), in order to assess the initial cancer stage of the gene network. Further, the
network score is computed after every methylation cycle and tested against these value-
ranges. For example, a network score of 18 indicates that the network is in carcinoma in
situ stage. If its score is 54 after a number of methylation cycles, then the gene network is
considered to be in invasive carcinoma, meaning that the tumour has progressed over the
time period, (mimicked by simulation). The value-ranges from Table 5.1 are inferred from
1Similarly to the base E-G Network, (Chapter 4), the word ‘promoter’ is implicitly considered in formulation
‘gene methylation level’, which stands for ‘gene promoter methylation level’. When confusions can occur, the
word ‘promoter’ is specified explicitly.
2PMRA: Average percentage of methylated reference
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those used for DNAm level initialization step3, (Section 4.5), and considered for sensitivity
analysis, (Chapter 8).
Table 5.1: Cancer stage decision based on average promoter methylation level (PMRA
values) of the entire network
Average of network
methylation level
Cancer stages
0 - (<) 8 Healthy
8 - (<) 18 Carcinoma in situ
18 - (<) 65 Invasive carcinoma
65 - 100 Metastasis
Method (A) is, however, limited by its sensitivity to outlier genes; a single gene with
a high promoter methylation level can significantly increase the network score. Based on
this observation, method (B), the gene percentage method, was derived to evaluate cancer
stage. Here, the decision on network cancer stage is made in two steps: first, the highest
promoter methylation level (PMRA values) is determined in the gene network and second,
the percentage of genes that contain this methylation level is compared with two reference
(percentage) values, e.g. 20% and 80%, (Table 5.2).
Table 5.2: The relationship between percentage of highly methylated genes and cancer stage
(methylation level is given by PMRA values)
DNAm level 0 - (<) 20% 20 - (<) 80% 80% - 100%
0 - (<) 8 Healthy Healthy Healthy
8 - (<) 18 Healthy Carcinoma in situ Invasive carcinoma
18 - (<) 65 Carcinoma in situ Invasive carcinoma Metastasis
65 - 100 Invasive carcinoma Metastasis Metastasis
According to information from Table 5.2, if the highest methylation level in a gene net-
work is between 8 and 18, observed in less than 20% of total gene number, the gene network
is still considered to be in a ‘healthy’ stage, even if this range is accounted to be specific
to carcinoma in situ. However, if the same highest methylation level is recorded for more
than 80% of the total gene number, the respective gene network is in the invasive carci-
3The value-ranges used to initialize DNA methylation level are included in Table 4.3. In choosing these
values, the major assumption was that higher variation in DNAm level is observed as tumour progresses, e.g.
from 0 - 8 in ‘healthy’ phenotype, to 65 - 100 in metastasis.
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noma stage already, and does not represent carcinoma in situ. Similarly, for example, if the
highest methylation level ≈ 50 is ‘measured’ for around 12% and 82%, respectively, of all
genes included in two gene networks, the first network is the carcinoma in situ stage, while
the second network is already marked into metastasis. The values-ranges from DNAm level
are similar to those included in Table 5.1. A sensitivity analysis is necessary to investigate
these value-ranges; for example, methylation level intervals can be equilibrated, e.g. 0 -
33%, 33 - 67%, 67 - 100% or extended more, e.g. 0 - 5%, 5 - 95%, 95 - 100%.
The ‘network score’ and ‘percentage of highly methylated genes’ methods can be com-
bined if needed. For example, if the focus is on the epigenetic, (or methylation), landscape
of the entire cell, the first method may have a higher weight on the tumour progression
decision. Contrary, if the interest is on a specific set of genes, the second method may be
considered more applicable for purposes of analysis.
Discussion on cancer progression
The flow chart from Figure 5.1 is a schematic representation of the way in which tumour
progression is decided inside the E-G Network Model.
Initially, the network includes gene relationships within the lowest cancer stage. If sev-
eral gene relationships containing the same genes, but in different cancer stages, are found
in StatEpigen, the ones from the most advanced cancer stage are kept in a repository for
further refinement. After each methylation cycle, the network is rated, using the methods
described in the previous subsection. At this step, the gene network can be updated if it has
progressed to a more advanced cancer stage. Some of the actual gene relationships may be
overwritten, (by updated information for similar relationships from the repository). Addi-
tionally, new gene relationships corresponding to the current cancer stage can be included.
The gene framework is allowed to evolve over time, in order to register its ‘potential’ for
cancer progression.
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Figure 5.1: Schematic view of tumour progression possibilities in the E-G Network model
5.3 Implementation
The E-G Network enables analysis of methylation level changes for the entire gene network
over time and gives information on cancer initiation and progression. Given that epigenetic
patterns can be inherited through cell generations, [Probst et al., 2009], the DNAm level
was analysed after every stem cell division step, [Boman and Wicha, 2008; Clevers, 2011;
Papailiou et al., 2011]. Therefore, for the case studies described in this chapter, the major
considerations were that the gene network should mimic the molecular modifications inside
an (adult) colon stem cell and that the time step was realistic: for a methylation cycle is
the interval between two successive stem cell divisions, which was estimated to be equal to
around seven days, [Potten et al., 2003; Frank, 2007], (Section 2.4).
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The ageing and gender impact on micromolecular events
The influence of an individual’s age and gender with respect to genetic and epigenetic mod-
ifications over time was handled as follows. An AG parameter was proposed to describe the
impact of these factors on DNAm dynamics, with values inferred from available literature,
(e.g. Ferlay et al. [2014]). Given that a mutation event is considered to have lower impact
on DNAm level than hypo- and hypermethylation events, the ageing and gender influences
on mutation occurrence probabilities are described by a randomly-generated value, RMut,
lower than the corresponding AG parameter values. The AG parameter set has the same
value for a given gene network in its entirely, (as individual characteristics are constant for
a given cell), and is integrated into the DNAm level update step, (Section 4.5). Specif-
ically, the AG parameter affects the threshold of the micromolecular event probabilities,
(introduced in expression (4.12)), as shown below:
TH DNAMk(G) = 1− Pk(G)− SIG(G)−AG(ageing, gender) (5.1)
Thus, in addition to its dependence on the gene relationship probability values and to
the gene characteristics forming part of a signalling pathway, (i.e. Pk(G) and SIG(G)),
the probability threshold that permits micromolecular modifications on a given gene G,
TH DNAMk(G), is also influenced by individual’s age and gender.
Similarly, the influence of individual characteristics has been also considered with re-
spect to the DNAm-HM relationships, (Section 4.6). In model terms, the constant value of
the TH HM threshold, (used in expression (4.17) for updating DNAm and HM level based
on their interdependencies), has been replaced by a parameter based on ageing and gender.
Thus, the dual-relation HM and DNAm updates are now permitted only if the randomly-
generated Rand value is higher than that given by the TH HM parameter for a specific
ageing-gender group, i.e.:
Rand ≥ TH HM(ageing, gender) (5.2)
83
Genes sensitive to age-related methylation
Research, [Issa and Ahuja, 2000; Teschendorff et al., 2010], has also identified a specific
group of genes known to be sensitive to age-related methylation and this information can
be incorporated into E-G Network. In model terms, a coefficient, denoted as ‘sensitive to
an age-related methylation’, (SAM), was considered to affect the value of the probability
threshold that permits DNAm level modifications in the gene network. Thus, methylation
modification probability of a gene sensitive to age-related methylation is higher than that
of a gene without this feature. In addition, a coefficient, denoted as ‘age-sensitive gene’,
(ASG), was introduced to target to the individual age at which such age-related methylation
modifications can be observed. Therefore, the methylation update step expression becomes:
TH DNAMk(G) = 1− Pk(G)− SIG(G)−AG(ageing, gender)− SAM (5.3)
where
SAM
 ∈ (0, 1), if Ageing ≥ ASG;0, otherwise.
Network settings common to both case studies
In section 2.6, four major age groups were identified and described based on the risk of
CRC development. For both case studies described in this chapter, ten core age groups
were taken, (starting at age 38 going in 5 year steps to age 83: 38, 43, 48, 53, 58, 63, 68,
73, 78, 83). In addition, an example of AG parameter values, defined for the hypo- and
hypermethylation events, is provided in Table 5.3. Both age groups and value-ranges were
chosen based on literature which reported that CRC risk starts increasing at around 40 (in
hereditary CRC, [Cunningham et al., 2010]) and has its peak between 65 and 75, [Schole-
field, 2002]. The age-range was chosen in this way in order to span and slightly extend this
age range (from 40 to 75+), with the network ‘age 38’ viewed as one control sample, where
tumour progression is not influenced by ageing impact on genetic and epigenetic modifi-
cations, and the network for ‘age 83’ is another control sample, where ageing damps cell
dynamics, and consequently, aberrant changes involved in tumour development, [Campisi,
84
2003].
Authors have suggested that the 5-year interval is important in analysis of gender dif-
ferences reported in CRC development, [Frank, 2007; Brenner et al., 2007], and we have
followed this for the exploration here although in practice, of course, any time step could
have been chosen to investigate age profile overall. Indeed, in choosing a slightly extended
upper and lower bound for the age range considered, we have deliberately allowed for some
fuzziness in terms of whether age-difference is specific to a particular age-range or observed
more generally.
Table 5.3: Example of AG parameter values for different groups of individuals, based on
age-gender characteristics
Age-groups Male Female
<40 0 0
40 - 44 0.10 0
45 - 49 0.10 0.10
50 - 54 0.17 0.10
55 - 59 0.25 0.17
60 - 64 0.35 0.25
64 - 69 0.35 0.35
70 - 74 0.27 0.35
75 - 79 0.23 0.27
80+ 0.23 0.23
Note: The values from Table 5.3 are inferred from different statistical reports on CRC
incidence, e.g. GLOBOCAN 2012, [Ferlay et al., 2014], Cancer Research UK, [Cancer Re-
search UK, 2014b]. In model terms, the gene relationship probabilities in the gene network
are affected during the DNAm update step.
Analogously, an example for the TH HM parameter is included in Table 5.4, with
age/gender patterns taken for TH HM parameter value choice similar to those followed
for AG parameter value selection. The ASG value was set to 50 years, given that the spo-
radic CRC incidence was reported to increase after this age, [Issa et al., 1994]. Research
has indicated that abnormalities of signalling pathways can have high impact on cancer de-
velopment, (decided in the gene network based on methylation level, (Section 5.2)). Values
of 0.05 and 0.10 were taken for SAM and SIG based on tuning parameters: the probability
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of an event occurring for a gene G found in a signalling pathway was taken to increase with
maximum 0.50 the initial probability taken from StatEpigen database, (expression 5.3).
This extreme value is obtained when the gene network represents a male, age 60 - 70, (or
female, age 65- 75), e.g. AG = 0.35, and gene G is also sensitive to age-related methylation,
(e.g. SAM = 0.05), i.e. AG(age, gender) + SAM + SIG = 0.50. Other values are, of course,
also possible and sensitivity analysis for these parameters is planned, (Chapter 8).
Table 5.4: An example of the TH HM parameter for different groups of individuals, based
on age-gender characteristics
Age-groups Male Female
<40 0.60 0.60
40 - 44 0.55 0.60
45 - 49 0.55 0.55
50 - 54 0.48 0.55
55 - 59 0.39 0.48
60 - 64 0.39 0.39
64 - 69 0.28 0.39
70 - 74 0.28 0.28
75 - 79 0.37 0.28
80+ 0.37 0.37
Note: Similar to the values in Table 5.3, the values from Table 5.4 are inferred from dif-
ferent statistical reports on CRC incidence, e.g. GLOBOCAN 2012, [Ferlay et al., 2014],
Cancer Research UK, [Cancer Research UK, 2014b]. In model terms, they describe the
probability thresholds for permitting HM updates, based on DNAm - HM interdependen-
cies.
Initially, tumours of all patients were considered to be in carcinoma in situ. The goal
of the simulations was the investigation of instances when the gene networks moved to
the next cancer stage, invasive carcinoma. The focus was on promoter hypermethylation
information, and in order to decide on tumour progression, the average methylation level
for the entire gene network has been analysed, (using the network score method described
in Section 5.2). Therefore, an increase in the average methylation level of the gene network
can be associated with tumour development. The features of each case study are described
below.
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5.3.1 Case study 1 on ‘Combined ageing and gender influence’
Genes such as APC, MGMT, MLH1, KRAS, TP53 are considered to be key-genes in CRC,
given the impact on tumour development of any changes, (Section 2.6). Based on this
information, four different gene networks were built according to the following criteria:
1. The first network, (‘APC-TP53’ network), was created including data on conditional
relationships between micromolecular events affecting APC, TP53 and other genes.
2. The second network, (‘KRAS-BRAF’ network), included the conditional relation-
ships between KRAS and BRAF and other genes.
3. The third network, (‘APC-MGMT’ network), utilised the conditional relationships
between APC, MGMT and other genes.
4. The fourth network, (‘APC-MLH1’ network), incorporated the conditional relation-
ships between APC, MLH1 and other genes.
The network size in each case was similar in terms of the number of nodes and edges,
which were in the range 9 - 15 and 10 - 18 respectively. The graphical data visualisation
was created using Cytoscape, [Smoot et al., 2011], and network structures are illustrated in
Figure 5.2. The study was designed to analyse 100 patient profiles for each gender, (with 10
male and 10 female profiles generated for every age subgroup) and for every gene network.
These patients are wholly synthetic, generated from set of possible parameter values
given in Table 4.3, (Section 4.5). Specifically, this case study focused on the following
questions:
1. What is the relationship between younger and older patients regarding rapidity of
tumour progression, (advance to the next cancer stage)?
2. Is there a marked difference between males and females in terms of methylation level
observed over time?
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5.3.2 Case study 2 on ‘Gene sensitive to age-related methylation’
In order to analyse the impact of aberrant methylation of gene sensitive to age-related
methylation, two gene networks, namely ‘APC-BRAF’ and ‘APC-IGF2’, were built from
empirical data on relationships between APC and other genes, (e.g. MLH1, TP53), with
a focus on promoter hypermethylation information. The major difference between the two
was, thus, the replacement of the BRAF gene with the IGF2 gene, (since the latter is con-
sidered as being potentially sensitive to age-related methylation, [Issa and Ahuja, 2000]).
The conditional relationships between these key genes and others in the ‘APC-BRAF’ and
‘APC-IGF2’ networks were also taken into account.
a) ‘APC-BRAF’ network
b) ‘APC-IGF2’ network
Figure 5.3: Structure of the ‘APC-BRAF’ (a) and the ‘APC-IGF2’ (b) gene networks. The
IGF2 gene is considered to be sensitive to age-methylation, therefore the focus was on
the ageing impact on the methylation level deregulations inside a cell, (mimicked by the
network), with aberrant modifications of the IGF2 gene. The networks were built using
conditional gene relationships data from the StatEpigen database. Legend: Circle - gene in
network, Edge - gene relationship.
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The network structures are illustrated in Figure 5.3. Similar to the previous case study,
100 patients profiles have been generated for each gender for both gene networks, (i.e.
synthetic patients).
5.3.3 Implementation details of the E-G Network
Class description and diagram
The E-G Network model is an object oriented framework (written using C++), where the
major classes are the following, (with the class diagram illustrated in Figure 5.4):
• BayesianNetwork - This is considered the main class of the E-G Network model as
it encodes the gene network functionality and assures the communication between
the model core and external applications. For instance, preprocessing of the biolog-
ical data, (i.e. removing duplicates from the initial data and those relationships re-
ported to have zero probability), loading an individual’s characteristics, building the
gene graph, resolving the potential circuits, evaluating the gene network, calculating
the gene pathway scores, processing ‘cellular divisions’, are several of the actions
performed by the BayesianNetwork objects. Among other elements, a BayesianNet-
work object contains a NetworkSettings object and a collection of GeneRelationship
objects.
• NetworkSettings - All characteristics presented by an individual, (e.g. ageing, gender,
heredity, viral and bacterial infection), are loaded into a NetworkSettings object and
transmitted to the BayesianNetwork in one step.
• GeneRelationships class - connects information on gene relationships from StatEpi-
gen database, [Barat and Ruskin, 2010], (encoded by the GeneEvent class), and gene
characteristics, (e.g. gene name, gene sensitivity to ageing, methylation level), which
are encoded by the Gene class. In addition, the class initializes the gene methylation
level based on cancer stage information.
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Figure 5.4: Class diagram for the E-G Network model. The dark-shaded diamond shape
indicates the composition relationship between classes, (i.e. the component lifecycle is
controlled by the container-class: if the latter is destroyed, the former is destroyed as well).
For example if a BayesianNetwork object is destroyed, the instances representing the com-
pound graph elements (nodes and edges) are also destroyed. In addition, the relationship
between the numbers of instances of classes is represented, when information on precise
ratio between those instances is known (e.g. Gene and GeneRelationship classes), by pre-
cise integer values; otherwise, when a variable number of compound instances is contained
within a class, (e.g. GeneRelationship and BayesianNetwork classes), the ’*’ sign is used.
• GeneEvent - This handles causal relationships between two molecular events, (e.g.
hyper/hypomethylation, mutation), affecting two genes of a certain ‘cancer stage,
cancer type’ pair. It represents the information from StatEpigen database.
• Gene - This encodes information on gene characteristics, (e.g. name, type - tu-
mour suppressor, oncogene, caretaker; methylation level), and information on ‘self-
relationship’, (Section 4.2), and on signalling pathways that include it. Moreover, it
‘communicates’ with H3 and H4 histone regarding modifications.
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• Histone - This class handles information on H3 and H4 histones and provided func-
tionality for the initialization and update of their modifications, (e.g. acetylation and
methylation), also based on the dual relationship between the DNAm and HM, (Sec-
tion 4.7).
Finally, the doxygen tool, [van Heesch, 2008], was used to generate code documenta-
tion, which can be accessed online, at the following url:
http://www.computing.dcu.ie/ iroznovat/documentation/html/index.html.
Parallelisation strategies for the E-G Network
The case studies for the E-G Network integrated gene networks of modest size (nodes in
range 9 - 15 and edges in 10 - 18, respectively) and analysed ageing and gender influences
for a total of 1000 ‘patients’ with respect to cancer initiation, (i.e. transition between car-
cinoma in situ and invasive carcinoma). Given these settings, serial simulation took around
114 min. However, the aim is to evaluate risk factor impact on methylation level changes
in larger system size, (e.g. ∼ 100 genes), for larger patient number, (e.g. 103 for each
age/gender group per network), for longer time-periods, (e.g. to explore modifications be-
tween carcinoma in situ and metastasis), and for larger gene network set, (i.e. to mimic cell
population dynamics). In addition, given the main objective of our research to investigate
CRC dynamics in multi-scale systems, (Section 1.2.1), parallelisation implementation is
clearly needed to reduce simulation running time. However, development of parallelisation
strategies is not trivial and the main challenge is minimization of compute node communi-
cation overhead.
The performance of a parallel algorithm can be evaluated by speedup (SP ) and efficiency
(EP ) values:
SP = TS/TP (5.4)
EP = SP /P (5.5)
where P = processor number, TS = execution time for serial algorithm, TP = execution
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time of the parallel algorithm with P processors. While linear speedup, (achieved when SP
= P), or efficiency = 1 is ideal, this is not generally obtained in complex systems, (where
high communication between compute nodes is needed to represent relationships between
compound entities). Thus, rigorous analysis of system dynamics is necessary prior im-
plementation of parallelisation algorithm. In the E-G Network, communication is handled
using MPI paradigm, (Message Passing Interface) and two parallelisation strategies have
been identified. These target i) the ‘patient’ groups analysis and ii) methylation level up-
date step, (Section 4.5).
In the ‘age/ gender’ case studies, given that no communication was needed among sys-
tems, the main thread allocated a node to each ageing/gender group, (i.e. in total, 20 nodes/
network), and collected results at the end of the simulation. In this case, temporal paralleli-
sation was used, (i.e. iterations for the gene networks run simultaneously), and efficiency
close to 1 was achieved. Specifically, efficiency ranked from 0.87 for the ‘KRAS-BRAF’
networks to 0.99 for the ‘APC-BRAF’ systems, (speedup and efficiency values for each
gene network are included in Table 5.5). This strategy can be used also for testing a group
of identical gene networks, i.e. for cell population, (discussed in Chapter 8).
Table 5.5: Speedup and Efficiency values for each gene network included in the ‘age/ gen-
der’ case studies
Gene network Serial run-
ning time
Parallelisation
running time
Speedup (20
nodes)
Efficiency
APC - TP53 807 sec 43 sec 18.76 0.93
KRAS - BRAF 2275 sec 128 sec 17.77 0.88
APC - MGMT 758 sec 38 sec 19.94 0.99
APC - MLH1 900 sec 48 sec 18.75 0.93
APC - BRAF 1109 sec 56 sec 19.80 0.99
APC - IGF2 1029 sec 54 sec 19.05 0.95
Note: Results from Table 5.5 are based on tests run on 20 nodes/network, with 10
‘patients’/ node.
The second parallelisation method targets division of the gene network into subnet-
works, (i.e. spatial parallelisation). The challenge here is characterisation of the optimal
subnetwork size, (with respect to both node (gene) and edge numbers). A solution can be
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given by detection of ‘hub’4 genes and splitting the gene network in the way in which ev-
ery ‘hub’ gene determines a subnetwork. An immediate derived approach is running every
gene on a compute node, given that no communication between genes is needed during
methylation level update step. However, in both cases, communication master/ slave is nec-
essary after every methylation cycle in order to inform on the new gene methylation level,
(required for calculation of e.g. the average network mehtylation level, used in cancer de-
cision methods, (Section 5.2)). In this case, a solution for overhead reduction can be given
by extending time-interval for information exchange between master/ slave, (e.g. at every
4, 10, .. iterations). This work is ongoing and given communication in the gene network,
linear speedup is again not expected. However, parallelisation implementation in the E-G
Network is possible and would facilitate extended model testing.
5.4 Results and discussion
Methylation level was seen to increase for every patient during the simulations. This is due,
in part, to the fact that the current study included mostly data on promoter hypermethylation.
According to the first decision method (described Section 5.2) on methylation level increase
in the gene network, any tumour therefore advanced to the next cancer stage for all patients
over the time period of the simulation. For an individual patient, the time taken to tumour
advance to invasive carcinoma was given by the methylation cycle number, measured during
the simulation. Further, for each age/gender group, the average of the methylation cycle
numbers, denoted as methylation cycle number average, (MCA), was calculated. The results
obtained are discussed below.
5.4.1 Results for case study 1 on ‘Combined ageing and gender influence’
The MCA number at which the tumour advanced to invasive carcinoma is illustrated in
Figure 5.5 for each of the four networks.
4A ‘hub’ gene is considered to be a strongly-connected gene in the network, (subsection 4.5.2).
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Gender influence
Some gender differences can be observed in the analysed networks, where MCA numbers
recorded for males from one age subgroup are similar to those of females from the next age
subgroup. For example, results from the ‘APC - TP53’ network show that the time taken
for tumour progression in a female of age 53 is closer to that for a male of age 48 than to
that of a male of age 53, (i.e. MCA numbers corresponding to the fourth female and third
male ageing subgroups, (10,032 and 10,024), are closer than those for the fourth female
and fourth male age subgroups, (10,032 and 9,662)). The same remark can be made, for
example, for the MCA numbers seen for males of 63 years and females of 68 years from
the ‘KRAS - BRAF’ network, (the 6th male and 7th female subgroup respectively), where
MCAFemale,68 ≈ 9.188, MCAMale,63 ≈ 9.206 and MCAMale,68 ≈ 8.694.
Ageing influence
For an analysis on the age influence, the results shown in Figure 5.5, were regrouped into
four major age groups: less than 50 years, (< 50), between 50 and 64 years, (50-64),
between 65 and 74 years, (65-74), and higher than 75 years, (75+), as shown in Figure
5.6. This rearrangement was carried out to reflect age impact on tumour development,
specifically reported in the cancer literature: CRC risk increases significantly after age 50,
has its peak between 65 and 75 years and decreases slowly after age 75, due to age-related
influence on cell dynamics, [Christensen et al., 2009; SEER, 2013a; Cancer Research UK,
2014a; Ferlay et al., 2014].
The age influence can be seen in cancer development for all gene networks. The MCA
numbers are lower for the ‘65-75’ and the ‘75+’ age groups showing that progression to
invasive carcinoma is faster for those age categories than for younger patients (i.e. of ‘<50
years’ and ‘50 - 64 years’). For example, in ‘APC-TP53’ networks, while the MCA numbers
for the ‘<50 years’ group were≈ 10,200, those specific to ‘65-75’ age group were≈ 8,800
for both genders.
However, the age difference was far less marked in the ‘APC-MLH1’ network. One
plausible cause is the network structure, (Figure 5.2). (The ‘APC - TP53’, ‘KRAS - BRAF’
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and ‘APC - MGMT’ networks are represented by a star structure with only one ‘hub’ gene,
while the ‘APC - MLH1’ has a star structure with two ‘hub’ genes). Additionally, net-
work size and gene relationships that depend on the ‘hub’ gene can impact on these results.
Clearly, this is a preliminary analysis and further tests are needed to analyse other depen-
dent networks (e.g. APC-KRAS, APC-MCC), with e.g. three ‘hub’ genes (such as APC,
MGMT and MLH1) and similar number for connected nodes, as well as those networks
where no. nodes is increased, (e.g. to 100+).
5.4.2 Results for case study on ‘Gene sensitivity to age-related methylation’
The results obtained do indicate that time taken for tumour progression in ‘APC-IGF2’ was
shorter than that for the ‘APC-BRAF’ network. Since the IGF2 gene is sensitive to age-
related methylation, its abnormal promoter methylation makes a higher contribution to the
total network methylation level. Similar to the analysis of age influence from the previous
case study, results obtained were grouped into the four major age-groups, suggested by
the literature (i.e. <50, 50-64, 65-74 and 75+ years, respectively), for each gender. The
overall comparison on the MCA numbers corresponding to the ‘APC-BRAF’ and ‘APC-
IGF2’ networks is illustrated in Figure 5.7, and detailed information is provided in Table
5.6.
Specifically, the ‘APC-IGF2’ networks moved to invasive carcinoma during shorter
time-periods than the ‘APC-BRAF’ networks, where time differences recorded for these
networks were around 725, 620, 550 and 620 methylation cycles for the four major age-
groups respectively. ‘Gender difference’ was illustrated also by results of ‘APC-BRAF’
and ‘APC-IGF2’ networks, where the lowest MCA number, (corresponding to the shortest
time of tumour to progress from Stage 0 to Stage 1), was found for the ‘65-74 years’ and
‘75+ years’ groups in males and females, respectively.
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Figure 5.7: Comparison of time, (MCA number), at which the ‘APC-BRAF’ and ‘APC-
IGF2’ gene networks move to Invasive Carcinoma. Results refer to male (top), and female
‘patients’, (bottom). Legend: Results for the ‘APC-BRAF’ network are shown in blue and
those for the ‘APC-IGF2’ network in yellow.
While results provide some support for age-sensitive gene contributing to cancer growth,
further tests on other genes exhibiting age-related methylation are clearly also necessary to
assess relative impact on disease progression. In addition, further tests including larger net-
work samples should facilitate investigation not only of weather these differences are sig-
nificant in the statistical sense between these age groups but biologically supported, given
deregulations of age-sensitive genes such as IGF2.
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Table 5.6: Detail on MCA number results corresponding to gender and age-groups: <50
years, 50-64 years, 65-74 years and 75+ years, for both ‘APC-BRAF’ and ‘APC-IGF2’ gene
networks.
Gender Age-Group APC - BRAF APC - IGF2
Male <50 years 10,001 9,277
50 - 64 years 9,571 8,948
65 - 74 years 9,177 8,622
75+ years 9,445 8,825
Female <50 years 10,049 9,320
50 - 64 years 9,734 9,069
65 - 74 years 9,334 8,761
75+ years 9,316 8,738
5.5 Summary
Two methods have been proposed for deciding whether cancer progression occurs, based on
methylation level: i) average network methylation level and ii) percentage of highly methy-
lated genes. In addition, parallelisation strategies have been identified for the extended E-G
Network and the need of parallelisation implementation in the context of more complex sce-
narios for the gene network was highlighted. Moreover, the influence of ageing and gender
with respect to genetic and epigenetic modifications induced over time has been modelled
using the following steps:
• Definition and incorporation of an Ageing-Gender (AG) parameter in the methylation
level update step of the basic E-G Network Model in order to represent the impact of
an individual’s ageing and gender on DNAm level.
• Definition of the TH HM function accounting for ageing and gender, to accommodate
the update of the histone modification patterns based on DNAm - HM interdependen-
cies.
• Increased probability of methylation modification occurrence permitted for those
genes, identified as sensitive to age-related methylation for individuals > e.g. 50
years of age.
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Obviously, values of these quantities can be further refined as new data become avail-
able. In order to investigate the impact of ageing and gender on DNAm level in CRC
initiation, a case study was performed and four gene networks were considered. These in-
cluded information on a set of key-genes in CRC development and a spectrum of age for
both genders. In a second case study, abnormal changes of the IGF2 gene were also consid-
ered in terms of the effect on gene network. Results obtained to date showed that tumour
progression rate does appear to differ across patient groups and is influenced by ageing,
gender and associated gene characteristics. This rate was found to be higher for older, (i.e.
‘65+ years’), than for younger patients, (i.e. ‘< 65 years’), for men than for women, and for
those presenting with an aberrant modification in the IGF2 gene compared to those with-
out. These conclusions are based on methylation cycle number analysis. The model can
be refined to include incorporation of these features as can be shown to reproduce effects
of ageing and gender on methylation for some genes in agreement with clinical studies.
Not all genes seemed to be similarly age-influenced despite being treated similarly, which
argues for further refinement being needed in the way in which the model accounts for age.
Of course, experimented data are limited to date on these features also, but the model does
permit exploration of ‘what if’ scenarios, which may help in identifying possible outcomes
for mapping also onto real patient data.
A clear limitation of the E-G network model is the lack of precise information on the
real length of the methylation cycle and consequently, this component is approximated to
the colon stem cell cycle, which lasts around seven days, [Potten et al., 2003]. For ex-
ample, based on current results, the average methylation cycle number is equal to ∼8,690
for the 75+ years old female in ‘APC - TP53’ network. According to the stated relation
between real time and methylation cycle, this represents ∼167 years, which is obviously
highly unrealistic as the time required by a tumour to progress between carcinoma in situ
to invasive carcinoma for the 75+ years old female group or represents essentially infinite
latency. This result is clearly due to simplistic information on abnormal molecular modi-
fications observed in a (small) gene network, (i.e. less than 20 genes), in which only the
influence of ageing and gender factors was considered. However, CRC predisposition is
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influenced by other characteristics also, such as physical activity, diet, and environmental
factors, (Subsection 2.6.2). Exposure to chemicals such as arsenic and cadmium have been
reported to induce global DNA hypomethylation and histone modifications in cells leading
to colon cancer, [Hou et al., 2012]; in consequence, relevant environmental data should be
included in an extended analysis of tumour progression dynamics.
Another limitation is that the gene networks have mimicked only one stem cell, which is
obviously unrealistic for predicting cancer development. In addition, a cell communicates
with its neighbours through gap junctions, (regulated by the connexin family), and reduced
inter-cell communication has been reported also in CRC development, (associated with the
silencing of different connexin genes such as GJC1, due to promoter hypermethylation),
[Sirnes et al., 2011]. Thus, any realistic analysis of the DNAm levels must be extended to
cell populations and different cell types.
Recognition of the shortcoming in network-based methods of this type has motivated
the development of the AgentCrypt model, (described in the next chapter). This permits
DNAm variation to be investigated in the intestinal crypt over time and enables focus on
aberrant modifications within abnormal systems, exposed to potential carcinogens.
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Chapter 6
AgentCrypt - an Agent-based Model
of Intestinal Crypt Dynamics
6.1 Introduction
The AgentCrypt is an agent based-model which has been developed to investigate methyla-
tion variation in the human intestinal tissues under the influence of different environmental
conditions. These include e.g. carcinogen and methylation inhibitors and methylation pat-
terns are thus of interest during both cancer initiation and progression. The AgentCrypt
model addresses, therefore, the second major research objective proposed in this thesis,
namely “To evaluate quantitatively methylation level variation in intestinal tissues under dif-
ferent external conditions during CRC initiation and progression”, (Subsection 1.2.1), and
its position in the overall Colorectal Cancer Model is highlighted in Figure 6.1. In Chapters
4 and 5, methylation level modifications over time was investigated for a human colon stem
cell, (represented by the gene network in E-G Network Model). The AgentCrypt adds to
this work on the analysis of the methylation modifications at tissue level. The remainder
of the chapter is structured, as follows. Initially, deregulation of the crypt dynamics, which
can induce aberrant methylation patterns over time are explored for the colon crypt sys-
tems, (Section 6.2). Subsequently, and motivated by the need of computational analysis in
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Figure 6.1: Structure of the Colorectal Cancer Model - focus on the AgentCrypt model
The relationships between model components may refer to R1) average methylation level
for gene network / intestinal cell; R2) patient features; R3) intestinal crypt dynamics, ex-
plored following bottom-up and top-down approaches.
the context of EWAS research, (Section 3.4), AgentCrypt is extended to small intestine tis-
sue. This extension takes account of the similarities in and differences between the structure
and dynamics of the colon and small intestine crypts, (Section 2.4). A comparative anal-
ysis is performed on methylation differences characteristic of intestinal tumour initiation,
(Section 6.3). The impact of external factors, such as carcinogens and epigenetic inhibitors
on methylation level is also investigated, (Section 6.4), and an overview of AgentCrypt
implementation is provided in Section 6.5. Two case studies and the results obtained are
described in Section 6.6, and model findings are summarised in the final section. The case
studies aim i) to quantify the methylation variation in normal and abnormal crypts, (both
carcinogen-affected and unaffected), within the colon and small intestine tissues; and ii) to
investigate the effect of a set of potential methylation inhibitors with respect to methylation
modifications in intestinal crypt groups over time.
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6.2 AgentCrypt for Colon Crypt Dynamics during Cancer Ini-
tiation
As seen in Chapter 2, intestinal crypts contain several different cell types1 and have some-
what different structure dependent on tissue type. The crypt cells follow different cycles of
generation to death, and the number of cells of each type and the state achieved in the cell
cycle with respect to other cells determine the ‘health’ of the crypt system. The AgentCrypt
is a computational model, which employs the agent-based paradigm, and is used to the
structure and dynamics of the intestinal crypts, which include colon and small intestine
type. AgentCrypt focuses on the analysis of the DNAm modifications in intestinal sys-
tems, induced by deregulations in cellular mechanisms during cancer initiation. The ABM
features have been presented (Section 3.3.2), and the composition and dynamics of the in-
testinal crypt have been described (Subsection 2.4). Thus, the colon crypt can be modelled
using the ABM approach as follows:
1. the colon crypt consists of a large number of cells of different types: stem, progenitor
and fully-differentiated. It can be viewed, therefore, as a complex system with het-
erogeneous components. In model terms, the cells are the agents and the crypt itself,
together with its neighbours are the environment of the agents.
2. inter-cell influences are represented by agents interactions;
3. the cell ability to perform e.g. division, differentiation or apoptosis at a specific time
point is modelled as autonomously for each agent;
4. the influences of the mother-crypt neighbour, carcinogens and methylation inhibitor
are represented as agent reactivity, (i.e. its ability to respond to a stimulus received
from its environment);
5. finally, cell ageing is modelled in terms of the adaptive/ ‘self-learning’ ability of an
agent.
1Stem, progenitor and (fully-)differentiated cells are present in both colon and small intestine crypts. In
addition, Paneth cell population is located at the base of the small intestine crypt, (Figure 2.2).
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6.2.1 Colon Crypt Structure and Dynamics
Agent communication within the colon crypt mimics the interdependencies between three
cell types, namely, (a) stem cells, (Stem), (b) progenitor cells, (Prog), (c) fully-differentiated
cells, (Diff) , (Figure 6.2). Stem cells are located at the crypt centre, progenitor cells (i.e.
the transit cells) are present in stem cell group proximity, at both left and right sides and
finally, fully differentiated cells occupy the top of the crypt. Both progenitor and differen-
tiated cells migrate upwards during their lifetime. Additionally, due to the crypt structure,
interdependencies between cell-agent neighbours are considered in AgentCrypt and the ‘co-
efficient of influence’, ICoef(C’, C), is introduced as a model input parameter (to provide
characterisation of these cell inter-relations).
Figure 6.2: Structure and dynamics of a normal colon crypt - Simplified representation
Stem cells, (located at the crypt centre), can undergo symmetrical or asymmetrical division,
(when two new stem cells or a stem and a progenitor cells, respectively, are born, and
mother-stem cell is replaced by a daughter stem cell). Progenitor cells, (i.e. the transit
cells), can also divide, (with a higher rate than the stem cells), but relatively few times.
Finally, fully differentiated cells occupy the top of the crypt and can undergo apotosis, i.e.
effective removal from the crypt.
Image adapted from the Integrative Biology Project Office, Oxford University Computing
Laboratory. url: http://www.integrativebiology.ac.uk/colon-cryptic-dynamics.html
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Cell Cycle Cell cycle is defined to be the set of possible actions performed by agents
over time and generally includes updates of methylation level, cellular division, differentia-
tion and apoptosis. However, the cellular actions performed during a cycle depend on the
cell type. Specifically, in order to describe the way that cell methylation level evolves, the
‘methylation level update’ step is introduced into the crypt framework as a cell action per-
formed by all cell types within the colon crypt. In addition, different cell actions are defined
for each cell type, based on its characteristics, (summarised in Table 6.1). Thus, after the
methylation level step, which is mandatory for every cell, a stem cell can undergo division
or apoptosis, a progenitor cell can divide or differentiate, and the cycle of a differentiated
cell can terminate through apoptosis.
Table 6.1: Cell actions specific to each cell type within the colon crypt
Cell Type Cell Action Name Action in AgentCrypt Model
Stem cell symmetrical /
asymmetrical
division
Two stem cells / a stem and a progenitor cell,
respectively, are added to the colon crypt. The
mother stem cell is replaced by one daughter
stem cell, while the other daughter cell is lo-
cated to the left or right of the mother cell’s
initial position, within its cell type groups.
apoptosis, (i.e.
‘programmed
death’)
The stem cell is removed from the colon
crypt.
Progenitor cell cell division The progenitor cell is replaced by one of its
daughters after division; the two new progen-
itors are inserted on the same side of the crypt
as the mother cell, but migrate to the end of
the branch.
differentiation The progenitor cell loses its ability to divide
further, becoming a differentiated cell. Relo-
cated to the differentiated cell group.
Differentiated cell apoptosis The differentiated cell is removed from the
colon crypt.
6.2.2 Cell Ageing
Cell ageing, refers to the number of cell cycles since a cell was born and has also been
taken into account in the crypt framework. While a stem cell can continue to divide over an
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unlimited time period, a progenitor cell has time-limited proliferation capability, which de-
creases as the cell ages and eventually ceases, [Masutomi et al., 2003; Sharpless et al., 2004;
Liu and Rando, 2011; Schepers et al., 2011]. As a corollary, cell’s differentiation capability
increases over time. Cell ageing also influences the dynamics of apoptosis such that an
older differentiated cell will clearly have a higher chance of dying and being removed from
the crypt than a younger cell, [Sharpless et al., 2004; Liu and Rando, 2011; Schepers et al.,
2011]. In model terms, over a cell cycle, each cell C from a crypt generates random values,
(i.e. PC ∈ [0, 1]), for every specific action A that relates to that cell. (PC(A) thus represents
the probability of the cell C executing the action A, where A can be cell division, differen-
tiation or apoptosis). Threshold values, (TCellType ∈ [0, 1]), are considered for each cell
type to control actions taking place and are determined by the logistic functions introduced
in expressions (6.2) - (6.3), (calculation shown further). Thus, an action A can occur only
if PC(A) > TCellType(A). Given that a stem cell is replaced by one of its daughter cells in
normal systems during symmetrical division, cell ageing is considered to have no influence
on stem cell-agent actions and threshold values for stem cell division, (either symmetrical
or asymmetrical), are defined as model input parameters. However, given that progenitor
and differentiated cells have limited lifetime, their actions, (i.e. division, differentiation
and apoptosis), are considered to be influenced by cell ageing. Since logistic regression,
(described by logistic or sigmoidal functions), can estimate the probability of an event to
occur based on a set of independent variables, [Cramer, 2002], in model terms, a family
of sigmoidal functions, with the following general form, has been proposed to compute the
threshold values for progenitor and differentiated cell actions over time:
f(t) = 1/[1 + e±a(t−c)] (6.1)
where: t = current cell age (i.e. the number of cycles since the cell was born), sign
(+/-) indicates an increase/decrease in cell action probability over time. The parameter ‘c’
is associated with cell cycle duration, which is considered to be, in average, around 2.5
days for progenitor, (c = 2.5), and one day for differentiated cells, (c = 1), for the test cases
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reported here. However, other values are also possible and a sensitivity analysis for ‘cell
lifetime’ parameter is planned, (Chapter 8). Additionally, the parameter ‘a’ is linked to
the number of actions performed by cells. Thus, given that a progenitor can undergo both
division and differentiation, a = 2, whereas for differentiated cells, a = 1, (as apoptosis is the
single specific action for this cell type). Considering these parameter values and expression
(6.1), the threshold values for cell division and apoptosis in the test cases are calculated
using expressions (6.2) - (6.3), and are illustrated in Figure 6.3.
Figure 6.3: a) Progenitor division and b) Differentiated cell apoptosis over time
The progenitor division ability decreases over time, as the threshold increases with age.
In addition, the probability of a cell death increases given that the apoptosis threshold de-
creases during cell ageing.
For example, if a progenitor cell C1 generates a value PC1(Division) = 0.70 in the sec-
ond day since it was born, given that PC1(Division)> TPROG(Division), (with TPROG(Division)
' 0.27, calculated with expression (6.2)), cell C1 will perform division. However, if the
same value PC1(Division) = 0.70 is generated in e.g. the fourth day of cell C1 lifecycle,
given that PC1(Division) < TPROG(Division), (with TPROG(Division) ' 0.95), cell C1
will be unable to divide, so undergoes differentiation.
ProgDiv(t) =
1
1 + e(−2)×(t−2.5)
(6.2)
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DiffApoptosis(t) =
1
1 + e(t−1)
(6.3)
6.2.3 The Colon Crypt Group
For a real biological system, such as the colon, crypts are part of tissue structure and clearly
do not exist in isolation. Hence, observation on cancer initiation, made based on infor-
mation regarding abnormal modifications within a single crypt, would be unrealistic. In
consequence, the analysis of aberrant changes is extended to the Colon Crypt Group, which
considers a large number of crypts and can provide information on an increase in ‘tissue
area susceptibility’ to tumour development. The Colon Crypt Group is defined as a collec-
tion of n crypts found in the colon neighbourhood, where n > 0 is a model input parameter.
The main characteristics of the Colon Crypt Group are i) crypt intra- and inter-dependencies
and ii) carcinogen and methylation inhibitor influences, (which target equally every crypt
within the group). The main assumption made for the AgentCrypt model applied to these
groups is that crypt intra- and inter-dependencies, together with cell type, dictate methyla-
tion level dynamics within cells. As noted in Subsection 2.4.2, abnormal changes in con-
nexin gene expression can lead to deregulation of the cell cycle and influence on cell methy-
lation patterns. Crypt inter-influences have been also reported, [Humphries and Wright,
2008], and these are also, therefore, taken into account during the methylation level update
step in AgentCrypt. In addition, carcinogens are considered to have a direct impact on crypt
dynamics as these relate to cell division, differentiation and apoptosis; consequently, they
have indirect influence on methylation level modifications within cells. Very recently, pos-
sibilities for methylation inhibition have been explored, [Lohse et al., 2011; Santer et al.,
2011; McCabe et al., 2012], and AgentCrypt also proposes a mechanism for exploring the
methylation inhibitor influence in the human intestinal tissue. Outputs of the model are
information on the average DNAm level within cells in a Colon Crypt Group. A simplified
overview on the entities and relationships involved in this version of the AgentCrypt model
is illustrated in Figure 6.4.
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Figure 6.4: Colon Crypt Framework - Simplified Structure Representation
The focus of the AgentCrypt model is on the aberrant DNAm level within cells from the
colon crypt group. The dynamics of DNAm are dictated by cell and crypt interdependencies
and cell type. In addition, DNAm level is influenced indirectly by carcinogens, which have
a direct impact on cell dynamics. Different potential methylation inhibitors can be also
applied and their effect on DNAm can be explored.
6.2.4 Methylation level update within the Colon Crypt Group
Methylation levels in the model are taken to be values within the range [0, 1]2, where the
healthy phenotype is characterised by a high average methylation level in the cell, (i.e.
≈1), but decreases as cancer progresses. Initially, the crypt group is considered to be in
a healthy state and the methylation level for every cell is initialized as ‘healthy’, using
data from a study on genome-wide DNA methylation analysis of normal colon and colon
adenocarcinoma, performed in 22 pairs of colorectal cancer and adjacent tissues and 19
samples from healthy individuals, (GEO3 accession GSE42752, [Naumov et al., 2013]).
2Values from range [0, 1] correspond to the percentage of methylation level measured in a given sample.
3GEO = Gene Expression Omnibus database, [Barrett et al., 2013]
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Cancer is considered to have progressed if there is decrease in the average methylation
level calculated for the entire group.
Given that global hypomethylation has been associated with ageing, [Pogribny and
Vanyushin, 2010], cell methylation level in AgentCrypt is considered to decrease over time.
In model term, cell methylation level at time t+1 is given by cell methylation level at time
t, minus methylation level lost during this time interval, i.e.:
M ′(C) = M(C)−ML(C) (6.4)
where: M(C), M’(C) = methylation level of cell C in the current and next Time-step,
respectively. ML(C) represents methylation level value removed during the current update
step for cell C and is calculated based on three major elements, (given by crypt intra- and
inter-influences, (Section 2.4)):
1. methylation decrease specific to cell C at a given time, due to ageing, (a random value
DM ∈ [10−5, 10−4]);
2. the influence of the cell neighbours, (from both left and right sides), computed based on
neighbour cell methylation level, the ‘coefficient of influence’ (subsection 6.2.1), and a
randomly generated value, (R ∈ [5 × 10−2, 10−1]), which indicates that the influences
between same two cells can be variable over time. However, if the crypt is normal, no
neighbour-cell influences have been considered with respect to methylation level modi-
fications. (Expression (6.6) is proposed to calculate the cell neighbours influences.)
3. the influence of the Cr crypt neighbours, CNI(Cr). This is calculated based on the
average methylation level of crypt neighbours, AverMethyl(Cr’), and the Inter-Crypt
Coefficient, (model input parameter, ICC ∈ [10−3, 10−2]), which indicates individual
predisposition for intestinal tumour development. For example, ICC parameter has a
higher value for an individual presenting the inflammatory bowel syndrome4 than for an
individual with no such disease. The CNI(Cr) is computed using expression (6.7) and
4Inflammatory bowel syndrome has been associated with an increased risk of CRC development, (Section
2.4).
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has the same value for all cells of a given crypt Cr, i.e. every cell is affected in the same
way by the mother crypt neighbours.
Specifically, methylation level differences between two successive time-steps in colon
crypt group are described by expressions (6.5) - (6.7), (with variable defined in Table 6.2):
ML(C) = DM + Infl(Left, C) + Infl(Right, C) + CNI(Cr) (6.5)
Infl(C ′, C) =

R×M(C ′)× ICoef(C ′, C), if the colon crypt is abnormal;
0, otherwise.
(6.6)
CNI(Cr) = ICC ×
∑
CrNabr∈{NeighboursofCr}
AverMethyl(CrNabr) (6.7)
The dominant term here is that for Infl(C’, C), which can lead to considerable methy-
lation level differences between abnormal and normal cells. This would imply that the
environment of the cell influences methylation modification dynamics inside the cell.
Table 6.2: Variable definitions for methylation level update step
Parameter name Parameter description
ML the methylation value that will be removed during the cur-
rent update step;
DM ageing-related methylation decrease specific to cell C at a
given time, (a random value ∈ [10−5, 10−4]);
M(C’) methylation level of cell C’ in the current Time-step, (∈ [0,
1]);
ICoef (C’, C) coefficient of cell C’ influence on cell C; model input pa-
rameter with value ∈ [10−3, 10−2]
Infl(Left, C), Infl(Right,
C)
the methylation value that is added to cell C due to
left/right neighbour influences;
CNI(Cr) the neighbour-crypt influences on the Cr crypt;
R random value from [5 × 10−2, 10−1];
ICC the Inter-Crypt Coefficient, (model input parameter, with
a value from [10−3, 10−2]);
AverMethyl(Cr’) the average methylation level of the Cr’ crypt, (computed
based on the methylation level of every compound cell);
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While methylation level is conserved during cell division, methylation level changes occur
during cell differentiation, [Klug et al., 2010; Meissner, 2010; Kaaij et al., 2013], and the
parameter DiffMethCoef is introduced to indicate such modifications. Thus, methylation
level after cell C differentiation can be computed based on methylation level of cell C
before undergoing differentiation:
MDIFF (C) = MPROG(C)×DiffMethCoef (6.8)
where: MPROG(C), MDIFF (C) = methylation level of cell C before and after differenti-
ation step, respectively, and DiffMethCoef = the methylation value removed during cell
differentiation step, (model input parameter, with a value ∈ [0, 1]).
6.3 Extension to the small intestine tissue
The small intestine and colon tissues share a number of features, which can be considered
also in terms of crypt structure (Section 2.4). Thus, AgentCrypt has been extended to mimic
and inspect the dynamics of the small intestine crypt during cancer initiation. The methy-
lation level in every cell within the small intestine crypt is initialized from study data on
genome-wide DNA methylation profiling, (GEO accession GSE50475, [Lay et al., 2014]).
In model terms, the major change is the inclusion of a Paneth cell group, where maximum
and minimum Paneth cell numbers, (i.e. MaxPanethNo and MinPanethNo), are additional
input parameters. Thus, the Paneth cell-agent, which can either migrate to the crypt base
or undergo apoptosis, is included as a fourth type in AgentCrypt. The progenitor cell cycle
is modified also to permit differentiation into Paneth cells and the relationship describing
cell-agent interdependencies is extended to integrate the Stem-Paneth and Paneth-Paneth
influences in addition to those considered for the colon crypt, (subsection 6.2.1). Moreover,
based on expression (6.1) and given that Paneth cell lifetime has been approximated to 20
days, [Sancho et al., 2003; Clevers and Bevins, 2013], the Paneth cell probability to undergo
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apoptosis during its cycle is described by:
PanethApoptosis(t) =
1
1 + e(t−20)
(6.9)
6.4 External influences
Influences of the external factors such as carcinogenes and methylation inhibitors have been
considered also in AgentCrypt and their impact on methylation level is explored through
intestinal crypt groups.
6.4.1 Carcinogens influences
Carcinogen influence permits molecular abnormalities to accumulate, (with faster dynamic),
and facilitates cell growth, [Papailiou et al., 2011]. In model terms, carcinogen presence is
associated with deregulations in crypt dynamics rather than in terms of direct impact on
methylation level. Thus, carcinogens affect threshold values characteristic of each cellular
action within AgentCrypt, by addition/subtraction of a percentage δ1 from the threshold
value, δ1 ∈ [0, 100], (an input parameter). Given that stem cell division and apoptosis are
rare events, threshold values characteristic to this cell group are fractionally modified by
the product fStem ×δ1 value, where fStem ∈ [0, 1], (an input parameter). Hence, under
the influence of carcinogens, the threshold value for cell division is lower than that within
a normal system, with complementary probability of cell proliferation increased. Similarly,
threshold values for apoptosis are increased in affected systems, leading to decrease in the
normal rate of cell death.
6.4.2 Methylation inhibitor activity
Epigenetic drugs are considered a promising option in cancer therapy and several methy-
lation and acetylation inhibitors are already being applied in blood cancer, (discussed in
Section 2.7). Therefore, the AgentCrypt model was extended also to investigate the influ-
ence of potential methylation inhibitors in the intestinal crypt over time.
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Major drug features are efficacy, (which represents the maximum response achieved
after drug application), and potency, (which measures drug amount needed to produce a
specific effect). These can be characterised by a drug response curve, which is represented
by a sigmoidal (or logistic) function and indicates relationship between drug dose and effect,
(i.e. response to treatment). A drug response curve is described typically by a slope factor
and EC50, or half maximal effective concentration, (representing drug concentration that
determines 50% efficacy). As a percentage, therefore, EC50 ∈ [0, 0.50]; thus, efficacy has a
value in [0, 1] range. If slope = 1, the drug response curve has a standard slope; otherwise,
it has a ‘variable slope’. In general, inhibitors are considered to have a standard slope.
In addition, information on time to ‘inflection point’ (IP), (when drug curve changes its
concavity, i.e. effect starts increasing or decreasing) is typically part of the drug response
curve description. Efficacy is illustrated therefore, by drug response curve peak, (the higher
the peak, the greater the efficacy), and potency is displayed by dose-response curve level at
a point on x-axis (a lower value of x for given response suggests greater potency), (Figure
6.5). The general form of logistic function, (expression (6.10)), can be adapted to describe
drug response curve, (expression (6.11)).
f(x) =
c
1 + e−Slope×x
(6.10)
DRC(t) =
EFF
1 + e−Slope×(t−IP )
(6.11)
where: t = time since drug/ inhibitor was applied, EFF is drug efficacy and EFF = 2× EC50,
Slope = slope of drug response curve, IP = inflection point of drug response curve, EC50 =
half maximal effective concentration.
In AgentCrypt, the presence of an inhibitor affects the methylation level update step
during a cell cycle, (given by expression (6.4)), and methylation modifications are gradually
blocked, since the inhibitor effect is considered dependent on the time elapsed since the drug
has been introduced to the system. Specifically, the inhibitor influence increases initially
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Figure 6.5: Drug Efficacy and Potency indicated by Drug response curve
High peak and left position of a drug reposnse curve indicate high efficacy and potency
Image adapted from:
http://classconnection.s3.amazonaws.com/370/flashcards/641370/png/untitled1321511264457.png
up to a maximum value, (i.e. reaches inhibitor efficacy), and maintains a constant level
for a specific time-period, (denoted as the Inhibitor Maximum Efficacy Time (IMET)), after
which, inhibitor effect decreases. In the model, inhibitors are considered to have standard
slope, (i.e. Slope = 1), as noted earlier. Based on these and expression (6.11), the effect of
a methylation inhibitor is characterised by a combination of two logistic functions, denoted
as the inhibitor response curve, (IRC), (expression 6.12), and IMET.
IRC(t) =

EFF
1+e−(t−IPINCR)
, if t ≤ IMET, i.e. ‘increase’ phase ;
1− EFF
1+e−(t−IPDCR)
, otherwise, (‘decrease’ phase).
(6.12)
where t is time (days) since the inhibitor was applied, EFF represents drug efficacy, calcu-
lated based on EC50, (with EFF = 2 × EC50), and IPINCR and IPDCR are inflection points
of drug effect (i.e. times at which inhibitor effect increases and decreases, respectively).
EC50, IPINCR and IPDCR are model input parameters and are also dominant terms here.
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Thus, IRC(t) value is closer to 0 if EC50 ≈ 0 and increases to 1 as EC50 increases. In
addition, a higher IPINCR value implies later IRC(t) increase, i.e. lower potency. Finally,
higher IPDCR implies prolonged effect of the drug.
Example: An example of methylation inhibitor influence is given for a set of three in-
hibitors during a time-period of around 90 days, (≈ one quarter of year). The effect of
the first inhibitor, I1, is taken to start increasing around seven days after application, (i.e.
IP1INCR = 7); for the second and third inhibitors, I2 and I3, the increase is taken around
fourteen and twenty one days, respectively, after application, (i.e. IP2INCR = 14, IP3INCR
= 21). In addition, while the same efficacy applies for inhibitors I1 and I2, a relatively low
value is assigned to efficacy of inhibitor I3, (e.g. EC150 = EC250 = 50%, EC350 = 40%).
Finally, IMET was taken≈ 50 days. The inhibitors described by these settings are given by
expression (6.13), and their effect over time-period of 90 days is illustrated in Figure 6.6.
Considering both efficacy and potency features, inhibitors I1 and I3 can be seen as the most
and least efficient, respectively, within this set. (Inhibitors I1 and I2 have similar efficacy,
but I1 has higher potency than I2. I3 has both efficacy and potency lower than I1).
Inhibitor1, (I1) : IP1INCR = 7 days, IP1DCR = 90 days,EC150 = 50%; (6.13)
Inhibitor2, (I2) : IP2INCR = 14 days, IP2DCR = 90 days,EC250 = 50%;
Inhibitor3, (I3) : IP3INCR = 21 days, IP3DCR = 90 days,EC350 = 40%.
Methylation modifications, ML, occur over time, and in intestinal systems with no in-
hibitors, methylation level is updated using expression (6.4), (subsection 6.2.4). In crypts
for which methylation inhibition applies, methylation level changes are reduced by a value
depending on strength of inhibitor effect: higher effect determines higher methylation re-
duction. Thus, in inhibitor-influenced systems, methylation level variation is given by
ML× (1− IRC(t)) and based on this and on expression (6.4), the expression for methy-
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Figure 6.6: Comparison between the effect of three potential inhibitors on methylation level
over a time-period of 90 days defined by the following settings: i) Inhibitor 1: IP1INCR =
7 days, IP1DCR = 90 days, (green); ii) Inhibitor 2: IP2INCR = 14 days, IP2DCR = 90 days,
(orange); iii) Inhibitor 3: IP3INCR = 21 days, IP3DCR = 90 days, (blue); iv) IMET ≈ 50
days. Inhibitor1 and Inhibitor3 can be considered the most and less efficient, respectively,
within this set.
lation level updates between two successive time-steps in the intestinal crypt becomes:
M ′(C) = M(C)−ML× (1− IRC(t)) (6.14)
where M’(C), M(C) = methylation level of cell C in the current and next Time-step, respec-
tively, and ML = methylation modification between current and next Time-step; t = time
since the inhibitor was applied and IRC(t) = inhibitor effect at time t. For example, if the
inhibitor effect at time t is maximum, i.e. IRC(t) = 1, methylation variation between times t
and t+1 is equal to zero, (expression 6.15). However, if no inhibitors are applied, i.e. IRC(t)
= 0, methylation variation achieves a maximum, (given by expression 6.4).
M ′(C) = M(C)−ML× (1− 1) = M(C)−ML× 0 = M(C)⇒M ′(C)−M(C) = 0
(6.15)
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Figure 6.7: Class diagram for the AgentCrypt model. The dark-shaded diamond shape in-
dicates the composition relationship between classes, (similar to the E-G Network Model,
Chapter 5), while the empty diamond indicates the aggregation relationship between
classes, i.e. the component lifecycle is not controlled by the container class: if the con-
tainer class is destroyed, aggregated instances are not destroyed - only the association be-
tween container class and compound instances is affected.
6.5 Implementation details of the AgentCrypt
Similar to the E-G Network, (Chapter 4), AgentCrypt code is object-oriented, implemented
using C++. Using the same programming language for developing both models facilitates
their connection and integration into a single multi-scale framework for CRC dynamics.
The AgentCrypt structure is represented by the following major classes, with their rela-
tionships shown in the class diagram (Figure 6.7):
• Cell - This class describes cell-agent characteristics, including the division, differen-
tiation and apoptosis functionality.
• Crypt - This class handles the functionality of the intestinal (both small intestine and
colon) crypts; a Crypt object contains a large number of Cell objects and can contain
a set of Inhibitor objects.
• CryptGroup - This class represents the tissue level in the AgentCrypt model and
mimics characteristics of the Intestinal Crypt Group. A CryptGroup object contains
a collection of Crypt objects. The CryptGroup class also offers functionality for
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handling information on individual characteristics, (i.e. the NetworkSettings class
from the E-G Network Model, (Section 5.3.3)).
• Inhibitor - This class encodes methylation inhibitor characteristics and describes
functionality for calculating inhibitor response curve values over time.
Similar to the E-G Network, the Mersenne Twister is used as the random number genera-
tor and Visual Leak Detector, [CodePlex, 2014], is integrated in AgentCrypt for detecting
plausible memory leaks in code. Finally, the code documentation is generated again with
the doxygen tool, [van Heesch, 2008], and can be accessed online at the following url:
http://www.computing.dcu.ie/ iroznovat/documentation/html/index.html.
6.6 Results and discussion
AgentCrypt was applied to analysis of DNA methylation modifications within both small
intestine and colon crypt groups, in healthy and malignant systems, (and under assumed
carcinogen influence). This case study was used to explore evolution of intestinal crypt
mechanisms. In addition, two ‘plausible’ methylation inhibitors, described in subsection
6.4.2, were considered in intestinal crypt systems and their impacts on methylation level
were investigated during cancer initiation. Input parameters are grouped as follows: a)
Table 6.3 contains information on cell numbers specific to colon and small intestine crypts,
respectively; and b) Table 6.4 contains information on intestinal crypt dynamics, such as
coefficient of influence introduced in subsection 6.2.1. The data are organized such that
information from Table 6.3 is tissue-specific, while data contained in Table 6.4 are common
to both colon and small intestine crypt groups. These values are derived from literature
(Section 2.4), or considered as potential input data sets; other values are possible as well
and a sensitivity analysis is certainly needed for every parameter, (discussed in Chapter 8).
Tissue-specific parameter values
The total cell number is approximated to 2000 cells and 260 cells in colon and small intes-
tine crypts, respectively, informing on InitCellNumber parameter value in intestinal sys-
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Table 6.3: Input parameter values on cell number for small intestine and colon crypts
Parameter name Value in the
colon
Value in the
small intes-
tine
InitCellNumber 2000 260
InitStemCellNumber 16 6
MaxTotalCellNo (2 × InitCellNumber) 4000 520
MaxStemNo (2 × InitStemCellNumber) 32 12
MinStemCellNumber 1 1
MinCellNumber
(PercMIN × InitCellNumber, PercMIN = 50%)
1000 130
InitPanethCellNumber 0 10
MaxPanethCellNumber (2 × InitPanethCellNumber) 0 20
MinPanethCellNumber
(PercMIN × InitPanethCellNumber, PercMIN = 50% )
0 5
InitProgCellNumber
(PercPROG × InitCellNumber, PercPROG = 25%)
500 65
MaxProgNo (2 × InitProgCellNumber) 1000 130
MinProgCellNumber
(PercMIN × InitProgCellNumber, PercMIN = 50% )
250 32
tems. In addition, stem cell group consists of around 16 - 19 cells in the colon, (e.g.
InitStemCellNumber = 16 in colon), and 1 - 6 cells in small intestine crypt, (e.g. Init-
StemCellNumber = 6). Major crypt phenomena, such as ‘crypt fission and the ‘bottleneck
effect’, were reported to occur over long time-periods in normal crypts. ‘Crypt fission’ is
characterised by cell population augmentation and was associated with doubling stem cell
number. The ‘bottleneck effect’ is represented by cell group reduction and decrease in stem
cell number up to a single stem cell. Based on these, it can be considered that MaxStemNo =
2 × InitStemCellNumber, MaxTotalCellNo = 2 × InitCellNumber and MinStemCellNum-
ber = 1. Paneth cells are present in a relatively small number at the base of small intestine
crypt and are absent from normal colon crypt. Given these, Paneth cell number in normal
systems, InitPanethCellNumber, is considered to be equal to zero in colon and close to stem
population size in small intestine crypt, (e.g. InitPanethCellNumber = 10 cells). Given no
precise information available on progenitor group size, the progenitor cell number in the
model is taken equal to a percentage of crypt cell population size, e.g. PercPROG = 25%.
Finally, similar to maximum cell numbers which are double of normal cell numbers, the
122
minimum cell numbers are calculated as a percentage of normal cell population sizes, (e.g.
PercMIN = 50%).
Common parameter values
The parameter values from Table 6.4 are chosen based on several criteria, such as: i) the
system computational performance, (e.g. cell numbers in crypt), ii) a framework-defined
‘inter-cellular influence hierarchy’ based on cell type, (according to which, for example, the
influence of a stem cell on a progenitor is higher than the reverse and the influences between
cells of the same type are represented by a common value for the whole system), (i.e.
coefficient of influence), iii) ‘middle’ changes induced by carcinogens on cell dynamics,
(e.g. carcinogen influence ≈ 50%) and iv) low methylation level differences occurring
during cell differentiation.
Table 6.4: Input parameter values of intestinal crypt dynamics used in the AgentCrypt for
both small intestine and colon crypt
Parameter group Parameter name & value
Crypt number per group n = 10.
Threshold values TStem(SymDivision) = 0.99;
TStem(AsymDivision) = 0.94.
Cell cycle duration ProgCellCycle = 2.5;
DiffCellCycle = 1.
Methylation level change due to cell dif-
ferentiation
DiffMethCoef = 90%;
Carcinogen influence δ1 = 50%;
fStem = 0.1;
Coefficient of influence ICoef(Stem, Stem)= 0.002;
ICoef(Paneth, Paneth) = 0.002;
ICoef(Prog, Prog) = 0.002;
ICoef(Diff, Diff) = 0.002;
ICoef(Stem, Prog) = 0.003;
ICoef(Stem, Paneth) = 0.003;
ICoef(Prog, Stem) = 0.001;
ICoef(Prog, Diff) = 0.003;
ICoef(Diff, Prog) = 0.001;
ICoef(Paneth, Stem) = 0.001;
CYPT INTER COEF = 0.001.
Given that probabilities for stem cell division and apoptosis to occur are considerable
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low in normal systems, significant high values are assigned for stem cell action thresholds,
(e.g. TStem(SymDivision) = 0.99, TStem(AsymDivision) = 0.94). Stem cell cycle was ap-
proximated to seven and five days in human colon and small intestine, respectively, and
intestinal tissues are characterised by high cell turnover rate, (Section 2.4). Based on these,
lifetime was considered around 2.5 days for progenitors and one day for differentiated cells
in both crypt types. Given limited precise information on intestinal tissue dynamics, param-
eter values included in Table 6.4 are proposed for the test cases presented in this chapter.
However, alternative values are also possible and a sensitivity analysis is required to inves-
tigate system behaviour with various value-ranges for input parameters, (Chapter 8).
6.6.1 Case study on DNA methylation level variation during intestinal cancer
development
Initially, DNAm variation in the small intestine and colon crypt over time was considered.
Specifically, three major systems, namely i) the healthy crypt, ii) the aberrant crypt and iii)
the carcinogen crypt, were defined and incorporated in this test case. DNAm level changes
are permitted for all three crypt types, but intra-crypt communication was not considered
to affect cell methylation level in the healthy crypt case. Under carcinogen influence, cell
action threshold values are modified (δ1), as described in Section 6.4.1. Three groups of
10 crypts were defined for each system type, (i.e. healthy, aberrant and carcinogen crypt),
and a comparison of DNA methylation variation was performed for both small intestine and
colon tissues. The set of input parameters, that describe these systems, is given in Table 6.3
and 6.4.
The crypt groups were allowed to evolve over time, (simulation time of 550 iterations,
approximated to 1.5 years in colon tissue) and the analysis considered both intra- and inter-
tissue comparisons, (addressing elements of Research Objective 3, (Section 1.2.1)). Based
on individual crypt methylation level (given by the average methylation level of the com-
pound cells), the average methylation level was calculated for each crypt group, (illustrated
by Figure 6.8). This shows that although average methylation level values decreased for
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Figure 6.8: Comparison between methylation levels recorded in a) colon and b) small in-
testine
The average methylation level is calculated for each of the healthy, aberrant and carcinogen-
influenced crypt groups within both the small intestine and colon over a 550-day period.
The highest methylation level is recorded in the healthy crypt groups for both tissue types,
while the lowest methylation level (i.e. the highest decrease) is observed in the ‘carcinogen’
crypt groups.
each crypt group during the simulation, updates followed different patterns for healthy,
aberrant and carcinogen-influenced crypts. Differences between final and initial average
methylation levels are given in Table 6.5, for both colon and small intestine crypt groups.
Specifically, methylation differences observed are ≈1.58% in healthy, ≈7.44% in aberrant,
and ≈7.64% in carcinogen-affected systems in colon tissue, and ≈1.83%, ≈7.39% and
≈7.64% in corresponding crypt groups in the small intestine. The lowest methylation level
decrease over time was recorded for healthy crypts, (interpreted as changes in methyla-
tion level due to ageing), while the highest hypomethylation difference was observed in
the ‘carcinogens’ groups. The average methylation level within aberrant crypt groups de-
creased by≈5.85% in the colon and with≈5.55% in the small intestine in comparison with
that recorded for healthy systems. Differences in average methylation level decrease be-
tween carcinogen and healthy crypt groups were ≈6.05% in the colon and ≈5.81% in the
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small intestine. These results on the methylation level loss between the ‘aberrant - healthy’
and ‘carcinogen - healthy’ group-pairs indicate that while carcinogens do not have a di-
rect impact on epigenetic mechanisms, methylation patterns are differently affected in the
systems where these influences are present. In addition, results indicate an increase in av-
erage methylation level of the small intestine during the first week, (∼ 30 days, equivalent
to Paneth cell cycle duration, (Section 2.4)), a pattern not shown in the colon. A cause of
this phenomenon can be related to Paneth cell group presence in the small intestine and the
way in which crypt methylation level is influenced by cell dynamics. Specifically, although
cells initially have similar methylation level, the differentiated cell population will, after a
period of time, will contain lower methylation level than stem and progenitor cells, (due
to demethylation during differentiation). In addition, an increase in crypt methylation level
can occur between two successive time points when differentiated cells undergo apopto-
sis and stem/ progenitor cells divide, (transmitting accurate methylation information). In
the colon, given that the differentiated cell population is extended during every progenitor
differentiation, the decrease in methylation level is maintained over time. However, this
is not exhibited by the small intestine, where progenitors can differentiate also into Paneth
cells, resulting in no changes in differentiated cell population. In consequence, if several
differentiated cells die, an increase in crypt methylation level can be recorded.
Finally, relatively higher values were recorded in the colon, (though broadly compara-
ble), suggesting that colon may be more sensitive than small intestine tissue with respect
to methylation level dynamics induced by abnormal conditions. This is also an interesting
observation given that simulation time was relatively short in comparison with cancer devel-
opment time, (i.e. ≈1.5 years versus several decades). Thus, further tests should consider
longer time-periods for intra- and inter-tissue analysis of methylation level modifications.
6.6.2 Case study on methylation inhibitors influence
The impact of methylation inhibitors on intestinal crypt methylation level was analysed in
a second case study, in small intestine tissue, using inhibitors with the highest and lowest
effect from the set defined in expression (6.13), i.e. I1, (IP1INCR = 7 days, IP1DCR =
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Table 6.5: Difference between the Final and Initial Average Methylation Level, recorded
for Healthy, Aberrant and Carcinogen Crypts within the Colon and Small Intestine Groups
System Type Row Measurement Colon Small intestine
Healthy R1 Initial level 0.49997; 0.49988;
R2 Final level 0.48411; 0.48150;
R3 δR2−R1 -0.01586; -0.01838;
Aberrant R4 Initial level 0.49988; 0.49983;
R5 Final level 0.42546; 0.42589;
R6 δR5−R4 -0.07442; -0.07394;
Carcinogen R7 Initial level 0.49990; 0.49986;
R8 Final level 0.42349; 0.42338;
R9 δR8−R7 -0.07641; -0.07648.
90 days, EC150 = 50%), and I3, (IP3INCR = 21 days, IP3DCR = 90 days, EC350 = 40%).
Similar to the previous case study, methylation levels in the respective crypt groups was
initialized using data from GEO accession GSE50475 dataset. In addition, four crypt groups
were defined as follows:
• S1: normal crypt group, with no inhibitor applied;
• S2: abnormal crypt group, with no inhibitor applied;
• S3: abnormal crypt group with inhibitor I1 applied;
• S4: abnormal crypt group with inhibitor I3 applied;
These test systems were allowed to evolve over 90 days, (i.e. ∼ quarter year) and four
synthetic individuals were comprised in this case study. The average methylation level was
recorded for every system, (illustrated in Figure 6.9).
Results indicate that methylation level decreased in every system defined; however, dif-
ferent patterns of variation were observed, (average methylation changes for the simulation
are shown in Table 6.6). Specifically, the differences recorded between the final and initial
methylation level for each system are i) ≈ 1.65% in S1, (healthy crypt group), ii) ≈2.66%
in S2, (abnormal system with no inhibitor applied), iii) ∼ 1.75% in S3, (abnormal system
with inhibitor I1 applied) and iv) ≈2.06% in S4, (abnormal system with inhibitor I3 ap-
plied). Lowest and highest differences can be seen in systems S1 and S2, i.e. the normal
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Figure 6.9: Comparison between average methylation level in four different intestinal crypt
systems, over 90 ‘days’, where different methylation inhibitor patterns were applied. S1
(green) and S2 (red), refer to normal and abnormal systems, respectively, and are considered
to be ‘control groups’, given that no inhibitors were applied. Inhibitors I1 and I3 have been
applied in S3 (blue) and S4 (black), respectively.
and the abnormal systems with no inhibitor applied, respectively. Given that inhibitor I1
was observed to have a higher effect than inhibitor I3 over time, (Figure 6.6), the difference
for system S3 (with I1 applied), is less than that for S4, (with I3). Differences of ≈ 0.60
and 0.90% in average methylation level decrease over time can be seen among abnormal
systems, with and without inhibitors applied, i.e. S2 - S3: 2.66% - 1.75% ≈ 0.90% and S2
- S4: 2.66% - 2.06% ≈ 0.60%. As expected, methylation inhibition does result in lower
average methylation variation, which implies that some of epigenetic ‘control’ is possible
and this has clear therapeutic value. However, % changes are still small and one issue for
future work is how much deviation can be tolerated by the system before significant effects
are observed. In addition, future work is planned to target methylation analysis in systems,
where inhibitors are applied either sequentially, e.g. I1 then I3, or combined, e.g. I1+I3.
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Table 6.6: Difference between the Final and Initial Average Methylation Level in the set of
crypt groups
Crypt sys-
tem/Methylation
level
S1 (healthy) S2 (abnormal,
no inhibitors)
S3 (abnormal
+ I1)
S4 (abnormal
+ I3)
Initial
(Mi)
0.4999333 0.49989 0.4998907 0.499836
Final
(Mf )
0.4834276 0.4732609 0.4823474 0.4792197
Difference
(∆ = | Mf -
Mi)|
0.0165057 0.0266291 0.0175433 0.0206163
6.7 Summary
AgentCrypt focuses on DNAm level variation, induced during cancer initiation and pro-
gression, in cells within the small intestine and colon crypt groups. The main contribution
of AgentCrypt is to highlight methylation variation with respect to potential carcinogen and
inhibitor influence. The main entities in AgentCrypt consists of stem, progenitor and differ-
entiated cells in the colon, with the addition of the Paneth cell group in the small intestine.
AgentCrypt integrates rules for every cell type in order to describe specific actions related
to methylation update, cell division, differentiation and apoptosis. Considered to have a
major impact on the cell cycle, ageing was also included in AgentCrypt, with mathematical
expressions proposed to describe how progenitor, differentiated and Paneth cells undergo
division and apoptosis. The main assumption of AgentCrypt is that cell methylation level
can be influenced by both cell and mother-crypt neighbours in abnormal systems, due to
intra- and inter-crypt influences. However, no inter-cell influences on methylation level
were considered in ‘healthy’ crypts, (characterised by no alterations of inter-cellular gaps).
AgentCrypt implementation also considered carcinogen and methylation inhibitor in-
fluences. While methylation inhibitors have a direct impact on methylation modifications
over time, carcinogens influence cell division, differentiation and apoptosis, without affect-
ing methylation patterns directly. Fluctuations of the methylation inhibitor effect were also
considered, and the inhibitor response curve expression proposed to describe the dynamics
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of blocking methylation modifications over time. Two case studies were built to analyse the
impact of such factors on intestinal cancer development.
Experimental data, (GEO accession GSE42752 and GSE50475), were used to initialize
the model which was allowed to evolve over a period of 550 days. Crypt groups were ob-
served and average methylation level was recorded. Differences were higher for carcinogen
influenced systems and overall methylation level were more stable in the small intestine
than in the colon crypt group. In addition, methylation level changes were inhibited un-
der different patterns in abnormal systems, during a 90 days - period. Inhibitor effect was
marked for abnormal crypt groups, with largest average methylation differences observed∼
0.60 - 0.90% lower when inhibitor was present. An interesting observation is that the final
methylation level in abnormal systems with inhibitors applied, (measured after 90 days), is
similar to methylation level measured after around 20 - 30 days in abnormal crypts, with
no inhibitors. Thus, a difference of around 60 - 70 days can be observed between abnor-
mal systems, implying that inhibitor presence can shrink tumour progression. However,
no inhibitor considered was able to restore methylation to normal levels. Employment of
multiple, (combined), inhibitors, which complement each another with respect to effect
over time, may offer a solution, but clearly, additional tests are required to determine the
appropriate inhibitor characteristics.
AgentCrypt described dynamics of different intestinal crypt systems focusing on in-
dividual cell activity. However, it is also important to investigate overall cell population
deregulations in order to understand abnormal changes within intestinal crypt leading to
cancer development. This specific analysis at intestinal tissue level is performed using the
LogisticCrypt model, presented in the next chapter.
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Chapter 7
LogisticCrypt - a Logistic Model of
Intestinal Crypt Structure
7.1 Introduction
Based on the need to interpret base level features of a system as these impact on system
behaviour as a whole, the LogisticCrypt model has been developed to perform comparative
analysis between colon and small intestine tissues with regard to cell number deregulations
observed in abnormal systems, (i.e. to target our third research objective, namely “To assess
the effect of deregulation on intestinal crypt dynamics with regard to tumour development”,
(Section 1.2.1)). Specifically, these mechanisms refer to both cell proliferation and inci-
dence of major intestinal crypt phenomena1, which have been associated with increased
risk of cancer development, (Chapter 2). The LogisticCrypt model describes crypt struc-
ture with regard to number of each cell type, (i.e. stem, progenitor, fully-differentiated and
Paneth cells), at given time. Study focus is on two elements:
1. cell division, differentiation and apoptosis rates within the intestinal crypt;
2. cell competition related to ‘crypt space’.
1Major crypt phenomena are ‘crypt fission’ (longitudinal crypt division) and the ‘bottleneck effect’ (crypt
regeneration from a common ancestor-cell). The occurrence of both phenomena has been reported in normal
intestinal crypts only over long time periods, approximated with 25 years for ‘crypt fission’ and 8.2 years for
the ‘bottleneck effect’, (Chapter 2).
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Figure 7.1: Structure of the Colorectal Cancer Model - focus on the LogisticCrypt model
The relationships between model components may refer to R1) average methylation level
for gene network / intestinal cell; R2) patient features; R3) intestinal crypt dynamics, ex-
plored following bottom-up and top-down approaches.
The position of the LogisticCrypt model in the Colorectal Cancer Model is highlighted
in Figure 7.1. Thus, while AgentCrypt, (Chapter 6), characterises intestinal crypt dynam-
ics, following a bottom-up approach, with information passed from cellular to tissue level,
LogisticCrypt aims to complement this information through a top-down approach, where
the prevalence of each cell type is determined by cell division, differentiation and apopto-
sis rates and restricted by intestinal crypt capacity. In order to achieve cross-comparison
between intestinal tissues, LogisticCrypt was built initially to mimic crypt structure in the
colon, (Section 7.2), and subsequently extended to the small intestine, (Section 7.3). In
addition, similar to AgentCrypt, carcinogen influence is considered in order to investigate
intestinal crypt modifications during tumour development. Implementation details are pro-
vided in Section 7.4 and the results obtained from the analysis of crypt deregulations, (e.g.
aberrant increase in stem cell division), are described in Section 7.5. Finally, main contri-
butions and limitations of the top-down model are presented in Section 7.6.
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7.2 Modelling the colon crypt
In LogisticCrypt, the colon crypt consists of three main cell populations, namely stem, pro-
genitor and differentiated cell groups, for which, specific actions are considered, citepReya2005.
Similarly to the AgentCrypt model, (Chapter 6), stem cells can undergo both symmetrical
and asymmetrical2) division or apoptosis, progenitors can divide or differentiate, and dif-
ferentiated cells are removed from crypt following apoptosis, (Figure 7.2), [Potten et al.,
2003; Frank, 2007; Humphries and Wright, 2008; Khalek et al., 2010; Vaiopoulos et al.,
2012]. While in AgentCrypt, the focus was on individual cell behaviour, LogisticCrypt
aims to investigate colon crypt dynamics at cell population level, i.e. to explore variations
of the cell population size over time, as these can indicate tumour development, [Humphries
and Wright, 2008; Vaiopoulos et al., 2012], (Chapter 2). In colon crypt, stem cell number
increases only during symmetrical division, (by addition of new stem cells), and decreases
during apoptosis. The progenitor cell group enlarges following both progenitor and asym-
metrical stem cell divisions and diminishes during differentiation. Augmentation in differ-
entiated cell set is determined by progenitor differentiation, while reduction of differentiated
cell population size is caused by apoptosis.
The LogisticCrypt describes intestinal crypts based on stem, progenitor and differen-
tiated cell number and rates for both symmetrical and asymmetrical stem cell division,
(RateStemSymDiv and Rate
Stem
AsymDiv), for stem and differentiated cell apoptosis, (Rate
Stem
Apoptosis
and RateDiffApoptosis, respectively) and for progenitor division and differentiation rates, (Rate
Prog
Div
and RateProgFullDiff , respectively), considered with values ∈ [0, 1] (fractions). For example,
the number of stem cells that undergo apoptosis at a given time t is equal to RateStemApoptosis ×
Stem(t). In addition, given that three possible cell actions are defined for stem cell group,
(namely symmetrical and asymmetrical divisions and apoptosis), the sum of these cell ac-
tion rates is ≤ 1, (shown in expression (7.1)). The inequality indicates that a stem cell
subgroup performs no action during a time-interval, (i.e. neither division or apoptosis), as
stem cell division or apoptosis are rare events in normal colon crypts, (which are triggered
2Two new stem cells or a stem and a progenitor cells are born during symmetrical and asymmetrical divi-
sions , respectively. In both situations, the mother stem cell is replaced by one daughter stem cell.
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Figure 7.2: Intestinal Cell Actions in the LogisticCrypt model
A stem cell can divide symmetrically or asymmetrically, resulting into two new stem cells
or a stem and a progenitor cells, respectively. In addition, a stem cell can undergo apop-
tosis, following which, it is removed from crypt. A progenitor can divide into two new
progenitor cells or differentiate into a fully-differentiated cell. A differentiated cell can un-
dergo apoptosis, being removed from the crypt, [Potten et al., 2003; Humphries and Wright,
2008].
by abnormal changes that affect crypt homestasis, [Bach et al., 2000]). Similar, the sum of
the progenitor cell division and differentiation rates is ≤ 1, (expression 7.2).
RateStemSymDiv +Rate
Stem
AsymDiv +Rate
Stem
Apoptosis ≤ 1 (7.1)
RateProgDiv +Rate
Prog
FullDiff ≤ 1 (7.2)
At every time-step, each cell type group is updated according to its specific actions.
Thus, the stem cell population at time t+1 is composed from stem cells found in the colon
crypt at the previous time-step, t, in addition to the new stem cells, (born through stem cell
symmetrical division during this interval), minus dead stem cells that underwent apoptosis
during the same time-period. The numbers of new and removed stem cells are calculated
based on stem cell symmetrical division and apoptosis rates, respectively. Based on these,
the expression for stem cell number updates is:
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Stem(t+ 1) = Stem(t) +BornStem(t+ 1)−DeadStem(t+ 1) (7.3)
BornStem(t+ 1) = Stem(t)×RateStemSymDiv
DeadStem(t+ 1) = Stem(t)×RateStemApoptosis ⇒
Stem(t+ 1) = Stem(t) + Stem(t)× (RateStemSymDiv −RateStemApoptosis)
where BornStem, DeadStem = new and removed stem cell numbers, respectively, at
time t+1. Analogously, the progenitor cell population at time t+1 is given by the total of i)
progenitors found in crypt at time t and ii) new progenitors, (born through both progenitor
and asymmetrical stem cell division), from which, the group of progenitors that underwent
differentiation is removed. The size of the differentiated cell group at time t+1 is com-
puted from the differentiated cell number at time t, plus the number of new differentiated
cells, (originated from progenitors), minus differentiated cells that underwent apoptosis. In
conclusion, the progenitor and differentiated cell updates are given by:
Prog(t+ 1) = Prog(t) + Stem(t)×RateStemAsymDiv + Prog(t)× (RateProgDiv −RateProgFullDiff )
(7.4)
Diff(t+ 1) = Diff(t) + Prog(t)×RateProgFullDiff −Diff(t)×RateDiffApoptosis
(7.5)
with variables defined as given in Table 7.1.
Table 7.1: Variable definitions for LogisticCrypt in the colon crypt
Prog(t), Diff(t) the numbers of progenitor and differentiated cells, respec-
tively, observed in crypt at time t;
Prog(t+1), Diff(t+1) numbers of above cell types at time t+1;
RateProgDiv and
RateProgFullDiff
the rates of progenitor cell division and differentiation, re-
spectively;
RateDiffApoptosis the rate differentiated cell apoptosis.
Intra- and inter-specific competitions are also incorporated into LogisticCrypt to de-
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scribe crypt dynamics. In such systems, an increase in one species’ population restricts the
expansion of the other populations, (due to inter-specific competition), and an increase in
population size leads to decrease in population growth rate, (due to intra-specific competi-
tion), (subsection 3.3.3).
7.2.1 Modelling cell intra- and interspecific competition
Intra-specific competition, indicated by the Density-Dependence Coefficient, DDC, (Sub-
section 3.3.3), is represented for every cell type within the colon crypt, where the DDC
values for stem, progenitor and differentiated cells, (i.e. DDCSTEM , DDCPROG and
DDCDIFF , respectively), are computed based on expression (3.4), as discussed further.
The DDCSTEM (t) value is calculated using expression (7.6), based on the stem cell
carrying capacity, i.e. maximum stem cell number defined for colon crypt, (MaxStemNo),
and stem cell number found in colonic system at time t, Stem(t). DDCSTEM (t) takes a
value between 0 and 1, which is closer to 1 when Stem(t) is much smaller than MaxStemNo,
and closer 0 when Stem(t) reaches stem cell carrying capacity, (i.e. Stem(t)'MaxStemNo).
Thus, theDDCSTEM (t) value declines as stem cell population size increases, and the addi-
tion of theDDCSTEM (t) coefficient to stem cell population growth rate, (i.e. RateStemSymDiv−
RateStemApoptosis), indicates that the latter decreases, as well, as stem cell population extends.
While expression (7.3) describes stem cell population growth in systems with no competi-
tion, expression (7.7), (which integrates DDCSTEM (t)), is proposed for stem cell number
updates in colon crypt with intra-specific competition over time.
DDCSTEM (t) =
[MaxStemNo− Stem(t)]
MaxStemNo
(7.6)
Stem(t+ 1) = Stem(t) + Stem(t)× (RateStemSymDiv −RateStemApoptosis)×DDCSTEM (t)
(7.7)
where: MaxStemNo = stem cell carrying capacity, i.e. maximum stem cell number de-
fined for colon crypt; Stem(t+1), Stem(t) = stem cell numbers at time t+1 and t, respectively;
RateStemSymDiv, Rate
Stem
Apoptosis = stem cell symmetrical division and apoptosis rates, respec-
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tively. Similarly, the density-dependence coefficient is calculated for progenitor cells, using
expression (7.8), and is considered during the progenitor cell update step. Thus, the initial
expression (7.4), used for progenitor cell number dynamics, changes to expression (7.9).
DDCPROG(t) =
[MaxProgNo− Prog(t)]
MaxProgNo
(7.8)
Prog(t+ 1) = Prog(t) + [Stem(t)×RateStemAsymDiv+ (7.9)
+ Prog(t)× (RateProgDiv −RateProgFullDiff )]×DDCPROG(t)
where MaxProgNo is maximum progenitor cell number in colon crypt, DDCPROG(t)
is the density-dependent coefficient for progenitor cell group and the rest of variables are
defined in Table 7.1. Analogous, density-dependence coefficient and update step for differ-
entiated cells are given by expressions (7.10) and (7.11), respectively. Considering crypt
structure, the carrying capacity for differentiated cells is calculated based on the maximum
numbers for i) total, ii) stem and iii) progenitor cells allowed in colon crypt, i.e. MaxTotal-
CellNo, MaxStemNo, and MaxProgNo, respectively.
DDCDIFF (t) =
[MaxTotalCellNo−MaxStemNo−MaxProgNo−Diff(t)]
(MaxTotalCellNo−MaxStemNo−MaxProgNo)
(7.10)
Diff(t+ 1) = Diff(t) + [Prog(t)×RateProgFullDiff −Diff(t)×RateDiffApoptosis]×DDCDIFF (t)
(7.11)
where DDCDIFF (t) = density-dependent coefficient for differentiated cells at given time
t and the other variables are defined as given in Table 7.1.
Given that the stem cell number range is known, (i.e. 16 - 19 in colon and 1-6 in small
intestine, (Section 2.4)), the inter-specific competition describes the relationship between
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the progenitor and differentiated cells within the colon crypt. Specifically, this refers to
the total number of progenitor and differentiated cells from the crypt that must always be
less than or equal to the crypt capacity without stem cell number, (expression 7.12). Thus,
given that the crypt capacity is limited, an increase in progenitor cell number determines a
decrease in differentiated cell population size.
Prog(t) +Diff(t) ≤MaxTotalCellNo−MaxStemNo (7.12)
Considering expressions (7.6) - (7.12), the cell population changes in colon crypt over
time are determined based on a set of 12 parameters, namely i) stem, progenitor and dif-
ferentiated cell numbers at time t, ii) the maximum sizes of total, stem and progenitor cell
populations, and iii) the rates of stem and progenitor cell divisions, stem and differentiated
cell apoptosis and progenitor differentiation. A major phase in the LogisticCrypt model
development is minimization of the set of the input parameters needed to describe the colon
crypt dynamics. This can be achieved using relationships between model parameters and
the steps made for parameter group reduction are discussed in the next subsection.
7.2.2 Relationships between cell action rates in the healthy colon crypt system
The relationship between model dependent and independent parameters relies for plausibil-
ity on knowledge of the mechanisms which characterise the healthy colon crypt. This is a
system of different cell types, where cell action rates ensure low fluctuations in any cell type
number in successive time-steps, [Van Leeuwen et al., 2006; Humphries and Wright, 2008;
Leedham and Wright, 2008]. Thus, phenomena such as ‘crypt fission’ and the ‘bottleneck
effect’, (introduced in Chapter 2), can occur in normal systems only over long time-periods.
In order to compute the relationship between cell division, differentiation and apoptosis
rates in the healthy3 colon crypt, an ‘abstract’ system, with no variations on cell number
over time, is initially considered. In such system, the cell number differences between two
3Given that cell cycle is affected during tumour development, the relationships between cell action rates
in abnormal systems are calculated based on corresponding relationships in healthy crypts, but taking account
also of deregulations of cell division, differentiation and apoptosis, [Van Leeuwen et al., 2006; Humphries and
Wright, 2008; Leedham and Wright, 2008].
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successive time-steps, i.e. t and (t+1), are equal to zero for each cell type:
Stem(t+ 1)− Stem(t) = 0 (7.13)
Prog(t+ 1)− Prog(t) = 0 (7.14)
Diff(t+ 1)−Diff(t) = 0 (7.15)
The steps performed to identify a relationship between stem cell division and apoptosis
rates in such a system are presented further. For a complete summary of how other relation-
ships, (including progenitor division and differentiation, differentiated cell apoptosis rates),
are calculated, see Appendix D.
Stem cell group - calculation of cell action rate relationships Relationships between
stem cell action rates are calculated based on expressions for i) stem cell number updates
in colon crypt over time, ii) sum of all stem cell action rates and iii) ‘no fluctuation in stem
cell population size’ condition. The calculation procedure is given by:
Input: Expression (7.1) for sum of all stem cell action rates:
RateStemSymDiv + Rate
Stem
AsymDiv + Rate
Stem
Apoptosis ≤ 1
Expression (7.7) for stem cell number updates in colon crypt over time:
Stem(t+1) = Stem(t) + Stem(t) × (RateStemSymDiv - RateStemApoptosis) × DDCSTEM (t),
with DDCSTEM (t) 6= 0
Expression (7.13) for no variations in stem cell compartment:
Stem(t+1) - Stem(t) = 0
Output: RateStemSymDiv ? Rate
Stem
Apoptosis ? Rate
Stem
AsymDiv
Calculation: Given expression (7.13), Stem(t+1) - Stem(t) = 0
+expr.(7.7)
=⇒
Stem(t) + Stem(t) × (RateStemSymDiv - RateStemApoptosis) × DDCSTEM (t) - Stem(t) = 0⇒
(RateStemSymDiv - Rate
Stem
Apoptosis) × DDCSTEM (t) = 0⇒
RateStemSymDiv - Rate
Stem
Apoptosis = 0, (given DDCSTEM (t) 6= 0)⇒
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RateStemApoptosis = Rate
Stem
SymDiv (7.16)
From expressions (7.1) and (7.16),⇒
RateStemSymDiv ≤
(1−RateStemAsymDiv)
2
(7.17)
According to expression (7.17), stem cell population dynamics can be described by only
two parameters, namely symmetrical and asymmetrical stem cell division rates.
Progenitor and differentiated cell groups - summary of relationship calculation be-
tween cell action rates
Further, the relationships between progenitor cell action rates are based on expressions for
i) progenitor cell updates, ii) sum of progenitor cell action rates in colon crypt and iii) ‘no
variations in progenitor cell compartment’ condition, (with calculation details provided in
Appendix D):
Input: Expression (7.2) on sum of progenitor cell action rates in colon crypt:
RateProgDiv +Rate
Prog
FullDiff ≤ 1
Expression (7.9) on progenitor cell updates:
Prog(t+1) = Prog(t) + [Stem(t)×RateStemAsymDiv + Prog(t)×(RateProgDiv −RateProgFullDiff )]×
DDCPROG(t)
Expression (7.14) for no variations in progenitor cell compartment:
Prog(t+1) - Prog(t) = 0
Output: RateProgDiv ? Rate
Prog
FullDiff
Solution: Given expressions (7.9) and (7.14)⇒
RateProgFullDiff =
Stem(t0)
Prog(t0)
×RateStemAsymDiv +RateProgDiv (7.18)
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In addition, using expression (7.2)⇒
RateProgDiv ≤
[1− Stem(t0)Prog(t0) ×RateStemAsymDiv]
2
(7.19)
According to expression 7.18, the progenitor differentiation rate can be calculated based
on i) the initial stem and progenitor cell number and ii) the progenitor and asymmetrical
stem cell division rates. Progenitor population growth over time is controlled by expression
(7.19), which indicates that an increase in stem cell symmetrical division rate determines a
decrease in progenitor division rate.
Finally, the differentiated cell apoptosis rates can be calculated based on i) initial size of
each cell type population and ii) the rates of progenitor and symmetrical stem cell divisions,
as indicated by expression (7.20); (again, complete calculation procedure is provided in
Appendix D).
Input: Expression (7.11) on differentiated cell updates:
Diff(t+1) = Diff(t) + [Prog(t)×RateProgFullDiff - Diff(t)×RateDiffApoptosis]×DDCDIFF (t)
Expression (7.15) for no variations in differentiated cell compartment:
Diff(t+1) - Diff(t) = 0
Expression (7.18) for progenitor differentiated rate:
RateProgFullDiff =
Stem(t0)
Prog(t0)
×RateStemAsymDiv +RateProgDiv
Output: RateDiffApoptosis ? Rate
Prog ? RateStem
Solution: From expressions (7.11) and (7.15)⇒
RateDiffApoptosis =
Prog(t0)
Diff(t0)
×RateProgFullDiff , (complete calculation steps provided in Ap-
pendix D).
In addition, using expression (7.18) to replace RateProgFullDiff ,⇒
RateDiffApoptosis =
Prog(t0)
Diff(t0)
× [Stem(t0)
Prog(t0)
×RateStemSymDiv +RateProgDiv ] (7.20)
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Relationships between cell action rates in healthy systems
Given the evidence of ‘crypt fission’ and the ‘bottleneck effect’ in a normal intestinal crypt,
low variation in stem cell number exists over time, [Yatabe et al., 2001; Jin et al., 2009],
(Subsection 2.6.1). Thus, the relationship between the symmetrical division and apoptosis
rate of the stem cell in ‘no variation’ systems), (expression (7.16)), should be extended to
permit small fluctuations in stem cell population size over time, i.e.
RateStemApoptosis = Rate
Stem
SymDiv ± δCOLON , with δCOLON ∈ (0, 1) (7.21)
where ±δCOLON indicates low changes in stem cell number over time. In case of ‘+’,
stem cell apoptosis rate is higher than stem cell symmetrical division rate, i.e. stem cell
population size decreases (more stem cells die than are born). In case of ‘-’, division rate is
higher than apoptosis rate and stem cell number increases.
Stem cell symmetrical division and apoptosis rates can be deduced based on time needed
for major crypt occurrence in healthy human crypts, which was approximated to 8.2 years
and 25 years for the ‘bottleneck effect’ and ‘crypt fission’, respectively, [Yatabe et al.,
2001; Graham et al., 2011]. The crypt cycle within a normal system is defined to start with
a decrease in stem cell number, (inducing the ‘bottleneck effect’), followed by an expan-
sion of the stem cell compartment, (which precedes ‘crypt fission’). For example, a set
of values, with RateStemApoptosis = 0.01 and Rate
Stem
SymDiv = 0.003 during ‘bottleneck effect’
(i.e. RateStemApoptosis > Rate
Stem
SymDiv) and Rate
Stem
SymDiv = 0.0115 during ‘crypt fission’ (i.e.
RateStemApoptosis < Rate
Stem
SymDiv), was found to be plausible for describing both major crypt
phenomena in reported time, (i.e. 8.2 and 25 years respectively, as illustrated in Figure 7.3).
A stem cell cycle is given by stem cell division, approximated to seven days in human
colon, [Potten et al., 2003; Frank, 2007]. Based on these, time for the ‘bottleneck effect’
to occur is ≈ 1 cycle/week × 52 weeks/year × 8.2 years = 426.4 cycles. Similarly, time
period for ‘crypt fission’ incidence is ≈ 25 years × 52 cycles/year = 1300 cycles. Other
values for these rates are also possible and there is certainly a need to perform a sensitivity
analysis for colon crypt parameters, (phase discussed in Chapter 8).
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Figure 7.3: Stem cell numbers over three successive Colon Crypt cycles
A crypt cycle is considered to start with a decrease in stem cell number until the ‘bottleneck
effect’ is observed, after which, the stem cell number increases until it reaches a maximum
value (fission). Red points are used as markers for the crypt cycle. The interrupted line
shows the decrease in stem cell number recorded after crypt fission.
In conclusion, the set of independent variables needed to describe colon crypt dynamics
is given by i) stem cell and progenitor division rates and ii) the initial size for each cell type
population. Other parameter values can be calculated, (e.g. for progenitor differentiation
rate) using expressions (7.16), (7.18), and (7.20). Thus, the size of colon crypt parame-
ter group is reduced from initial twelve to six. In addition, major crypt phenomena were
simulated by the LogisticCrypt model based on a set of plausible values for stem cell sym-
metrical division and apoptosis rates, (e.g. RateStemApoptosis = 0.01 and Rate
Stem
SymDiv = 0.003
during ‘bottleneck effect’ and RateStemSymDiv = 0.0115 during ‘crypt fission’).
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7.3 LogisticCrypt - Extensions
7.3.1 LogisticCrypt for the small intestine tissue
Given the similarities4 between the structure of colon and small intestine crypts, (Chapter
2), the LogisticCrypt model is extended to investigate cell population dynamics in small
intestine. Information on Paneth cell group is integrated, as follows. Similarly to (fully-)
differentiated cells, ‘apoptosis’ is considered to be the single action performed by Paneth
cells, given that Paneth cells are differentiated cells, [Umar, 2010]; in addition, progenitor
differentiation into Paneth cells is added to progenitor action set, [Kim et al., 2005]. In
consequence, two new parameters, namely rates for progenitor differentiation into Paneth
cells and Paneth apoptosis, (i.e. RateProgPaneth and Rate
Paneth
Apoptosis, respectively), are included
in LogisticCrypt, in addition to those used for the colon crypt. Intra-specific competition
features are considered also for Paneth cell population, where the the density-dependence
coefficient for Paneth cell group at a given time t, DDCPANETH(t), is calculated based on
Paneth cell carrying capacity, MaxPanethNo, and Paneth cell number at time t, Paneth(t),
(expression (7.22)). Based on these, Paneth cell population at time t+1 is given by i) Paneth
cell group at time t, ii) new Paneth cells, minus iii) the set of Paneth cells that underwent
apoptosis during the last time interval, (expression (7.23), with variables defined in Table
7.2).
DDCPANETH(t) =
[MaxPanethNo− Paneth(t)]
MaxPanethNo
(7.22)
Paneth(t+ 1) = Paneth(t) + [Prog(t)×RateProgPaneth− (7.23)
− Paneth(t)×RatePanethApoptosis]×DDCPANETH(t)
4Paneth cell type is the fourth cell type specific to small intestine crypt, in addition to stem, progenitor
and differentiated cells, found also in the colon crypt. Paneth cells are differentiated cells, (derived from
progenitors), reported in relative small number in comparison with differentiated and progenitor population
size, and are located at crypt base in small intestine crypt. Paneth cell presence in colon crypt is considered a
marker for tumour development, [Sancho et al., 2003; Kim et al., 2005; Nicolas et al., 2007; Humphries and
Wright, 2008; Umar, 2010; Clevers and Bevins, 2013], (Section 2.4), (Chapter 2).
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Table 7.2: Variable definitions for LogisticCrypt for the small intestine crypt
Parameter name Parameter description
DDCPANETH(t) The density-dependence coefficient related to Paneth cell
at time t;
MaxPanethNo the carrying capacity for the Paneth cells;
Stem(t), Prog(t), Prog(t+1),
RateStemSymDiv, Rate
Stem
Apoptosis,
RateStemAsymDiv, Rate
Prog
Div ,
RateProgFullDiff , Rate
Diff
Apoptosis
parameters as defined for colon crypt in 7.1;
Paneth(t), Paneth(t+1) the Paneth cell numbers observed in small intestine crypt
at t and t+1, respectively;
RateProgPaneth the rate of progenitor differentiation into Paneth cells,
(model input parameter with value in the interval [0, 1]);
RatePanethApoptosis the rate of Paneth cell apoptosis in the small intestine.
Given the inclusion of ‘progenitor differentiation into Paneth cells’ to progenitor action
set, expressions for progenitor cell dynamics are also changed. Specifically, progenitor cell
population size at time t+1 is now calculated based on i) population size at time t, ii) new
progenitors, (born through progenitor and asymmetrical stem cell divisions), from which,
iii) the number of progenitors that underwent differentiation into both (fully-)differentiated
and Paneth cells, is subtracted, (extending, thus, expression (7.9), used for progenitor group
updates in colon crypt):
Prog(t+ 1) = Prog(t) + [Stem(t)×RateStemAsymDiv+ (7.24)
+ Prog(t)× (RateProgDiv −RateProgFullDiff −RateProgPaneth)]×DDCPROG(t)
In addition, the sum of all progenitor action rates is given by:
RateProgDiv +Rate
Prog
FullDiff +Rate
Prog
Paneth ≤ 1 (7.25)
The relationships between cell action rates in the healthy small intestine crypt are cal-
culated similarly to those from the healthy colon crypt, where the ‘no - variation’ small
intestine system is described by:
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Paneth(t+ 1)− Paneth(t) = 0 (7.26)
Stem(t+ 1)− Stem(t) = 0 (7.27)
Prog(t+ 1)− Prog(t) = 0 (7.28)
Diff(t+ 1)−Diff(t) = 0 (7.29)
Since in the model, the inclusion of Paneth cell group was not linked to changes in stem
cell population dynamics, (expression (7.23)), the relationship between stem cell action
rates in the healthy small intestine crypt is similar to expression (7.21), (used in the colon
crypt), i.e.:
RateStemApoptosis = Rate
Stem
SymDiv ± δSI , with δSI ∈ (0, 1) (7.30)
Given the modifications introduced in progenitor dynamics set, the relationships be-
tween progenitor action rates can be summarised by expressions (7.31) and (7.32), (again,
full calculation provided in Appendix D). These are calculated based on i) progenitor cell
updates, ii) sum of all progenitor cell action rates in small intestine and iii) ‘no variations in
progenitor cell compartment’ condition:
Input: Expression (7.14) for no variations in progenitor cell compartment:
Prog(t+1) - Prog(t) = 0
Expression (7.24) on progenitor cell updates:
Prog(t+1) = Prog(t) + [Stem(t)×RateStemAsymDiv + Prog(t)×(RateProgDiv −RateProgFullDiff−
RateProgPaneth)]×DDCPROG(t)
Expression (7.25) on sum of all progenitor cell action rates in small intestine:
RateProgDiv +Rate
Prog
FullDiff +Rate
Prog
Paneth ≤ 1
Output: RateProgDiv ? Rate
Prog
FullDiff ? Rate
Prog
Paneth
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Solution: Given expressions (7.14) and (7.24)⇒
RateProgFullDiff =
Stem(t0)
Prog(t0)
×RateStemAsymDiv +RateProgDiv −RateProgPaneth (7.31)
In addition, using expression (7.25)⇒
RateProgDiv ≤
[1− Stem(t0)Prog(t0) ×RateStemAsymDiv]
2
(7.32)
Thus, the rate of progenitor differentiation into (fully-) differentiated cells,RateProgFullDiff ,
depends on the rates of i) asymmetrical stem cell and progenitor divisions, RateStemAsymDiv
and RateProgDiv respectively, (similar to the colon crypt), and ii) progenitor differentiation
into Paneth cells,RateProgPaneth. An increase inRate
Prog
Paneth determines a decrease inRate
Prog
FullDiff
.
In addition, RateProgDiv is independent by Rate
Prog
Paneth, but depends on Rate
Stem
AsymDiv, (ex-
pression 7.32).
Finally, relationships between cell action rates are calculated for differentiated and
Paneth cells. The differentiated cell apoptosis rate is given by i) initial stem, progenitor and
differentiated cell numbers, ii) stem and progenitor division rates and also iii) progenitor
differentiation into Paneth cell rate, (expression (7.33)). Based on these, it can be observed
that while an increase of either stem or progenitor division rate causes an increase in differ-
entiated cell apoptosis rate, an increase of RateProgPaneth induces a decrease of Rate
Diff
Apoptosis,
(in order to maintain the cell number equilibrium in normal systems). In addition, Paneth
cell apoptosis rate depends on progenitor differentiation in Paneth cell rate, (expression
(7.34)), and, in healthy small intestine crypts, an increase in the latter determines an in-
crease in the former.
RateDiffApoptosis =
Prog(t0)
Diff(t0)
× [Stem(t0)
Prog(t0)
×RateStemAsymDiv +RateProgDiv −RateProgPaneth]
(7.33)
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RatePanethApoptosis =
Prog(t0)
Paneth(t0)
×RateProgPaneth (7.34)
7.3.2 Carcinogen influence
The carcinogen influence in LogisticCrypt is associated with modifications in the cell action
rates that determine cell population growth. Specifically, since cell proliferation is given by
both increased division and decreased apoptosis rates, the stem and progenitor cell division
rates are increased by a value δ2, where δ2 ∈ [0, 1], (input), while the apoptosis rates, for
both fully-differentiated and Paneth cells, are decreased by the same δ2 value. For example,
the expression for carcinogen impact on symmetrical stem cell division rate is:
RateStemSymDiv ← RateStemSymDiv × (1 + δ2) (7.35)
The δ2 parameter was considered for a sensitivity analysis, with δ2 ∈ {5%, 10%, , 50%};
the results are discussed in subsection 7.5.2.
7.4 Implementation details of the LogisticCrypt model
Adopting the same rationale as before, for E-G Network & AgentCrypt models, the Logis-
ticCrypt was also developed as an objected oriented model using C++. The LogisticCrypt
class is the main class and provides functionality for handling crypt dynamics based on
fixed rate values of cell division, differentiation and apoptosis. The intestinal crypt char-
acteristics, e.g. the stem cell number, are stored in a LogisticModelSettings object and
transmitted in a single step to the LogisticCrypt object. The class diagram for this model is
simple and is illustrated in Figure 7.4.
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Figure 7.4: Class diagram for the LogisticCrypt model
7.5 Results and discussion
LogisticCrypt function was investigated through test cases which explored crypt dynamics
following modifications in stem and progenitor cell groups and consideration of carcinogen
influence in intestinal crypts, (Subsection 7.3.2). Specifically, the focus was on a com-
parison between ‘healthy’ and ‘affected’ crypts with regard to the occurrences of i) crypt
fission, (doubling of the no. of stem cells), [McDonald et al., 2006; Jin et al., 2009], and
the ‘bottleneck effect’, (reduction of the no. of stem cell to 1), [Yatabe et al., 2001]; and ii)
tumour growth, (i.e. total cell group at maximum), in carcinogen-affected and unaffected
systems. Both intra- and inter-tissue comparisons on crypt phenomena are discussed.
Cell number parameter values A set of input parameters, which describes cell popula-
tion size in a normal system for each intestinal tissue, is included in Table 7.3. These values
were considered a potential setting group for the systems included in the simulations pre-
sented here, (discussion on parameter value choice follows). However, other values for cell
number parameters, (e.g. Paneth cell number), should be considered also, and the need of a
sensitivity analysis of this parameter set is anticipated, (discussed in Chapter 8). Given that
cell population size was approximated to around 2000 cells and 260 cells in healthy colon
and small intestine crypt, respectively, [Sancho et al., 2003; Nicolas et al., 2007; Khalek
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et al., 2010; Vaiopoulos et al., 2012], (Section 2.4), these values were assigned to the ‘ini-
tial cell number’ parameter, i.e. InitCellNumber, in each intestinal tissue. Similarly, the
stem cell number at time t0, Stem(t0), was set to be 16 - 19 cells in colon and 1 - 6 cells in
small intestine crypt, [Sancho et al., 2003; Brittan and Wright, 2004; Khalek et al., 2010],
(Section 2.4).
Table 7.3: Input parameter values used in LogisticCrypt for the cell numbers in the intestinal
crypts
Parameter name Parameter value in
the colon crypt
Parameter value in the
small intestine crypt
Stem(t0) 16 6
InitCellNumber 2000 260
Paneth(t0) 0 10
Prog(t0)
(0.25 × InitCellNumber)
500 65
MaxStemNo
(2 × InitStemCellNumber)
32 12
MinStemCellNumber 1 1
MaxProgNo 1000 130
MaxPanethCellNumber 0 20
MaxTotalCellNo
(2 × InitCellNumber)
4000 520
Precise information on progenitor and Paneth cell numbers in healthy human intestinal
crypts was not found to be available. In consequence, the progenitor cell compartment
was considered to occupy initially a percentage of crypt space, (e.g. PercPROG = 25%).
Thus, the initial progenitor cell number, Prog(t0)≈500 cells in colon crypt, (25% × 2000
cells), and 65 cells in the small intestine crypt. The Paneth cell group at the bottom of
the small intestine crypt is relatively small, so the initial Paneth cell number, Paneth(t0),
was approximated to 10 cells in small intestine, and no cells in the colon crypt, (as absent
for healthy colon tissue). Finally, the maximum stem cell number, MaxStemNo, was set to
twice the initial stem cell number Stem(t0), (since ‘crypt fission’ leads to doubling stem
cell population size in intestinal crypts, [McDonald et al., 2006; Jin et al., 2009], (Section
2.6)). Similarly, the maximum numbers for i) total, ii) progenitor and iii) Paneth cells were
taken to be double initial numbers of these cell groups. Moreover, given the evidence of the
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‘bottleneck effect’ in normal systems, (associated with decrease in stem cell population to
a single stem cell, [Yatabe et al., 2001], (Section 2.6)), the minimum stem cell number was
set to 1:
MaxStemNo = 2× Stem(t0) (7.36)
MaxTotalCellNo = 2× InitCellNumber (7.37)
MaxProgNo = 2× Prog(t0) (7.38)
MaxPanethNo = 2× Paneth(t0) (7.39)
MinStemCellNumber = 1 (7.40)
Cell action rate parameter values In addition to cell number parameters, a set of input
parameters, (included in Table 7.4), is proposed to describe cell action rates; (with a sen-
sitivity analysis for this parameter group discussed in Chapter 8). The values of stem cell
division and apoptosis rates in normal systems, included in the test cases presented here,
are the same as those of the stem cell action rates, used to simulate the occurrence of ma-
jor crypt phenomena in healthy colon crypt, (Subsection 7.2.2). Specifically, RateStemApoptosis
was considered equal to 0.01, RateStemSymDiv to 0.003, (during the ‘bottleneck effect’ phase)
and RateStemSymDiv to 0.0115 per week, (during ‘crypt fission’ phase). Both symmetrical and
asymmetrical stem cell divisions are rare events; however, the latter was reported to have
a higher occurrence rate than the former. In consequence, asymmetrical stem cell division
was assigned to a higher value than those considered for symmetrical cell division rate,
(e.g. RateStemAsymDiv = 0.02 per week, which indicates that around 2% from stem cell popu-
lation perform asymmetrical division every week). While differentiated cell life-cycle was
approximated to several hours in intestinal crypt, the lifetime for Paneth cells was reported
to be around 20 - 30 days, (Section 2.4). Based on these, the rate of progenitor differenti-
ation into Paneth cells, was approximated with a small value, e.g. 0.05, i.e. RateProgPaneth =
0.05 per day. In addition, given that three possible actions were defined for progenitors, a
value of 0.33, was considered forRateProgFullDiff . Thus, the progenitor division rate could be
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Table 7.4: Input parameter values used in LogisticCrypt for the intestinal crypt
Parameter name Parameter description
Cell action rates RateStemSymDiv = 0.003 per week; (value used for the sym-
metrical stem cell division during the ‘bottleneck effect’
phase).
RateStemSymDiv = 0.0115 per week; (value used for the sym-
metrical stem cell division during the ‘crypt fission’ phase).
RateStemApoptosis = 0.01 per week;
RateStemAsymDiv = 0.02 per week;
RateProgDiv = 0.38 per day;
RateProgPaneth = 0.05 per day;
Carcinogen influence δ2 ∈ {0.05, 0.10, .. 0.50}.
calculated using expression (7.31) and approximated to 0.38, i.e. RateProgDiv = 0.38 per day.
Finally, ‘the carcinogen impact on cell action rates’ parameter, δ2, was integrated in a sen-
sitivity analysis, with respect to tumour growth occurrence, i.e. changes of cell population
size in crypt systems over time.
7.5.1 ‘Crypt fission’ and the ‘bottleneck’ effect
Comparison on the crypt fission time-point between the small intestine and colon was
achieved by considering a group of eleven crypts for each tissue, where the rate of sym-
metrical stem cell division was increased from 0.015, (healthy crypt), to 0.039 per week, in
the tenth abnormal crypt, (i.e. ‘the most affected’ one), by increments of ∼ 10% between
consecutive crypts. Similarly, for the ‘bottleneck effect’ simulations, the stem cell division
rate, considered to be 0.003 in a ‘healthy crypt’, was decreased across a group of ten abnor-
mal crypts for each tissue to around 0.001 per week (in the 10th abnormal crypt), by∼ 10%
between each consecutive crypt. Given that colon stem cell cycle was approximated to one
week and the time-period of ‘crypt fission’ occurrence to 25 years, the simulation time was
taken equal to 1300 iterations or stem cell cycles, (i.e. 25 years × 52 weeks/ year ≈ 1300
weeks). At the end of these simulations, both ‘bottleneck effect’ and ‘fission’ phenomena
were recorded in normal and all abnormal crypts, with time to occurrence shown in Table
7.5 for both intestinal crypt groups.
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Table 7.5: Time-steps (Weeks) for ‘Crypt Fission’ and ‘Bottleneck Effect in the colon and
small intestine crypt groups
Crypt
Phe-
nomenon
Tissue
Type
Cr 1
Healthy
Cr
2
(Ab
1)
Cr
3
(Ab
2)
Cr
4
(Ab
3)
Cr
5
(Ab
4)
Cr
6
(Ab
5)
Cr
7
(Ab
6)
Cr
8
(Ab
7)
Cr
9
(Ab
8)
Cr
10
(Ab
9)
Cr
11
(Ab
10)
Crypt Colon 1388 1068 852 697 582 492 421 362 314 275 241
Fission Small
Intestine
710 547 436 357 298 252 215 186 161 140 123
Bottleneck Colon 487 467 451 437 424 414 406 398 391 386 381
Effect Small
Intestine
334 228 220 212 208 203 199 195 192 189 186
Intra-tissue comparison The average time-period, measured to ‘crypt fission’ occur-
rence, (i.e. time taken to reach the maximum limit of 12 and 32 cells in the small intestine
and colon crypts, respectively in each 11-crypt group), was found to be ≈ 311 weeks in
the small intestine crypt group, (with standard deviation5 StDevSIF ission ≈ 178 weeks, over
1300 iterations), and ≈ 608 weeks in the colon crypt group, (with StDevColonF ission ≈ 364
weeks). The longest and the shortest times correspond to the first and the 11th crypt, re-
spectively, in each group. Specifically, these are approximated to 710 weeks and 123 weeks
for the small intestine, and to 1388 weeks and 241 weeks for colon crypt. While the first
crypt represents the normal system, defined by small changes of stem cell population size
over time, (induced by low difference between stem cell symmetrical division and apop-
tosis rates, e.g. ∼ 0.005, calculated based on RateStemSymDiv1 = 0.0115 and RateStemApoptosis =
0.01 per week), the 11th crypt mimics the most ‘affected’ system, represented by the high-
est difference between stem cell action rates from the whole crypt group, i.e. 0.029, (with
RateStemSymDiv10 = 0.039 and Rate
Stem
Apoptosis = 0.01 per week). Thus, the differences between
stem cell action rates, (which increased from 0.005 in normal system to 0.029 in the 10th
abnormal system), reduced the time-period for ‘crypt fission’ manifestation in the most ‘af-
fected’ crypt when compared with healthy crypts, with ∼ 1147 weeks in colon, (i.e. 1388
5Standard deviation is estimated based on crypt samples, using the following formula:
s =
√
1
n− 1 × Σ
n
i=1(xi − x¯)2 (7.41)
where x¯ = sample mean, N = sample size.
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weeks - 241 weeks), and with∼ 587 weeks in small intestine, (i.e. 710 weeks - 123 weeks),
(Table 7.5).
Similarly, the average time-period to occurrence of the ‘bottleneck effect’ was measured
in eleven crypts for both tissues, with values≈ 206 weeks in the small intestine crypt group,
(with StDevSIBottleNeck ≈ 17 weeks over 1300 iterations), and ≈ 422 weeks in the colon
crypt group, (with StDevColonBottleNeck ≈ 35 weeks). The extreme values of the time to the
’bottleneck effect’ occurrence were around 334 weeks and 186 weeks for the small intestine
crypt and 487 weeks and 381 weeks for the colon crypt, corresponding to the first crypt,
(i.e. normal system), and to the 11th crypt, (i.e the most ‘affected’ system), respectively.
The most ‘affected’ crypt was characterised by the highest difference between stem cell
apoptosis and symmetrical division rates, estimated to 0.009, (with RateStemSymDiv11 = 0.001
and RateStemApoptosis = 0.01 per week), when compared with other crypts; for instance, the
difference between the same rates was around 0.008 in the 6th crypt, (with RateStemSymDiv6
= 0.002 and RateStemApoptosis = 0.01 per week), and ∼ 0.007 (with RateStemSymDiv1 = 0.003 and
RateStemApoptosis = 0.01 per week) in the first crypt.
In conclusion, alterations of stem cell population dynamics can increase major crypt
phenomena incidence, leading to higher predisposition to tumour development in intestinal
systems.
Inter-tissue comparison While similar alterations were considered for stem cell dynam-
ics in both small intestine and colon crypt groups, results indicate that the time to occurrence
of major crypt phenomena is more variable in the latter case. Specifically, the standard de-
viation6 for the time-periods recorded for ‘crypt fission’ occurrence was StDevColonF ission ≈
364 weeks and StDevSIF ission ≈ 178 weeks, over 1300 iterations among the 11-crypt group
in colon and small intestine, respectively. Similarly, the standard deviation for the ‘bot-
tleneck effect’ incidence time was approximated to StDevColonBottleNeck ≈ 35 weeks and
StDevSIBottleNeck ≈ 17 weeks over 1300 iterations, among colon and small intestine crypt
groups, respectively. Thus, given that variance of time for major crypt phenomena for-
6It refers to sample standard deviation estimated with formula (7.41).
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mation was higher for colon that for small intestine crypt groups, the colon crypt group
seems more sensitive to deregulations in the stem cell compartment than the small intes-
tine crypt group. Similar findings on this difference between intestinal tissues have been
reported from a study on epidermal growth factor in rats with regard to crypt fission and
cell proliferation, [Berlanga-Acosta et al., 2001].
7.5.2 Tumour growth in systems with and without carcinogen influence
A second comparison between small intestine and colon crypts was performed to investigate
the time taken to reach maximum crypt capacity, i.e. 520 and 4000 cells in small intestine
and colon crypts, respectively, since this may signal abnormalities associated with tumour
growth. Specifically, the variation in total cell number was recorded in two systems, namely
S1 and S2, represented by groups of eleven crypts for each tissue, where different external
influences were applied to cell action rates, (as follows):
1. in S1, the progenitor cell division rate was increased by 5% between successive
crypts, in order to facilitate cell proliferation, while other cell action rates were main-
tained at initial values;
2. in S2, “carcinogen influence” was considered and every cell action rate was changed
according to specifications (subsection 7.3.2), with δ2 ∈ {0.05, 0.10, .. 0.50}.
At the end of the simulation, the total cell number reached the maximum limit in all
intestinal crypts in both systems, with time-periods for each crypt shown in Table 7.6
The average time taken for the S1 group was ≈ 318 days in small intestine (with
StDevSIProgDereg ≈ 22 days), and ≈ 1495 days in colon crypts, (StDevColonProgDereg ≈ 20
days). In the system with carcinogen influence applied, i.e. S2, the average time taken for
cell number extension was ≈ 70 days in small intestine and ≈ 116 days in colon, (with
StDevSICarcinogen ≈ 40 days and StDevColonCarcinogen ≈ 68 days, respectively). Therefore, the
average time taken for doubling of the initial cell number was around thirteen times shorter
in the colon crypt group subject to carcinogen influence, S2, (with changes in all cell divi-
sion and apoptosis rates), in comparison to the S1 group, (with only progenitor cell division
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Table 7.6: Time-steps (Days) to reach Maximum Crypt Capacity in systems with and with-
out Carcinogen influence
Group type Cr
1
Cr
2
Cr
3
Cr
4
Cr
5
Cr
6
Cr
7
Cr
8
Cr
9
Cr
10
Colon (S1) 1543 1514 1502 1494 1490 1487 1485 1482 1481 1478
Carcinogen
Colon (S2)
279 181 138 113 97 86 77 71 65 61
Small Intes-
tine (S1)
372 337 324 316 308 308 306 304 303 302
Carcinogen
Small In-
testine
(S2)
166 109 83 69 52 52 47 44 40 38
rate affected). Similarly, the total cell number in the small intestine crypt group increased
faster in S2 than in S1, where the ratio between these systems was≈ 4.50. Although similar
cell action rate alterations were considered for both colon and small intestine crypt groups,
it appears that the impact on crypt dynamics was considerably higher for the colon than for
the small intestine in terms of tumour development. These results support the conclusion
stated in the previous test case, which suggests that the small intestine is less sensitive than
the colon with respect to cell cycle changes over time. In addition, results are in agreement
with an earlier experimental study on cell proliferation in intestinal tissues in rats, described
in Berlanga-Acosta et al. [2001].
7.6 Summary
LogisticCrypt is a discrete model on crypt structure, (represented by stem, progenitor and
differentiated cells in colon, with addition of Paneth cell population in small intestine),
which is monitored during cancer development. LogisticCrypt considered both intra- and
interspecific competitions among cell populations within the intestinal crypt. The ‘healthy
crypt’, which permitted low variations in cell numbers over time, was described by a set of
values on stem and progenitor cell division rates in the colon, and, additionally, by differ-
entiation rate into Paneth cells in the small intestine. Other cell actions rates, e.g. stem cell
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apoptosis, were deduced from equilibrium equations and calculated based on relationships
between all cell types within normal systems, (a step that facilitates reduction of the set of
input parameters needed to describe the intestinal crypt).
A sensitivity analysis for a) stem cell division rate and b) ‘carcinogen impact’ on crypt
dynamics was performed with respect to time-scales needed for i) ‘crypt fission’ and ‘bottle-
neck effect’, and ii) tumour growth occurrence. When comparing between tissues, shorter
average time-intervals for both ‘fission’ and ‘bottleneck effect’ were recorded for the small
intestine than for the colon crypt group. However, higher variance for these times of occur-
rence was recorded for the latter compared to the former, suggesting that the colon crypt is
more sensitive to alterations in stem cell compartment than the small intestine crypt. Mod-
ifications on progenitor division rate were also considered as well as carcinogen influence
for each tissue type. Results for carcinogen impact on cell proliferation (tumour growth),
indicated that the extension of the cell population to crypt capacity was accelerated by a
factor of 13 for the colon and 4.50 for the small intestine in carcinogen-influenced crypt
groups compared to systems with increase in progenitor cell division rates only. This ap-
pears to indicate that the colon crypt is more sensitive to deregulations in cell action rates
than the small intestine crypt, a conclusion in agreement with an earlier experimental study
on crypt fission and cell proliferation in small intestine and colon crypts in rats, [Berlanga-
Acosta et al., 2001]. However, LogisticCrypt results are inevitably tentative, given limited
information on crypt phenomena in small intestine tissue. In LogisticCrypt, the cell action
rate was considered to be equal for small intestine and colon crypts, although cell prolif-
eration was reported to be more rapid in the former case, [Berlanga-Acosta et al., 2001].
Thus, further work on LogisticCrypt must include scenarios which consider differences in
cell action rates between tissue types.
Finally, sensitivity analysis is certainly needed for the rest of unknown parameters, (e.g.
maximum progenitor cell number, progenitor cell division rate), and is discussed in the next
chapter.
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Chapter 8
Concluding discussion and future
work
8.1 Summary and conclusions
Epigenetics has emerged only recently as a fundamentally important area of biological and
medical research that has implications for our understanding of human diseases including
cancer, autoimmune and neuropsychiatric disorders. The motivation of this work is the con-
siderable interest generated in investigation of genetic and epigenetic features in terms of
how these contribute to disease, in this case colorectal cancer development. In this Thesis,
a cross-scale computational model was presented for CRC dynamics, which aims to help in
analysis of aberrant changes observed at micro-molecular, cellular and tissue levels in ma-
lignant intestinal systems. Novel components were required as follows. A network-based
framework, i.e. the E-G Network Model, was built initially to study interdependencies be-
tween genetic and epigenetic signals recorded at different CRC stages. This was extended to
include and assess the impact of different risk factors, (such as ageing and gender) on micro-
molecular events in tumour pathways. Subsequently, an agent-based model, AgentCrypt,
was developed to describe the dynamics of the human intestinal system, (within both colon
and small intestine tissues). This was used to evaluate the aberrant methylation variation
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induced by deregulations of the crypt mechanisms in malignant systems, influenced by
various factors. In addition, several potential inhibitors were considered for methylation
modifications in abnormal intestinal crypts and their effect evaluated with respect to tu-
mour initiation. Finally, a logistic model, LogisticCrypt, was built to provide information
on the intestinal crypt structure at specific time points and to facilitate the investigation of
aberrant changes in cell number with respect to tumour initiation and progression.
Main findings
The role of epigenetic events in cancer development was outlined and the importance of un-
derstanding interdependencies between micro-molecular signals, (genetic and epigenetic),
was demonstrated with a view to potential use as targets for personalized cancer therapies.
Model types and major databases on cancer dynamics were reviewed and in some case, used
as primary data resources. The background research indicated that a single model formula-
tion has limited capability to investigate malignant changes, since large sets of parameters
are needed to characterise human biological system. In consequence, hybridised models are
required to represent the aberrant molecular mechanisms in tumour development, from cel-
lular to whole-body scales. This motivated development of the component models reported
in this Thesis.
The first computational component of the multi-scale model, i.e. the genetic and epige-
netic signals network, integrated empirical data on conditional relationships between micro-
molecular events observed at different CRC stages. Information on signalling pathways
involved in CRC development, (e.g. Wntβ catenin, MAPK), was included from KEGG
Pathway database, [Kanehisa et al., 2014], and other sources. The framework permitted
analysis of the impact on DNA methylation level of interdependencies between aberrant
modifications. The framework enabled introduction of the ‘methylation cycle’ to denote the
process of updating gene methylation level inside the network, based on five key-elements.
In addition, an algorithm was developed for identification of the most plausible pathways
in gene networks based on the conditional relationships between genetic and epigenetic
events. A limitation at this model developmental stage, however, was lack of precise infor-
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mation on real time methylation cycle and consequently, this was approximated by stem cell
cycle for the human colon. The novelty of the framework formulation rests on proposing
two criteria to evaluate the tumour progression inside a gene network: a) average network
methylation level, (network score), and b) percentage of genes highly methylated due to the
influence of abnormal genetic and epigenetic changes.
The genetic and epigenetic events framework was extended to enable ‘customisation’
of malignant systems, (represented by the gene network), by incorporating information on
patient characteristics, (e.g. ageing, gender), considered to have a crucial impact on cancer
mechanisms. Information on a key-group of genes, (e.g. IGF2, ER, [Issa and Ahuja, 2000]),
reported to be sensitive to age-related methylation, was integrated into the gene network.
For these specific genes, a coefficient was inferred from reported studies to denote the rela-
tionship between ageing and methylation patterns and was included in the methylation level
update algorithm. This enhancement offered potential for improved overall investigation of
colorectal tumour-genesis through ‘patient typing’ in terms of malignancy development
features.
A comparative analysis on DNAm variation over time was performed in normal and
abnormal systems, for both colon and small intestine crypts using an agent-based model
to mimic major influences in intestinal systems. Global methylation level decrease was
marked for the colon compared with the small intestine, although similar alterations were
induced in both tissues. These results suggest that the methylation patterns inside the colon
crypt are more sensitive to deregulations in the proximal tissue than those recorded inside
the small intestine. In addition, methylation level decrease was accelerated by carcinogen
influence. This result is important in guiding further analysis on the effect of environmental
factors on epigenetic mechanisms. Finally, a set of potential methylation inhibitors with
different potencies over time was proposed and applied in abnormal intestinal systems and
the impact on methylation level investigated.
A second comparative analysis between the colon and small intestine was performed to
determine time taken to occurrence of recognised crypt phenomena in the intestinal crypt.
Results were more variable for the colon crypt, compared with the small intestine crypt,
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suggesting that the former is more sensitive to alterations in cell division, differentiation and
apoptosis rates than the latter. Similar observations were concluded from an experimental
study on crypt fission and cell proliferation in rat intestinal tissues, described in Berlanga-
Acosta et al. [2001].
8.2 Future work
Connecting model-components in a multi-scale computational model for CRC dynam-
ics
An obvious limitation of the AgentCrypt model is the absence of information on patient
characteristics, (e.g. ageing, gender). Given the overall aim of a multi-scale computational
model for CRC dynamics, (i.e. representing CRC specifics at micro-molecular, cellular and
tissue layers), the final step is to connect AgentCrypt to the E-G Network Model. Specif-
ically, there is a need to link information on (i) micro-molecular layer (gene relationship,
genetic and epigenetic mechanisms), (ii) cellular/ tissue level (cell/ crypt interdependen-
cies), (iii) personal characteristics (e.g. ageing, gender, heredity) and (iv) carcinogen influ-
ences (e.g. tobacco usage, chemical exposure), in order to analyse tumour pathways and to
identify potential targets for epigenetic inhibitors that can be explored in cancer therapy. A
link between the gene network and the agent-based model is feasible, as initialization and
update of the methylation level status inside a cell is driven by AgentCrypt, (which relies on
the strength of gene dependencies to set some of the input parameters). This E-G Network
- AgentCrypt combined model can be extended to integrate information on inhibitors for
methylation on specific key-genes from tumour pathways in order to analyse their effect
at cellular/ tissue level. This approach may improve understanding of aberrant molecu-
lar events observed for genes such as APC, KRAS, which are known to have a crucial
role in CRC initiation and progression, [Jones and Baylin, 2002]. In addition, given inter-
est in studying the combined effect of two or more epigenetic inhibitors in solid tumours,
[Hatzimichael and Crook, 2013], the E-G Network - AgentCrypt model can be extended to
investigate the consequences of using epigenetic inhibitor combinations in the colon tissue
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during cancer development.
Sensitivity analysis for the parameter sets integrated in the E-G Network, AgentCrypt
& LogisticCrypt
Given the lack of precise biological information available on intestinal crypt systems during
cancer development, extensive sensitivity analysis is necessary for the set of parameters
included in the Colorectal Cancer Model. This analysis is necessary for further validation as
parameter changes should lead to model outputs which can be marked for known patterns.
In addition, parameter variation can indicate more sensitive factors in cancer development,
providing new hypotheses to be tested.
Tests should integrate alternative values for the gene network parameters, including net-
work size, simulation time, the d-value used for identification of d-plausible pathways, the
coefficients for the genes that were i) identified in signalling pathways, or ii) reported to be
sensitive to age-related methylation, i.e. SAM and SIG coefficients, (E-G Network). Some
adjustments are likely also for the value-ranges considered for the relationships between
epigenetic event level and cancer stages, incorporated in i) DNA methylation and histone
modification initialization and update steps and ii) cancer progression decision methods,
(Tables 4.3 - 5.2). Resources such as GEO database can be also consulted for gene pro-
moter methylation level in CRC, (similar as for the global methylation level in intestinal
cells that was used in the AgentCrypt for colon and small intestine systems). Moreover, the
E-G Network model can be extended to include also average gene methylation level and
to analyse global hypomethylation over time. Analogously, different value-ranges must be
considered for the AG and TH HM parameters, (Tables 5.3 - 5.4), which describe ageing
and gender impact on micro-molecular events. The sensitivity analysis will be carried out
systematically, for larger sample sizes, (e.g. 1000 synthetic patients), with focus on the
assessment of cancer progression within gene networks.
In addition, sensitivity analysis should address the parameter set used for the intestinal
crypt structure and dynamics. Specifically, i) the crypt intra- and interdependencies and
their weights in updating DNAm level, (i.e. ICoef, CNI and DiffMethCoef); ii) carcinogen
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contribution coefficients, (i.e. δ1); iii) the value - ranges for every cell type number, (e.g.
MaxProgNo); iv) cell cycle duration, (e.g. for progenitor cells); as well as v) the cell rates
of division, differentiation and apoptosis, (LogisticCrypt).
Parallel implementation for E-G Network and AgentCrypt
Parallel implementation is anticipated for extension of the E-G Network and AgentCrypt
models to accommodate the complexity of intestinal crypt dynamics during cancer devel-
opment. For example, the time for a single simulation, run using AgentCrypt for 550 it-
erations, in an ‘i7-2600, 3.40 GHz, 8 GB RAM’ system, was around 12 - 13 the minutes
for small intestine and around 10 hours for the colon. However, the further developmen-
tal phase is not trivial, and in complex systems, with high communication overhead, the
speedup, (Section 5.3), of such approach can be difficult to estimate. Several strategies
already identified during model development target parallelisation for
i. the group of ‘individuals’, (where an ‘individual’ is mimicked by AgentCrypt using
the Intestinal Crypt Group). Given that every individual is independent with respect
to intestinal tissue dynamics from every other individual, every Intestinal Crypt Group
can run on a distinct compute node and no communication is needed between nodes.
The speedup in this case is almost linear given that the Intestinal Crypt Group are
analysed concurrently.
ii. a single ‘individual’, (i.e. one Intestinal Crypt Group in AgentCrypt). The Intestinal
Crypt Group can be split between a group of compute nodes, with every Crypt running
on a single node. However, given ‘inter-crypt influences’ considered in AgentCrypt,
communication between nodes does exist in this case and linear speedup is not antici-
pated.
iii. ‘chunks of cells’, (i.e. inside the Crypt in AgentCrypt). Given the parallelisation fea-
tures, (illustrated in Figure 6.4), a Crypt can be divided in cell sets of same of similar
sizes, with every group allocated to a distinct compute node. Slave compute nodes can
calculate cell methylation level and decide on cell division, differentiation and apop-
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tosis and once cell methylation level and actions are determined, the master node is
informed and updates crypt structure. Limitations at this level are clearly given by
communication between nodes and linear speedup is not possible. However, commu-
nication is reduced by using ‘chunks of cells’ instead of running every cell on distinct
node. In addition, algorithm efficiency seems also influenced by crypt phenomena.
While is a crypt with a large cell number, all allocated nodes run, (are ‘busy’), and
the overall job is divided, in a crypt with a small cell number, only a part of consid-
ered nodes work and the remainder is in ‘waiting’ state, causing decrease in algorithm
efficiency. Thus, of high importance is choosing node number and cell group size.
iv. the gene network, (E-G Network Model). Parallelisation at this level involves gene
network division into subnetworks with similar node and edge numbers, in order to
homogenize time needed for updates among the set of subnetworks. However, commu-
nication between sub-networks is obviously required and speedup is again, not linear.
Parallelisation is available for the ageing/gender case study (Chapter 5). Other compo-
nents are in the preliminary development stage, (e.g. for methylation level update in the
AgentCrypt), but this work is ongoing.
Development of a graphical interface and visualisation
The code documentation file mentioned in Chapter 5 was provided in order to facilitate
understanding of technical details on model implementation. The future plan is to develop
a graphical interface for the Colorectal Cancer Model, in order to help non-computational
scientists use the framework. Thus, input information such as patient characteristics, (e.g.
ageing, gender), tumour specifics, (e.g. mutation of a specific gene), or time-period consid-
ered for prediction, (e.g. 3-5 years), could be easily imported through a graphical interface
into the model, in order to be used for analysis. Additionally, a visual representation of the
output data, (e.g. the way in which crypt dynamics change under carcinogen influence),
would also be of value.
Other Inclusions / Extensions:
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Inclusion of nutrition and physical activity influence in the Colorectal Cancer Model
Studies have shown that, while a diet containing more vegetables and fruits and a more
active program of physical exercises can help reduce CRC risk, a high intake of red meat
and alcohol and a limited amount of physical activity have been associated with increased
risk, [Ryan-Harshman and Aldoori, 2007; Harriss et al., 2009]. In addition, the influence
of nutrition with regard to epigenetic modifications was recently reported also, (reviewed
in Parle-McDermott and Ozaki [2011] and references therein). Ideally, therefore, the influ-
ence of lifestyle characteristics should be taken into account as an extension of the model
presented here. In terms of such an extension, the aim would be to determine a quantitative
coefficient to represent the impact of these risk factors on gene methylation level, (based on
data from reported statistical studies), and to link this information to the update step.
Inclusion of miRNAs
MiRNAs are involved in cell cycle phases and their deregulation has been observed for dif-
ferent cancer types, (Subsection 2.3.3). MiRNA potential for CRC diagnosis and prognosis
has been recently reported, (reviewed in Luo et al. [2011]; Schetter et al. [2011]; Mene´ndez
et al. [2013] and references therein). Therefore, the plan would be to integrate relevant
data on miRNAs into the Colorectal Cancer Model, to link these changes to information on
methylation level from the gene network and to analyse their influence at tissue level, (i.e.
on crypt dynamics).
Extension to other types of cancer, (e.g. liver and lung cancer)
While colorectal cancer was the initial focus, the model presented here has been designed
to be generalizable also to other types of cancer. Therefore, more general terms, such as
‘carcinoma in situ’, have been used to denote colon cancer stages in the framework, instead
of more disease-specific usage. Based on similar mechanisms observed in cancer develop-
ment among different tissues at molecular or cell level, (e.g. common genes involved in
tumour pathways, high cell division rate), a future long-term plan would be to extend the
current framework to other types of solid cancer, such as liver and lung. The difficulty, as
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usual, is parametrisation and this extension is non-trivial. The task would involve refining
existing metrics from the Colorectal Cancer Model and integrating information on tissue-
specific malignant phenomena, (such as the high impact of tobacco usage in lung cancer,
[Hecht, 2003], or viral infection in liver cancer, (reviewed in Herceg and Vaissie`re [2011];
Dandri and Locarnini [2012] and references therein).
8.3 Final remarks
The Colorectal Cancer Model aims to investigate the tumour mechanisms at three main lay-
ers, namely the micro-molecular, cellular and tissue levels. The E-G Network Model can
be used as a prototype-tool to aid prediction of CRC development based on information on
micro-molecular interdependencies, and towards personalised medicine. AgentCrypt can
be seen as proof of concept to be used in epigenetic epidemiology, to accommodate in vivo
and in vitro experiments on tissue-specific methylation modifications. Finally, Logistic-
Crypt can be considered a prototype tool for investigating the dynamics of a multi-species
system characterised by intra- and interspecific competition. Full scale-up, in computa-
tional terms, remains a challenge for the future.
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Appendix A
Glossary
5hmC, 5fC and 5caC are DNA methylation variants resulted sequentially from methyla-
tion cytosine (5mC) oxidation processes, which are regulated by the Tet (ten eleven
translocation) protein group, as illustrated by the following relationships:
5mC oxidation−−−−−−→ 5hmC oxidation−−−−−−→ 5fC oxidation−−−−−−→ 5caC.
Acetylation is addition of an acetyl group to a chemical compound.
Agent-based model (ABM) consists of units or entities at basis level, to which attributes
are assigned.
Age Sensitive Gene (ASG parameter) indicates age when methylation level changes of a
gene sensitive to age-related methylation are observed.
Apoptosis is the process of programmed cell death.
Bayesian network is a network of genes in which change of a given gene is conditional
on change of one or more other genes.
Benign (tumour) does not invade nearby tissues or spread throughout the body, i.e. not
cancerous.
Biomarker is an entity that characterizes specifically abnormal systems and can be used
to differentiate tumour from normal tissues.
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Cell is the the smallest structural and functional unit of an organism.
Cell cycle contains the set of events between two successive cell divisions.
Cell differentiation is the process during which a less specialized cell, (e.g. stem cell), be-
comes a more specialized cell type; in some cases, (e.g. colon), a fully-differentiated
cell loses the ability of performing further divisions.
Cell division is the process during which a parent cell divides into two daughter cells,
transmitting genetic information.
Cell proliferation is the process of increasing cell numbers, through cell division.
Cellular automaton is a discrete model consisting of large number of identical cells found
in a discrete number of states. All cells change state simultaneously, based on transi-
tion rules with their neighbours.
Chemotherapy is a standard cancer therapy, where cancerous cells are targeted by differ-
ent drugs.
Chromatin immunoprecipitation (ChIP) is a method for histone modification analysis,
which can be applied at both gene specific and genome-wide levels, also in combina-
tion with microarray and NGS technologies, (e.g. ChIP-chip, ChIP-Seq).
Chromatin is the combination of DNA and proteins that makes up the contents of the cell
nucleus. Chromatin is present in two forms: heterochromatin (highly condensed and
characterised by low levels of gene transcription), and euchromatin (less compacted
and characterised by high levels of gene transcription).
Chromosome is an organized arrangement or package of DNA in cell.
Chromosomal instability is a class of genomic instability characterised by deletions or
duplications of parts of chromosomes; it has been associated with malignant tumour
development.
2
Colonoscopy is the screening procedure that permits examination of the entire colon and
removal of detected polyps in the same session.
Colorectal cancer develops in the colon, rectum or in the appendix. It is also referred as
colon cancer, rectal cancer, bowel cancer or colorectal adenocarcinoma.
CpG Island Methylator Phenotype represents the malignant phenotype given by CpG
island hypermethylation of promoters in a group of genes.
Density-Dependent Coefficient determine the relationships between growth rate within
a population at a given time t based on population size at time t and its maximum
capacity permitted in a specific environment.
DNA, or deoxyribonucleic acid, is a double-stranded macromolecule that encodes the ge-
netic information in almost all living organisms and is composed from base pairs of
nucleotides. The nucleotides contain the bases adenine (A), guanine (G), cytosine
(C), and thymine (T). In nature, base pair affinities are A-T and G-C.
DNA methylation is a molecular process that involves the addition of a methyl group
to a cytosine or adenine ring. (Adenine methylation has been reported recently in
prokaryotes, [Aguilar and Craighead, 2013] and references therein.)
DNA methyltransferase family represents enzymes catalysing methyl group transfer to
DNA.
DNA repair is the process used by a cell to identify and repair abnormal changes in DNA.
d-Network Threshold (dNT) is a model coefficient that determines if gene pathways
found in a gene network are d-plausible, based on the value of d- model parameter.
Drug response curve is a curve measuring level of response of drug present over time.
Epigenetic events within a cell are heritable and reversible modifications that affect gene
expression but not the DNA sequence.
Epigenome refers to the totality of epigenetic markers in an organism.
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Epithelium is one of the four major animal tissue types, (along connective, muscle and
nervous), characterised by high cell division rate and little intercellular gaps. Epithe-
lium assures functions of e.g. tissue protection, hormone secretion, nutrient absorp-
tion, sensation detection.
Exon is the coding part of a gene that is used in translation to protein.
Familial adenomatous polyposis represents an incipient or initial stage of adenoma, char-
acterised by large numbers of polyps in both colon and rectal tissues, which can
progress to CRC if are not treated.
Gene is the basic physical and functional hereditary unit, comprises part of the DNA
sequence and determines a specific characteristic of an organism.
Gene expression is the process of synthesising the gene product, (protein or RNA).
Gene Expression Omnibus is a database of genetic and epigenetic data generated by high
throughput technologies. technologies
Genome consists of all the genetic material found in an organism.
Genotype is the gene collection for an individual. It refers also to the alleles inherited for
a specific gene.
Histone is a protein package of the DNA nucleosome sequence. There are five known
families of histones H1/H5, H2A, H2B, H3 and H4, grouped in two categories: the
core, (H2A, H2B, H3, H4) and the linker histones, (H1 and H5).
Histone acetyltransferases represent enzyme family catalysing acetyl group transfer to
histones.
Histone deacetylases represent enzyme family removing acetyl group from histones.
Histone demethylases represent enzyme family removing methyl group from histones.
Histone modification refers to addition of different chemical compounds (e.g. acetyl,
methyl) to histone ‘tails’, forming e.g. histone acetylation, methylation.
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Histone methyltransferases represent enzyme family catalysing methyl group transfer to
histones.
High-performance liquid chromatography is method for global DNA methylation anal-
ysis.
Histone variant is a variant form of a major histone modification. For example, H2A.X
and H2A.Z are histone H2A variants, while the H3.3 is a variant for histone H3.
Homeostasis is the balance or stable state that characterises the internal environment of a
normal biological system; this is usually altered in malignant tumour.
Hypermethylation is an increase in DNA methylation level.
Hypomethylation is a decrease in DNA methylation level.
Inhibitor Maximum Efficiency Time represents the time period with the highest inhibitor
effect.
Incidence rate of cancer is the rate per unit time of cancer occurrence in a population
scaled to the population size.
Inflammatory bowel disease represents a group of disorders involving inflammation of
different parts of the intestine. Its presence is considered to be a risk factor in bowel
cancer development.
Intron is a non-coding DNA/ RNA segment.
Leukaemia is a malignant disease of the blood-forming organs characterised by an aber-
rant increase in the white blood cells number.
Lymph is a transparent liquid, (composed from white blood cells, mainly lymphocytes),
which circulates through the lymphatic vessels and intercellular gaps and facilitates
substance exchange between blood and solid tissues.
Malignant implies ability to invade nearby tissues or spread throughout the body, i.e.
cancerous.
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Metastasis characterises the tumour extension from the initial (primary) tissue to other
parts of the body.
Methylation is addition of a methyl group to a chemical compound.
The methylation cycle number average (MCA) is the average time period after which
all gene networks within a given group advance to the next cancer stage.
Micro RNAs are small sequences of non-coding RNA molecule with role in cell cycle
regulation.
Microsatellite instability is the condition of increased mutation rate caused by deregula-
tions in the DNA mismatch repair mechanism.
Mortality rate = number of deaths per unit of time caused by a disease in a population
scaled to the population size.
Mutation is a modification in a DNA sequence. Mutations can be i) germline, (which can
be transmitted to offspring), and ii) somatic, (which are not passed on).
Neurodegenerative disorder refers to a group of diseases that primarily include affections
of the neurons in the human brain, (e.g. Parkinson’s, Alzheimer’s disease).
Next-Generation Sequencing is a collective name for more recent high throughput meth-
ods of determining e.g. variation at genetic and epigenetic levels.
Nucleotide is a compound consisting of a base, (A, G, C, T), sugar, and phosphate.
Oncogene is a gene that has potential to cause cancer.
Percentage of methylated reference measures the degree of methylation for a given gene.
When PMR values show variation across multiple runs, average PMR can be calcu-
lated based on reported PMR values.
Phenotype is composed from the observable characteristics of a living organism. A sim-
plified mathematical formula that describes the phenotype is: Phenotype = Genotype
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+ Environment + Epigenetics, incorporating both environment and Epigenetics influ-
ences in gene expression.
The polymerase chain reaction is a technology used to amplify one or more DNA se-
quence, generating large number of copies, (e.g. thousands, millions).
Polyp is a small growth protruding from a mucous membrane.
Progenitor cell is a cell, characterised by the ability of limited division number.
Protein is a molecule built from amino acids, (formed from triplets of nucleotide bases),
which governs functionality. Proteins characterise major components, (e.g. hair, skin,
etc.).
Proto-oncogene is a normal gene that can become an oncogene due to mutations or in-
creased expression.
Radiotherapy is standard for more advanced cancer stages and aims to destroy malignant
cells.
Recurrent (cancer) refers to malignant tumours; initially susceptible to treatment, which
reoccurs in an individual after a time-period during which the disease is non-detectable
(latent).
Residue is a small quantity of a substance.
Risk factor is a factor such as chemical exposure, tobacco usage, that may increase the
probability of disease development.
RNA, or ribonucleic acid, is a single-stranded macromolecule transcribing the genetic
information from DNA to proteins.
Sensitive to age-related methylation is a gene feature that indicates that methylation
levels of a given gene are influenced by ageing.
Sporadic refers to a tumour that occurs in a population without involving heritable pre-
disposition.
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Stage (cancer) is the degree of the cancer development and extension.
Stem cells can differentiate into diverse specialized cell types. Referred to as self-renewable
due to ability to produce new stem cells and considered to be the repair system of the
body.
Signalling pathway represents a set of inter-related molecules within a cell working to
control cell functions, including cell division or apoptosis.
Targeted therapy aims to detect and destroy malignant cells without affecting normal
cells. It can be applied for more advanced cancer stages, (e.g. metastasis), and also
in combination with chemotherapy.
Tumour refers to abnormal and uncontrolled cell proliferation.
Tumour suppressor gene is a gene that protects a cell from progressing one step along
the path to disease; it governs cell apoptosis.
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Appendix B
Extended information on CRC
Biological Background
Table B.1: Key genes in CRC development
Gene Sym-
bol
Gene characteristics
APC The molecular changes of the adenomatous polyposis coli, (APC), gene are linked
to the earliest beginning of CRC, being associated with FAP and sporadic cases,
[Fodde et al., 2001; Grady and Markowitz, 2002; Frank, 2007; Suehiro et al.,
2008]. The results presented in Suehiro et al. [2008] show an association between
the hypermethylation of APC and mutations of TP53 in colorectal neoplasms.
KRAS The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, (KRAS), gene is the
most commonly mutated RAt Sarcoma (RAS) family member in CRC, [Grady
and Markowitz, 2002]. Studies have reported that approximately 50% of ad-
vanced adenomas with APC mutations also have KRAS mutations, [Grady and
Markowitz, 2002]. A high influence is seen also in lung cancer, where KRAS was
observed as being mutated in 30% of cases, [Risch and Plass, 2008].
TP53 The tumour protein p53, (TP53), gene is a stress response gene involved in main-
taining genomic stability through the control of cell cycle progression, DNA re-
pair and apoptosis. Its inactivation leads to both decrease of tumour-cell death rate
and increase of their division rate, [Knudson, 2001]. A significantly high level of
changes in this TGS was reported in lung and colorectal cancers, [Risch and Plass,
2008; Suehiro et al., 2008].
Continued on next page
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Gene Sym-
bol
Gene characteristics
RASSF1A The Ras-associated domain family member 1, (RASSF1A), gene is considered to
be one of the most hypermethylated TSGs in various cancer types, such as breast,
[Dworkin et al., 2009], lung, [Dammann et al., 2003], ovarian, renal, prostate
and colorectal cancers, [Yoon et al., 2001]. Studies show that RASSF1A expres-
sion is significantly reduced in tumours, although it has a high level in normal
cells, [Dworkin et al., 2009]. Therefore, identification of high RASSF1A methyla-
tion level in carcinoma cells could become important in early detection of cancer,
[Dammann et al., 2003].
MCC Mutated In Colorectal Cancers (MCC) gene is considered to be involved in sev-
eral cellular processes, (e.g. proliferation, [Fukuyama et al., 2008], movement
of epithelial cells, [Arnaud et al., 2009]), and pathways, (e.g. Wnt, [Fukuyama
et al., 2008]), and to act as a TSG. MCC silencing, (due to promoter methyla-
tion), has been observed in sporadic forms of CRC, [Kohonen-Corish et al., 2007;
Fukuyama et al., 2008].
MLH1 The mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli), (MLH1), gene is
found to be mutated or aberrant methylated in the hereditary nonpolyposis forms
of the CRC, [Ogino et al., 2006b; Niv, 2007]. MLH1 is considered a ‘caretaker’
gene, since its expressed protein has a role in repairing DNA mismatches that
appear normally during DNA replication; abnormal changes in MLH1 expression
lead to genomic instability and cell proliferation, [Niv, 2007].
MGMT Another ‘caretaker’ gene that encodes DNA repair protein, [Herman and Baylin,
2003], the O6-methylguanine-DNA methyltransferase, (MGMT), is found to be
highly hypermethylated in adenomas, [Ogino et al., 2006b; Suehiro et al., 2008].
Additionally, aberrant methylation of APC followed by MGMT or MLH1 hyper-
methylation is associated with abnormal G-to-A transition in APC, [Suehiro et al.,
2008].
Table B.2: Colorectal cancer types
CRC Type Major characteristics
CIN CIN is characterised by genetic mutations involving the inactivation of TGSs such
as APC, p53, and the activation of oncogenes, (e.g. KRAS), [Grady, 2004].
CIMP CIMP is characterised by inactivation of different TSGs, (e.g. CDKN2A:p16,
IGF2, RUNX3), and DNA repair genes, (e.g. MLH1), caused by CpG islands
hypermethylation in their promoters, (reviewed in [Hughes et al., 2012]). In addi-
tion, activation of the BRAF proto-oncogene is considered to be an early event in
CIMP, [Hughes et al., 2012].
Continued on next page
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CRC Type Major characteristics
HNPCC HNPCC is characterised by germline mutations in the DNA mismatch repair
genes, e.g. in MLH1, MSH2, or MSH6 genes. In addition, the time-period for
developing CRC decreases in comparison with sporadic cases, (i.e. 2-3 years in
the former instead of 8-10 years in the later). Moreover, in the former case, the
malignant phenotype can be identified in younger individuals, (with average age
≈ 45 years), in comparison with the later, (with the average age ≈ 63 years),
[Cunningham et al., 2010].
FAP FAP is characterised by large numbers of adenomas in both colon and rectal tis-
sues, which can progress during short time-periods to CRC if are not treated.
Initially, the polyps develop as consequence of germline mutations in APC gene,
[Half et al., 2009].
MAP MAP is characterised by recessively inherited mutations in MUTYH gene causing
a number of polyps, (lower than in the FAP cases), [Half et al., 2009].
BRAF BRAF is a proto-oncogene, mutated in several human cancers, including
melanoma, ovarian, prostate and CRC, [McCubrey et al., 2006; Cho et al., 2006;
Ahmed et al., 2013]. In CRC, BRAF is one of the most commonly affected genes,
in addition to e.g. TP53 and KRAS, [Ahmed et al., 2013]. Drugs targeting BRAF
mutation have been already approved by FDA, (e.g. Vemurafenib , [Bollag et al.,
2012]) and are in use for melanoma.
Table B.3: Cancer predisposition based on ageing
Group
name
Description
Group 1 refers to children, (aged 0-14 years), and young adults, (15-29 years), and is char-
acterised by very low number of diagnosed cancer cases. An exception to this
observation is that of leukaemia, the most common childhood cancer, which has a
very low rate in adults, [Cancer Research UK, 2014a]. CRC incidence rate is esti-
mated to be below 5 per 100,000 population UK, (2009-2011), [Cancer Research
UK, 2014b].
Group 2 includes adults of 30-49 years and shows a slightly higher overall cancer predis-
position in females than in males. This is caused mainly by the high number of
breast cancer cases identified in this age range, [Frank, 2007]. CRC incidence is
still low, with the rate around 45 for male and 40 for females per 100,000 UK
population, (2009 - 2011), [Cancer Research UK, 2014b].
Continued on next page
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Group
name
Description
Group 3 is composed of adults aged 50-74 years and includes the highest number of de-
tected cancer cases from all age groups, with more cancer cases diagnosed in
males than in females. Some early studies reported that CRC incidence increases
markedly after 50 years, [Issa et al., 1994]. However, more recent reports noted
that although abnormal changes can appear in the colon even 10-15 years earlier
than malignant symptoms, CRC development mostly occurs between the ages 65-
75, with screening recommended between ages 50-75 or 40-75 for people with
familial colon cancer history, [Scholefield, 2002]. Estimated CRC incidence per
100,000 of the population was reported to be around 360 world-wide in 2012, and
around 220 in US, (2009-2011), [SEER, 2013a; Ferlay et al., 2014].
Group 4 is associated with the elderly, (i.e. of age greater than 75 years), and it char-
acterised by relatively high CRC incidence rate. For instance, estimated CRC
incidence per 100,000 individuals was reported to be around 200 world-wide in
2012, and around 250 in US, (2009-2011), [SEER, 2013a; Ferlay et al., 2014].
4
Appendix C
Resources
Table C.1: A list of Resources for Epigenetics Research (Urls accessed on 09/06/2014)
Resource name Description and url.
Epigenesys - Network of
Excellence
European community on Epigenetics;
url: http://www.epigenesys.eu/en/.
Epigenie - Informally
informative coverage of
Epigenetics
Resources for Epigenetics research including information on
technologies, webminars, meetings and products etc.;
url: http://epigenie.com/.
e3: Scientific Networking
for Epigenetic Experts
Information on conferences, meetings, resources for Epigenetics
researchers;
url: http://epiexperts.com/.
Galaxy A web-based, free framework for biomedical data research,
[Goecks et al., 2010];
url: http://galaxyproject.org/.
NCBI Epigenomics Repository for epigenetic modification data for whole-genome,
[Fingerman et al., 2011];
url: http://www.ncbi.nlm.nih.gov/epigenomics.
Table C.2: Databases accessed for genetic and epigenetic mechanisms in cancer and other
human diseases (Urls accessed on 09/06/2014)
Resource Description/ Database content
ArrayExpress Gene expression data from studies using microarray and high throughput sequenc-
ing technologies;
url: https://www.ebi.ac.uk/arrayexpress/.
Continued on next page
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Resource Description/ Database content
COSMIC Catalogue Of Somatic Mutations In Cancer database: Somatic mutations ob-
served in human cancers;
url: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/.
DiseaseMeth Methylation level in human diseases;
url: http://202.97.205.78/diseasemeth/.
Ensembl
Genome
Browser
The genome of different organisms, (including human, mouse);
url: http://www.ensembl.org/index.html.
GeneCards Gene annotation;
url: http://www.genecards.org/
HGMD Human Gene Mutation Database: Methylation level and mutation of cancer-
related genes;
url: http://www.hgmd.org/.
HHMD Human Histone Modification Database: Human histone modification;
url: http://202.97.205.78/hhmd/.
Histone
Database
Histone sequences;
url: http://genome.nhgri.nih.gov/histones/.
HIstome Information on histone modifications, variants and modifying enzymes in human
systems; url: http://www.actrec.gov.in/histome/index.php.
ICGC Data
Portal
Repository for output information from the ICGC projects;
url: https://dcc.icgc.org/.
KEGG Path-
way
Pathways involved in e.g. cellular processes, human diseases;
url: http://www.genome.jp/kegg/pathway.html.
MethDB Cancer methylation;
url: http://www.methdb.de/.
MethyCancer Methylation level of cancer-related genes;
url: http://methycancer.psych.ac.cn/.
MPromDb Information from ChIP-Seq experiments on gene promoters in mammalian bio-
logical systems;
url: http://mpromdb.wistar.upenn.edu/.
NCBI GEO Genomic data generated from microarray and NGS technologies;
url: http://www.ncbi.nlm.nih.gov/geo/.
NCBI Gene Gene annotation;
url: http://www.ncbi.nlm.nih.gov/gene
PubMeth Gene methylation level specific to various systems;
url: http://www.pubmeth.org/.
StatEpigen Conditional relationships between genetic and epigenetic events affecting differ-
ent genes in various cancer types;
url: http://statepigen.sci-sym.dcu.ie/.
TCGA Data
Portal
The TGCA data sets on exome, methylation, miRNA and clinical information for
different malignant phenotypes;
url: https://tcga-data.nci.nih.gov/tcga/.
2
Table C.3: A list of software developed for generating BN-applications, (software urls ac-
cessed 19/06/2014)
Tool type Tool name and url
Free Bayesian Network tools in Java, url: http://bnj.sourceforge.net/.
Chordalysis, url: http://sourceforge.net/projects/chordalysis/.
FDEP, url: http://www.cs.bris.ac.uk/ flach/fdep/.
GeNIe, url: http://genie.sis.pitt.edu/.
jBNC, url: http://jbnc.sourceforge.net/.
PNL: Open Source Probabilistic Networks Library,
url: http://sourceforge.net/projects/openpnl/.
Netice, url: http://www.norsys.com/.
Commercial Analytica, url: http://www.lumina.com/.
BayesServer, url: http://www.bayesserver.com/default.aspx.
BNet, url: https://www.cra.com/commercial-solutions/bnet-builder.asp.
Flint, url: http://www.lpa.co.uk/fln.htm.
Precision Tree, url: http://www.palisade.com/precisiontree/.
WEKA, url: http://www.cs.waikato.ac.nz/ ml/weka/.
Table C.4: Genes included in the E-G Network Model, with information on gene symbol
and name from the GeneCards database, [Safran et al., 2010]
Gene Sym-
bol
Gene Name
APC Adenomatous Polyposis Coli
BRAF v-raf murine sarcoma viral oncogene homolog B
CDKN2A:P14 Cyclin-dependent kinase inhibitor 2A
CDKN2A:p16 Cyclin-dependent kinase inhibitor 2
CRABP1 Cellular retinoic acid binding protein 1
GJC1 Gap junction protein, gamma 1, 45kDa
IGF2 Insulin-like growth factor II
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
MCC Mutated In Colorectal Cancers
MGMT O6-methylguanine-DNA methyltransferase
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)
MUTYH MutY homolog
NORE1 Ras association (RalGDS/AF-6) domain family member 5
NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
RASSF1A Ras-associated domain family member 1
SMAD4 SMAD family member 4
TP53 Tumour Protein p53
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Appendix D
Cell Rate Relationships in the
LogisticCrypt Component Model
The cell action rate expressions described here are deduced based on biological information
on intestinal crypt dynamics and structure indicated in e.g Potten et al. [2003]; Sancho
et al. [2003]; Kim et al. [2005]; Canavan et al. [2006]; Frank [2007]; Nicolas et al. [2007];
Humphries and Wright [2008]; Jin et al. [2009]; Khalek et al. [2010]; Umar [2010]; Bock
[2012]; Vaiopoulos et al. [2012]; Clevers and Bevins [2013], (Section 2.4).
D.1 Colon Crypt System
1. Rules applied to update cell numbers in colon crypt over time:
Stem(t+1) = Stem(t) + Stem(t) × (RateStemSymDiv - RateStemApoptosis) × DDCSTEM (t)
Prog(t+1) = Prog(t) + [Stem(t)×RateStemAsymDiv + Prog(t)× (RateProgDiv - RateProgFullDiff )]
× DDCPROG(t)
Diff(t+1) = Diff(t) + [Prog(t)×RateProgFullDiff - Diff(t)×RateDiffApoptosis]×DDCDIFF (t)
DDCSTEM (t) 6= 0; DDCPROG(t) 6= 0; DDCDIFF (t) 6= 0,
Stem(t0), Prog(t0), Diff(t0) = known values, being equal to respectively, the stem,
progenitor and differentiated cell number at initial time, i.e. t0.
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2. Relationships showing no variations on cell number over time:
Stem(t+1) - Stem(t) = 0
Prog(t+1) - Prog(t) = 0
Diff(t+1) - Diff(t) = 0
3. Calculation of relationship between parameters:
Stem(t+1) - Stem(t) = 0⇒
Stem(t) + Stem(t) × (RateStemSymDiv - RateStemApoptosis) × DDCSTEM (t) - Stem(t) = 0⇒
(RateStemSymDiv - Rate
Stem
Apoptosis) × DDCSTEM (t) = 0⇒
RateStemSymDiv - Rate
Stem
Apoptosis = 0, (given DDCSTEM (t) 6= 0)⇒
RateStemApoptosis = Rate
Stem
SymDiv
Prog(t+1) - Prog(t) = 0⇒
Prog(t) + [Stem(t)×RateStemAsymDiv + Prog(t)× (RateProgDiv - RateProgFullDiff )]×DDCPROG(t)
Prog(t) = 0⇒
[Stem(t) × RateStemAsymDiv + Prog(t) × (RateProgDiv - RateProgFullDiff )] × DDCPROG(t) =
0, (given DDCPROG(t) 6= 0)⇒
Stem(t) × RateStemAsymDiv + Prog(t) × (RateProgDiv RateProgFullDiff ) = 0⇒
Stem(t) × RateStemAsymDiv + Prog(t) × RateProgDiv = Prog(t) × RateProgFullDiff
At initial time, i.e. t0,⇒
RateProgFullDiff =
Stem(t0)
Prog(t0)
× RateStemAsymDiv + RateProgDiv
Diff(t+1) - Diff(t) = 0⇒
Diff(t) + [Prog(t) × RateProgFullDiff - Diff(t) × RateDiffApoptosis] × DDCDIFF (t) - Diff(t)
= 0⇒
2
[Prog(t)×RateProgFullDiff - Diff(t)×RateDiffApoptosis]×DDCDIFF (t) = 0 (given DDCDIFF (t)
6= 0)⇒
Prog(t) × RateProgFullDiff - Diff(t) × RateDiffApoptosis = 0
At initial time, i.e. t0,⇒
RateDiffApoptosis =
Prog(t0)
Diff(t0)
× RateProgFullDiff ⇒
RateDiffApoptosis =
Prog(t0)
Diff(t0)
× [Stem(t0)Prog(t0) × RateStemAsymDiv + Rate
Prog
Div ]
D.2 Small Intestine Crypt System
1. Rules applied to update cell numbers in small intestine crypt over time:
Stem(t+1) = Stem(t) + Stem(t) × (RateStemSymDiv - RateStemApoptosis) × DDCSTEM (t);
Diff(t+1) = Diff(t) + [Prog(t)×RateProgFullDiff - Diff(t)×RateDiffApoptosis]×DDCDIFF (t)
Prog(t+1) = Prog(t) + [Stem(t) × RateStemAsymDiv + Prog(t) × (RateProgDiv - RateProgFullDiff
- RateProgPaneth)] × DDCPROG(t)
Paneth(t+1) = Paneth(t) + [Prog(t) × RateProgPaneth - Paneth(t) × RatePanethApoptosis] ×
DDCPANETH (t)
DDCSTEM (t) 6= 0; DDCPROG(t) 6= 0; DDCDIFF (t) 6= 0, DDCPANETH 6= 0;
Stem(t0), Prog(t0), Paneth(t0) = known values, being equal respectively to, the stem,
progenitor and Paneth cell number at initial time, i.e. t0;
Diff(t0) = the number of fully-differentiated cells, (excepting Paneth cells that are
included in ‘Paneth’ group), at initial time, (t0).
2. Relationships showing no variations on cell number over time:
Stem(t+1) - Stem(t) = 0
Prog(t+1) - Prog(t) = 0
Diff(t+1) - Diff(t) = 0
Paneth(t+1) - Paneth(t) = 0
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3. Calculation of relationship between parameters:
Stem(t+1) - Stem(t) = 0⇒
RateStemApoptosis = Rate
Stem
SymDiv (same as for the colon crypt)
Prog(t+1) - Prog(t) = 0⇒
Prog(t) + [Stem(t)×RateStemAsymDiv + Prog(t)× (RateProgDiv - RateProgFullDiff - RateProgPaneth)]
× DDCPROG(t) - Prog(t) = 0 (given DDCPROG(t) 6= 0)⇒
Stem(t) × RateStemAsymDiv + Prog(t) × (RateProgDiv - RateProgFullDiff - RateProgPaneth) = 0⇒
Stem(t)×RateStemAsymDiv + Prog(t)× (RateProgDiv - RateProgPaneth) = Prog(t)×RateProgFullDiff
⇒
At initial time, i.e. t0,⇒
RateProgFullDiff =
Stem(t0)
Prog(t0)
× RateStemAsymDiv + RateProgDiv - RateProgPaneth
Diff(t+1) - Diff(t) = 0⇒
Diff(t) + [Prog(t) × RateProgFullDiff - Diff(t) × RateDiffApoptosis] × DDCDIFF (t) Diff(t)
= 0⇒
RateDiffApoptosis =
Prog(t0)
Diff(t0)
× RateProgFullDiff (same as for colon crypt)
At initial time, i.e. t0,⇒
RateDiffApoptosis =
Prog(t0)
Diff(t0)
× [Stem(t0)Prog(t0) × RateStemAsymDiv + Rate
Prog
Div - Rate
Prog
Paneth]
Paneth(t+1) - Paneth(t) = 0⇒
Paneth(t) + [Prog(t) × RateProgPaneth - Paneth(t) × RatePanethApoptosis] × DDCPANETH (t) -
Paneth(t) = 0⇒
Prog(t) × RateProgPaneth - Paneth(t) × RatePanethApoptosis = 0 (given DDCPANETH 6= 0).
At initial time, i.e. t0,⇒
RatePanethApoptosis =
Prog(t0)
Paneth(t0)
× RateProgPaneth
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Abstracts
Roznova˘t¸, I. A. and Ruskin, H. J. (2013). A Computational Model for Genetic
and Epigenetic Signals in Colon Cancer
Cancer, a class of diseases, characterized by abnormal cell growth, has one of the highest
overall death rates world-wide. Its development has been linked to aberrant genetic and
epigenetic events, affecting the regulation of key genes that control cellular mechanisms.
However, a major issue in cancer research is the lack of precise information on tumour
pathways, so that delineation of these and the processes underlying disease proliferation
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is an important area of investigation. A computational approach to modelling malignant
system events can help to improve understanding likely ‘triggers’, i.e. initiating abnor-
mal micro-molecular signals that occur during cancer development. Here, we introduce
a network-based model for genetic and epigenetic events observed at different stages of
colon cancer, with a focus on the gene relationships and tumour pathways. Additionally,
we describe a case study on tumour progression recorded for two gene networks on colon
cancer, carcinoma in situ. Our results to date showed that tumour progression rate is higher
for a small, closely-associated network of genes than for a larger, less-connected set; thus,
disease development depends on assessment of network properties. The current work aims
to provide improved insight on the way in which aberrant modifications characterize cancer
initiation and progression. The framework dynamics are described in terms of interdepen-
dencies between three main layers: genetic and epigenetic events, gene relationships and
cancer stage levels.
Roznova˘t¸, I. A. and Ruskin, H. J. (2013). Methylation Inhibitors and Carcino-
gens in an Agent-based Model for Colon Crypt Dynamics during Cancer Devel-
opment
Cancer, (uncontrolled cell proliferation), has demonstrably high impact on human life:
complex feelings and lifestyle changes, caused by malignancy, affect not only patients, but
also family and friends. Cancer origin has been linked to genetic and epigenetic abnor-
malities that target stem cells. Here, we introduce an agent-based model for colon crypt
dynamics, where the agents represent three cell types: stem, progenitor and differentiated
cells. Additionally, we describe two test cases developed to analyse the influence of epige-
netic inhibitors and carcinogens in tumour development. The focus is on the way in which
DNA methylation patterns can be affected by de-regulations in cellular mechanisms in the
colon crypt during cancer initiation and progression. Results to date have shown significant
differences in average DNA methylation level for crypts, where epigenetic inhibitors have
been temporarily or permanently present, in comparison to those with no such inhibitors.
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Considerable variation in methylation level has also been observed in systems affected by
carcinogens, compared to those unaffected.
Roznova˘t¸, I. A. and Ruskin, H. J. (2012). A Computational Model for Genetic
and Epigenetic Signals in Colon Cancer
http://ieeexplore.ieee.org/xpl/articleDetails.jsp?arnumber=6470302
Cancer, a class of diseases, which are characterized by abnormal cell growth, has one
of the highest overall death rates world-wide. Its development has been linked to genetic
and epigenetic events that aberrantly affect the regulation of key genes that control cellular
mechanisms. However, a distinct problem in cancer research is the lack of precise informa-
tion on tumor pathways, so the delineation of these and the processes underlying disease
proliferation is an important area of investigation. This has motivated the effort to build
computational models to help understand the molecular changes that lead to one or more
types of malignancy. The current work aims to develop a prototype network-based model
to describe cancer initiation and progression, with a focus on three main layers: micro-
molecular events, gene interactions and cancer stages.
Roznova˘t¸, I. A. and Ruskin, H. J. (2012). Modelling the Genetic and Epigenetic
Signals in Colon Cancer using a Bayesian Network
http://link.springer.com/chapter/10.1007%2F978-3-319-00395-5_
126
Cancer, the unregulated growth of cells, has been a major area of focus of research for
years due to its impact on human health. Cancer development can be traced back to aberrant
modifications in genetic and epigenetic mechanisms within the body over time. Given
time and cost implications of human genome experimentation, computational modeling is
increasingly being employed to improve understanding of mechanisms which determine
cancer initiation and progression. Here, we introduce a network-based model for genetic
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and epigenetic signals in colorectal cancer, with the focus on the gene level and tumor
pathways. The current framework also considers the influence of ageing for micromolecular
events in cancer development.
Szczesna, K., Sandoval, J., Modhukur, V., Kull, M., Rajashekar, B., Perrin, D.,
Barat, A., Raghavan, K., Roznova˘t¸, I. A., Huertas, D., Vilo, J. and Ruskin, H.
J. (2013). Complexity of Interdependent Epigenetic Signals in Cancer Initiation
http://www.nwo.nl/en/research-and-results/programmes/complexity/
meetings/eccs+meeting+2013
The aim of the Complexity of Interdependent Epigenetic Signals in Cancer Initiation
network is to determine epigenetic signals implicated in cancer initiation in one of the
best-characterized mouse carcinogenesis systems, the multistage skin cancer progression
model. This has been achieved through efforts on three interconnected layers (a) wet-lab
experiments, (b) bioinformatics assisted analysis, (c) computer-based modeling. We have
produced DNA methylation, gene expression, and histone modification data profiles from
four different cell lines that mimics graduated stages of skin carcinogenesis. The results
that we have generated after integration and computational models have been implemented
will be presented in the meeting.
Roznova˘t¸, I. A. and Ruskin, H. J. (2013). Interdependencies of Genetic and
Epigenetic Events in a Computational Model for Colon Cancer Dynamics
http://ercim-news.ercim.eu/en95/ri/interdependencies-of-genetic-
and-epigenetic-events-in-a-computational-model-for-colon-cancer-
dynamics
The aim of our current work is to investigate the interdependencies of genetic and epi-
genetic mechanisms leading to aberrations in cancer initiation and progression. The objec-
tives are to develop a computational model for colon cancer dynamics, linking microscopic
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effects to macroscopic outcomes, and to analyse the impact of different risk factors on ma-
lignant tumour development.
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